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Abstract 
 
Retinitis pigmentosa (RP) involves a group of hereditary diseases that cause progressive and 
severe visual impairment, with a prevalence of about 1 in 4,000 individuals worldwide. 
Unfortunately, there is currently no cure for RP and most patients become legally blind by 
age 40 due to the loss of retinal photoreceptors. The difficulty in finding a treatment relies on 
the complexity of its genetics. Although more than 3,000 mutations have been described to 
cause it, about 40-50% of RP cases still correspond to unknown patterns. In most cases, 
mutations affecting rods, which degenerate first, subsequently produce the death of the 
remaining photoreceptor cells, the cones.   
  
Several therapeutic approaches have been studied during the last decades. In 2011, our group 
discovered the neuroprotective properties of ‘Norgestrel’, a synthetic progestin used in the 
female oral contraceptive pill, in the retina. Norgestrel was shown to protect against retinal 
cell death in three different models: in vitro, in vivo and ex vivo, using retinal explants. In 
fact, two mouse models were used in order to demonstrate such protection, the balb/c 
induced light damage model and the genetic rd10 (Pde6b rd10–/rd10–) model of RP. Since 
then, some components of its mechanism of action have been elucidated, as is the case of the 
receptor through which it works, the progesterone receptor membrane component 1 
(PGRMC1); the neurotrophic factor basic fibroblast growth factor (bFGF) and its ability to 
reduce inflammation and gliosis in the diseased retina.  
 
Reactive oxygen species (ROS), have been traditionally associated with cellular damage, and 
have been  discovered to participate in signalling responses, including cellular responses that 
are protetective. The number of studies about their protective properties of ROS have 
increased in the last decades. Nevertheless, the accumulation of ROS and/or their persistance 
 v 
 
during time within cells have detrimental consequences. Antioxidant machinery is the 
defense mechanism that cells possess against harmful ROS. However, this system is not 
infallible. Worsening of several diseases including RP is known to be produced by the 
disregulation of intracellular ROS levels, which is known as ‘oxidative stress’. In 2016, we 
demonstrated that Norgestrel effectively reduces the damaging ROS levels in the balb/c light 
damage mouse model.  
 
In the current study, using the 661W cone photoreceptor-like cell line and retinal explants 
from rd10 mice, we demonstrated that ROS are used by Norgestrel to enhance cell survival. 
We found that such stimulation of pro-survival ROS levels occurs very rapidly, and is both 
PGRMC1 and bFGF-dependent (Chapter 3). Interestingly, we demonstrated that treatment 
with some antioxidants that prevent the up-regulation of ROS molecules, abrogates the 
Norgestrel-mediated neuroprotection and therefore, indicates that ROS are a crucial part of 
this survival response. However, little was known about the subsequent downstream 
mechanism in the Norgestrel-mediated signalling response that prevents cell death and thus, 
this study aimed to elucidate other processes that could be implicated in such a response 
(Chapter 4). Using the genetic rd10 mouse model of RP we additionally demonstrated that 
Norgestrel was able to reduce the levels of damaging ROS due to its antioxidant properties 
via stimulating the transcription factor nuclear factor erythroid 2 (NF-E2)-related factor-2 
(Nrf2) and its effector protein, superoxide dismutase 2 (SOD2) (Chapter 5).   
 
Taken together, this study highlights a dual nature of reactive oxygen species and we have 
demonstrated for the first time the implication of redox biology in the Norgestrel-mediated 
neuroprotection against retinal degeneration. 
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1.1. The retina in health and disease 
 
1.1.1. Visual processing 
 
Vision is considered the most important function for quality of life in humans, and the eye is 
responsible for this function (Huberman & Niell, 2011; Hirneiss, 2014; Qiu et al., 2014; 
Latham et al., 2015). The human eye is a slightly asymmetrical sphere composed of various 
tissues. The retina, a complex and light-sensitive structure, is one of them and consists of 
multiple layers of interconnected neurons (Cuenca et al., 2014; Ray et al., 2016). The 
identification of different types of retinal neurons began with Santiago Ramón y Cajal in 
1900, whose drawings are an incredible representation of such an organised structure 
(Masland, 2001; Llinás, 2003). This tissue contains both sensory neurons, the 
photoreceptors, that respond to light; and other neurons that form an intricate circuit for 
processing the signals that are sent to the brain through the optic nerve where the image is 
formed (Figure 1.1.1 and Figure 1.1.2) (Kolb, 2003; Roche et al., 2016).  
 
Figure 1.1.1. Schematic representation of the mouse retina. This schematic illustrates the variety 
of cell types and connections within the retina. Taken from Roche et al., 2016.  
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Figure 1.1.2. Nuclear layers within a wild-type C57 mouse retina. Fluorescent microscopic image 
of a C57BL/6 retinal section stained with Hoechst (blue) that reveals the cell layers present in the 
retina. ONL: outer nuclear layer, INL: inner nuclear layer, RGC: retinal ganglion cells. Scale bar 50 
µm. 
 
Visual processing takes place in a complex but organised system, starting with light that 
penetrates through several cell layers to reach the photoreceptors, where light and visual 
information is transformed into electrical signals (Marshel et al., 2011; Ray et al., 2016). 
Thus, neural signals are sent to the brain via different types of neurons (bipolar cells, retinal 
ganglion cells (RGC), horizontal cells and amacrine cells) through the optic nerve to neurons 
in the lateral geniculate nucleus, situated in the posterior thalamus (Marshel et al., 2011). 
Subsequently, this output is transmitted predominately to the layer 4 of the primary visual 
cortex (Horton, 2006; Marshel et al., 2011; Ray et al., 2016). In addition, there are two types 
of photoreceptors in the retina: cones and rods, responsible for two different kinds of vision. 
Both types contain a photopigment in the outer segment which absorbs the light, leading to 
changes in the membrane potential that cause synaptic transmission within cells mentioned 
above (Curcio et al., 1990; Lamb, 2013). Rod cells contain long cylindrical outer segments, 
have many disks and contain a high concentration of pigment (rhodopsin), responsible for 
dim-light vision. Such features enable rods to be extremely light sensitive, whilst cones 
require significantly brighter light in order to produce a signal and are primarily responsible 
for spatial acuity and colour vision (Warrant, 2009).  
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Interestingly, the human retina presents some differences when compared with the mouse 
retina as shown in figure 1.1.3. The most obvious difference is the size of the lens, which is 
substantially larger in the mouse retina. A key difference between the human and mouse 
retina is the presence of the macula in the human retina. The fovea is a cone-only region 
within the macula (Veleri et al., 2015) and the human retina contains about 120 million rod 
cells and 6 million cone cells concentrated mainly in the fovea. Thus this region contains a 
higher density of cones compared with the peripheral retina. In contrast, cones are equally 
distributed along the mouse retina. This difference between the human and mouse retina 
leads to peripheral to central degeneration in human retinitis pigmentosa (RP) and central to 
peripheral degeneration in the mouse RP, even though the disease in both species can be 
caused by identical genetic mutations.  
 
    
 
 
 
Figure 1.1.3. Difference between human and mouse retina. Modified from Veleri et al., 2015. 
 
The way in which visual inputs are converted in electrical signals is known as 
‘phototransduction’ and consists of five steps represented in figure 1.1.4. The process takes 
place within the disk membrane of the photoreceptor outer segment and it starts when a light 
photon is absorbed by a rhodopsin molecule, transforming it into its enzymatically active 
conformation, metarhodopsin II (R*). Once activated, the signal is amplified through 
repeated contacts with the G-proteins, transducins, to further activate cyclic nucleotide 
phosphodiesterases (PDE), which results in the hydrolysis of multiple diffusible second 
messengers: the cyclic guanosine monophosphates (cGMP). Such hydrolysis closes cGMP-
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gated channels due to the diminished cGMP concentration available for binding to the 
channels throughout the surface of the outer segment, decreasing the influx of Na+ and Ca2+ 
ions and leading to hyperpolarisation of the cell and subsequent signalling (Pugh, 1999; 
Leskov et al., 2000; Lamb & Pugh, 2006; Warrant, 2009).  
   
 
Figure 1.1.4. Representation of the phototransduction cascade. Shown is the outer membrane disk 
found in a rod cell. Step 1, activation of rhodopsin: Capture of a photon (hν) activates rhodopsin via 
a conformational change to R*. Step 2, activation of the G-protein: R* contacts with G-protein 
transducin (G) molecules that consist of three subunits: α, β and γ, with guanosine diphosphate (GDP) 
bound to the α subunit. This contact activates the molecule to G*, catalysing its activation by the 
release of bound GDP in exchange for cytoplasmic guanosine triphosphate (GTP). Step 3, activation 
of the PDE: This release expels the G-protein β and γ subunits leaving the α subunit. Step 4, 
hydrolysis of cGMP: G* α subunit binds inhibitory γ subunits of phosphodiesterase (PDE) activating 
its α and β subunits. Activated PDE hydrolyses cyclic guanosine monophosphates (cGMP). Step 5, 
closure of ion channels: Guanylyl cyclase (GC) synthesises cGMP. Reduced levels of cytosolic 
cGMP trigger cyclic nucleotide gated channels to close preventing further influx of Na+ and Ca2+. 
Modified from Pugh, 1999. 
 
As a result of this mechanism, one molecule of R* induces hydrolysis of more than a few 
hundred thousand of cGMP molecules during the time period when it is active (Kawamura & 
Tachibanaki, 2008). At the cessation of light, R* is inactivated by phosphorylation of a 
rhodopsin kinase (Chen et al., 1999; Kawamura & Tachibanaki, 2008). This process appears 
to be reasonably similar in mammalian cones and rods, only differing with respect to the 
photo-pigments used (Masland, 2001), which therefore, changes the rate of activation of both 
types of cells (Kawamura & Tachibanaki, 2008; Tachibanaki et al., 2012; Lamb, 2013). 
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1.1.2. Retinitis pigmentosa 
 
Due to its high structural and functional complexity, the retina is vulnerable to alterations 
from any sort of pathological injury. Inherited retinal diseases are a family of hereditary 
diseases where mutations affecting mainly photoreceptors lead to degeneration. Retinitis 
pigmentosa (RP) is included in these diseases (Fan et al., 2006). 
 
The term ‘retinitis pigmentosa’ was first used by the German physician Franciscus Donders 
in 1857 (Donders, 1857) and it includes a group of retinopathies characterised by an 
accumulation of retinal pigment deposits due to the loss of photoreceptors (rods and cones) 
and the adjacent retinal pigment epithelium (RPE) which leads to progressive blindness 
(Allard, 1983; Berson, 1993; Fan et al., 2006; Hamel, 2006; Dias et al., 2017). In most cases, 
the loss of rods causes the first symptom of RP: night blindness (nyctalopia). However, 
cones secondarily degenerate in the periphery of the retina causing a reduction of peripheral 
vision known as ‘tunnel vision’ (Hartong et al., 2006; Cuenca et al., 2014; Dias et al., 2017; 
Athanasiou et al., 2018), as shown in figure 1.1.5. By midlife, patients become legally blind 
when the defective regions gradually enlarge, affecting the central field as well (Allard, 
1983; Pagon, 1988; Herse, 2005; Kennan et al., 2005; Hamel, 2006). Furthermore, survival 
of cones appears to depend on rods and preservation of cones prevents patients becoming 
blind (Komeima et al., 2006, 2007; Tao et al., 2016). Nevertheless, there is currently no cure 
for RP. The prevalence of these disorders is 1:4000 individuals worldwide, being the most 
common cause of inherited blindness (Boughman et al., 1980; Berson, 1993; Haim, 2002; 
Hartong et al., 2006; Dias et al., 2017). 
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Figure 1.1.5. Progression of visual field loss in retinitis pigmentosa. (A) Normal vision. (B) Vision 
of a patient with RP: loss of peripheral vision (tunnel vision). 
 
Age-related macular degeneration (AMD) disorders are another type of inherited retinal 
diseases which are characterized by progressive destruction of the macula, produced by 
abnormalities in the RPE (Fan et al., 2006; Winkler et al., 2007). Thus, AMD is related to 
loss of central vision rather than loss of peripheral which occurs in RP. 
 
RP has been reported to be inherited in all the three Mendelian modes: autosomal-dominant 
(adRP, about 15-25% of the cases), autosomal-recessive (arRP, 5-20%) and X-linked (5-
15%) (Bunker et al., 1984; Wang et al., 2005; Hartong et al., 2006; Athanasiou et al., 2018), 
although about 40-50% of cases correspond to unknown patterns as represented in figure 
1.1.6 (Dias et al., 2017). The genetics of this disease is highly complex due to the fact that 
about 70 genes are involved and more than 3,000 mutations are known to cause it (Guadagni 
et al., 2015; Cheng et al., 2016; Dias et al., 2017). Due to such broad genetic complexity of 
RP, gene-specific therapies are challenging (Cuenca et al., 2014). The major causative genes 
(Figure 1.1.6) are the rhodopsin (RHO) gene that leads to about 25% of adRP; the Usher’s 
syndrome type IIA (USH2A) gene, which might cover about 15% of recessive disease; and 
the retinitis pigmentosa GTPase regulator (RPGR) gene that causes about 70% of X-linked 
cases (Wang et al., 2005; Hartong et al., 2006; Daiger et al., 2013). These three genes are 
found in about 30% of all cases of RP (Hartong et al., 2006; Dias et al., 2017). 
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Among the mutated genes that cause arRP, we find the gene that encodes the rod cGMP-
phosphodiesterase-6B subunit β (Pde6b) which is an essential component in the 
phototransduction cascade (Cote, 2004; Kennan et al., 2005). In fact, a correct function of 
this subunit is crucial for the whole protein function (Ullah et al., 2016; Gopalakrishna et al., 
2017). The rod Pde6b gene is located in the chromosome 5 and it has 22 exons. Pde6b 
mutations represent about 5% of arRP cases (Figure 1.1.6). 
               
 
Figure 1.1.6. Genes and their relative contribution to retinitis pigmentosa. The inheritance of RP 
consists of autosomal-dominant (adRP), autosomal-recessive (arRP), X-linked and unknown patterns. 
The main causative genes for them are rhodoposin (RHO), Usher’s syndrome type IIA (USH2A) and 
retinitis pigmentosa GTPase regulator (RPGR). Phosphodiesterase-6B (Pde6b) is also of interest 
throughout this thesis. 
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1.1.3. Genetic mouse models of retinitis pigmentosa 
 
Despite our understanding of the genetic abnormalities leading to RP, the mechanism by 
which many mutations, including the ones previously described, lead to cell death has yet to 
be fully elucidated. Unfortunately, the direct study of human RP is limited given the 
difficulty in obtaining relevant human tissue samples. As a result, animal models that present 
the same mutations found in humans and therefore are a good representation of the human 
disease both genetically and phenotypically have become as an invaluable tool for studies of 
RP. 
 
Perhaps the best characterised mouse model of retinal degeneration is the naturally occurring 
rd1 mouse (Pde6b rd1–/rd1–) since Keeler described it in 1924 (Keeler, 1924). However, in 
1990 it was determined that degeneration in the rd1 mouse model is caused by a point 
mutation in exon 7 of the β subunit of the Pde6b gene (Bowes et al., 1990; Pittler & Baehr, 
1991). Such mutation leads to a rapid loss of rod photoreceptors starting at postnatal day (P)9 
which ends at P18. A subsequent cone cell death is detected at P20 (Portera-cailliau et al., 
1994; Barhoum et al., 2008; Greferath et al., 2009). At P30, the majority of cones have also 
degenerated and thereafter, the degeneration becomes slower. Carter-Dawson et al. showed 
that as a consequence of a slower degeneration, 1.5% cones remain at P600 (18 months of 
age) (Carter-Dawson et al., 1979). Although this model has been widely used (Doonan et al., 
2003; Hart et al., 2005; Komeima et al., 2006; Usui et al., 2009), it presents some limitations 
in the study of RP due to the rapid loss of photoreceptors which coincides with retinal 
development (Sanyal & Bal, 1973; Carter-Dawson et al., 1979). 
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Alternately, another mouse model, the rd10 strain (Pde6b rd10–/rd10–), with a missense 
mutation in exon 13 of the same gene (Pde6b) was described (Chang et al., 2002, 2007; Han 
et al., 2013). The mutation is naturally produced by the exchange of an arginine by a 
cysteine at position 560 (Arg560Cys) of the protein (Chang et al., 2007). This mutation 
results in a slower retinal degeneration, starting with the death of rods around P18, peaking 
at P25 and finishing at P50 with the subsequent death of cones (Chang et al., 2002; Gargini 
et al., 2007; Barhoum et al., 2008; Samardzija et al., 2012; Roche et al., 2016). This reason 
and the fact that this mutation also causes RP in humans (McLaughlin et al., 1993), make the 
rd10 mouse a suitable model for studying retinal degeneration and developing therapeutic 
approaches for patients affected by hereditary retinal dystrophies. In this model, 
degeneration of photoreceptors follows a clear gradient from the central to the peripheral 
regions of the retina (Gargini et al., 2007; Roche et al., 2016) and it also occurs more rapidly 
in the central retina in comparison to the periphery (Barhoum et al., 2008). As seen in human 
RP, rods are lost first with cones persisting into adulthood (Gargini et al., 2007; Barhoum et 
al., 2008; Roche et al., 2016). 
 
In addition, not only photoreceptors are affected in the rd10 model, but also other retinal 
cells such as amacrine cells and bipolar cells, as well as photoreceptor synapses (Barhoum et 
al., 2008; Puthussery et al., 2009; Roche et al., 2016). According to this, glial cells, which 
can be divided into two types: microglia and macroglia (Müller glia and astrocytes), have 
been shown to respond dramatically during this period in the rd10 retina (Roche et al., 2016, 
2017a, 2017b; Roche & Wyse-Jackson et al., 2016). 
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1.2. Progesterone-induced neuroprotection 
 
Functions of female steroid hormones in the central nervous system (CNS) were classically 
associated with reproductive processes and sexual behaviour. In 1968 it was recognised that 
these molecules can reach the brain (McEwen et al., 1968). However, it has become clear in 
the last decades that they play alternative roles that have nothing to do with endocrine 
functions. For example, they can affect electrical activity in the brain and contribute to 
neuroprotection in the CNS (De Nicola, 1993; Joëls, 1997; Azcoitia et al., 1999; McEwen, 
1999; Schumacher et al., 2000). Studies in vitro, in vivo and in patients affected by diseases 
such as Alzheimer’s disease, have demonstrated their important neuroprotective effects 
(Henderson, 1997; McEwen, 1999; Vongher & Frye, 1999; Brinton, 2001).  
 
Among the hundred different types of steroids found in nature, the majority of them in the 
human body are derived from the membrane lipid cholesterol (Conn et al., 1950; Sanderson, 
2006; De Nicola et al., 2017). Steroid hormones can be divided into three groups depending 
on the place where are synthesised: corticosteroids (made in the adrenal cortex), sex steroids 
(made in the gonads or placenta), and neurosteroids, when they are made by neurons and 
other cells pertaining to the CNS (Joëls, 1997; Sanderson, 2006; De Nicola et al., 2017). 
These three groups have been related with neuroprotection during years (De Nicola, 1993; 
Cox, 1995; Joëls, 1997; Mannella et al., 2009; Guennoun et al., 2015). In this context, many 
of them have been proved to protect in some retinal diseases. Glucocorticoids, a group of 
corticosteroids, have been shown to induce photoreceptor survival (Fu et al., 1992; Wenzel 
et al., 2001, 2003; Bhisitkul et al., 2008; Glybina et al., 2009). Several human clinical trials 
of varying degrees of success have been also performed and all looked at the potential for 
glucocorticoids to act as anti-inflammatories in the eye as reviewed by Cebeci & Kir (Cebeci 
& Kir, 2015). In all of the aforementioned trials, visual acuity was improved through 
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corticosteroid administration. However, the mechanism of action by which this occurs, be it 
directly or indirectly on the photoreceptors, has not yet been elucidated. 
 
Progesterone, the progestin on which we are going to focus in this study, is included in the 
second and third group, sex steroids and neurosteroids (Baulieu et al., 2001; Guennoun et al., 
2015; Sánchez-Vallejo et al., 2015). Progesterone is a gonadal hormone synthesised 
primarily by the ovary in females, and the testes and adrenal cortex in the male (Singh & Su, 
2013; Sánchez-Vallejo et al., 2015). Although progesterone levels are normally higher in 
females, males also present substantial levels of this hormone (Oettel & Mukhopadhyay, 
2004; Singh & Su, 2013) and thus, may be equally important in both. This hormone has been 
found to have multiple functions in the CNS including the modulation of neuroprotection, 
neuroplasticity, neurogenesis and neuroinflammation (Petersen et al., 2013). Treatment with 
progesterone produces regenerative effects in brain injury models (Schumacher et al., 2000), 
such as the traumatic brain injury (TBI). In fact, studies with progesterone have achieved 
promising results for the treatment of TBI in phases II and III of clinical trials (Wright et al., 
2007; Xiao et al., 2008). 
 
Given the high complexity of RP genetics, a mutation-independent treatment strategy is 
highly desirable in the fight against degenerative blindness. As such, the concept of 
‘neuroprotection’ is one therapy currently under investigation for the treatment of retinal 
diseases (Doonan & Cotter, 2012; Trifunovic et al., 2012). Protective and regenerative 
effects of progesterone make it a promising solution to many of them.  
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1.2.1. Norgestrel 
 
Preclinical studies have raised great hope for the use of progesterone as a potential 
therapeutic agent due to its effectiveness on different diseases including spinal cord injury, 
brain ischemia, stroke, Alzheimer’s disease, multiple scleroris and TBI (Gonzalez Deniselle 
et al., 2003; Gonzalez et al., 2005; Compagnone, 2008; Espinosa-García et al., 2014; Yousuf 
et al., 2014; Qin et al., 2015; De Nicola et al., 2017). The Progesterone for Traumatic Brain 
Injury Experimental Clinical Treatment (ProTECT) study was carried out in order to 
establish drug safety (Wright et al., 2007). Following that, more clinical trials have been 
performed to demonstrate progesterone treatment reduces mortality in patients with TBI 
(Stein, 2011, 2013; Schumacher et al., 2016). As a result of such neuroprotection, 
progesterone effects were also studied in eye diseases, such as diabetic and ischemic 
retinopathies (Lu et al., 2008; Neumann et al., 2010), and specifically, retinal diseases 
(Feskanich et al., 2008; Sánchez-Vallejo et al., 2015). Sánchez-Vallejo et al. showed that 
oral administration of this hormone during several days, delays cell death happening in the 
rd1 mouse model (Sánchez-Vallejo et al., 2015). 
 
Furthermore, the role that progesterone plays in neuroprotection has become clear given that 
its synthesis is up-regulated in response to the injury produced by these diseases 
(Schumacher et al., 2016). Taken together, experimental observations strongly suggest that 
an increase in progesterone production by gonads and by neural cells might be part of a 
physiological process of neuroprotective responses. For this reason, progesterone and its 
synthetic analogues offer considerable promises as neuroprotectant agents. 
 
One of these synthetic analogues is levonorgestrel, commonly referred to as ‘Norgestrel’, 
which presents a similar structure as progesterone. Norgestrel, and the rest of steroids, 
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contains a four cycloalkane ring core (Figure 1.2.1). This compound is Food and Drug 
Administration (FDA) approved and is found at concentrations of 0.075-0.35 mg (daily 
dosage) in versions of the progesterone-only mini pill (Doonan & Cotter, 2012). Norgestrel, 
like other synthetic progestins, has been widely used in the reproductive medicine given that 
it is rapidly absorbed and has a longer half-life compared with progesterone, which allows 
the maintenance of stable levels in the blood.  
  
Figure 1.2.1. Chemical structures of progesterone and Norgestrel. 
 
Our group has demonstrated Norgestrel’s ability to protect damaged photoreceptors in three 
different models: in vitro, in vivo and ex vivo, using retinal explants (Doonan et al., 2011; 
Doonan & Cotter, 2012; Byrne et al., 2016a, 2016b; Roche & Wyse-Jackson et al., 2016; 
Wyse Jackson et al., 2016a, 2016b; Wyse Jackson & Cotter, 2016; Roche et al., 2017a, 
2017b; Ruiz-Lopez et al., 2017). Doonan et al. firstly showed that intraperitoneal 
administration of Norgestrel preserved photoreceptor cells in both a light-induced damage 
model and rd10 mice (Doonan et al., 2011). Since then, our knowledge about this compound 
has increased and our interest has foccused on elucidating its mechanism of action. 
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1.2.2. Progesterone and Norgestrel: mechanism of action 
 
As with most neurosteroids, progesterone acts through specific binding to cellular receptors 
(Friberg et al., 2009). Progesterone receptors A and B (PR A/B) have been classically 
thought to be responsible for progesterone signalling in CNS. These receptors are widely 
expressed and can modulate a variety of different physiological functions (Wen et al., 1994; 
Lange, 2008). However, progesterone, as a complex hormone, can also act through a variety 
of non-classical receptors (Moussatche & Lyons, 2012; Petersen et al., 2013; Qin et al., 
2015). These are: the progesterone receptor membrane component (PGRMC) family, 
featuring PGRMC1 and PGRMC2 (Cahill, 2007, 2017; Lösel et al., 2007; Peluso et al., 
2014) and the progestin and adipoQ receptor (PAQR) family (Zhu et al., 2003; Petersen et 
al., 2013), featuring membrane progesterone receptors α, β and γ (mPRα, mPRβ and mPRγ).  
 
Given both classical and non-classical receptors are important in the progesterone-mediated 
signalling, they are widely distributed in many tissues (Graham & Clarke, 2002; Han et al., 
2006), including the brain (Kato et al., 1994; Petersen et al., 2013; Singh & Su, 2013). This 
ubiquitous expression highlights their importance throughout the body. Progesterone binding 
to the receptor produces its dimerization and the subsequent interaction with several co-
regulatory proteins (Singh & Su, 2013; Grimm et al., 2016). This results in a response that 
can be generated by causing changes in gene transcription through transcription factors (Li et 
al., 1997; Faivre et al., 2008) or via non-genomic mechanisms by the interaction with signal 
transduction kinases and the use of second messengers (Boonyaratanakornkit et al., 2001; 
Jacobsen & Horwitz, 2012; Singh & Su, 2013). 
 
Studies about the different PRs present in the retina and their mechanism of action are very 
limited (Swiatek-De Lange et al., 2007). Nevertheless, in 2016 our group discovered that the 
Chapter 1 
16 
 
receptor target by which Norgestrel exerts its action is the PGRMC1 receptor in the 661W 
cone photoreceptor-like cell line and in both C57 and rd10 mouse retina (Wyse Jackson et 
al., 2016a). Interestingly, PGRMC1 expression was equal in male and female mice, 
demonstrating progesterone signalling plays and important role in both. PGRMC1 localises 
in the plasma membrane but following ligand binding, it is activated and translocated to the 
nucleus (Peluso et al., 2012; Wyse Jackson et al., 2016a). Nuclear PGRMC1 might be 
associated with regulation of transcriptional activity (Peluso et al., 2012). However, its 
function inside the nucleus following Norgestrel treatment is still unknown. 
 
One of the main effects discovered of Norgestrel-mediated response was the up-regulation of 
neurotrophic factors (Doonan et al., 2011; Doonan & Cotter, 2012; Byrne et al., 2016a; 
Wyse Jackson & Cotter, 2016; Ruiz-Lopez et al., 2017). Cytokines and neurotrophic factors 
are regarded as a possible therapeutic modality due to their effects in increasing proliferation 
and survival in different cell types and tissues (Kolomeyer & Zarbin, 2014). This is of 
interest given that such effects are also important in the treatment of retinal diseases (Désiré 
et al., 2000; Yip & So, 2000; Arroba et al., 2009, 2011; Bürgi et al., 2009; Zheng et al., 
2009; He et al., 2014; Kolomeyer & Zarbin, 2014; Arroba & Valverde, 2015). There is much 
evidence in the literature about how progesterone-mediated stimulation of these trophic 
factors induces neuroprotection (Schumacher et al., 2000; Gonzalez Deniselle et al., 2003; 
Gonzalez et al., 2005; Deutsch et al., 2013; Kolomeyer & Zarbin, 2014; Melcangi et al., 
2014). Therefore, the fact that the basic fibroblast growth factor (bFGF) and leukemia 
inhibitory factor (LIF) are part of the Norgestrel-mediated survival response is not surprising 
(Doonan et al., 2011; Byrne et al., 2016a; Wyse Jackson & Cotter, 2016; Ruiz-Lopez et al., 
2017).  
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1.3. Reactive oxygen species 
 
The term ‘reactive oxygen species’ (ROS) describes a group of molecules and free radicals 
(chemical species with one unpaired electron) that are generally metabolic by-products 
constantly formed as a consequence of endogenous physiological processes that involve 
oxygen consumption (Gilbert, 1994; Andreyev et al., 2005; Winterbourn, 2008). Since 
molecular oxygen (O2) possesses two unpaired electrons with the same spin in the outer 
shell, known as triplet state, is a not reactive molecule. However, when one of the two 
unpaired electrons is excited, its spin changes and the resulting species becomes a powerful 
oxidant that reacts with other pairs of electrons (Turrens, 2003). These reactions in which an 
exchange of electrons is produced are commonly known as ‘reduction-oxidation’ (redox) 
reactions as represented in figure 1.3.1. 
                                  
Figure 1.3.1. Schematic representation of reduction-oxidation (redox) reactions. Oxidation is the 
loss of electrons by a molecule, atom or ion with the subsequent reduction or gain of electrons by 
other. 
 
ROS molecules are the product of the partial reduction of oxygen. Superoxide anion (O2•–) 
results from the one-electron O2 reduction and it is the precursor of most of the other ROS 
types (Knowles et al., 1969; Turrens, 2003). Spontaneous or non-spontaneous superoxide 
dismutation produces uncharged hydrogen peroxide (H2O2) which can be partially reduced to 
hydroxyl radical (OH•) or fully reduced to form water (Davies, 1995; Keyer & Imlay, 1996; 
Turrens, 2003; Winterbourn, 2008).  
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ROS have long been associated with activation of death pathways and cellular damage 
(Chance, 1979; Gorman et al., 1997; Curtin et al., 2002; Rhee, 2006; Battistelli et al., 2016). 
In fact, both O2•– and OH• are unstable radicals that are responsible of such detrimental 
effects, especially OH•, which is considered one of the strongest oxidants in nature. ROS 
implication has also been documented in neurodegenerative diseases leading to 
mitochondrial dysfunction (England et al., 2006; Gandhi & Abramov, 2012; Kim et al., 
2015; Di Meo et al., 2016), and more specifically, in the worsening of retinal diseases 
including RP (Carmody et al., 1999; Cingolani et al., 2005; Carmody & Cotter, 2007; 
Winkler et al., 2007; Usui et al., 2009; Lange & Bainbridge, 2012; Eshaq et al., 2014; 
Campochiaro et al., 2015; Tao et al., 2016). The retina is a tissue highly affected by ROS 
given its elevated oxygen consumption rate (Eshaq et al., 2014) in order to convert light into 
electrical inputs as described before. Furthermore, some studies have also linked the 
photoreceptor cell death produced by the exposure to bright light with an increase in ROS 
production as reviewed by Winkler et al. (Winkler et al., 2007). It was then assumed that the 
faster the elimination of these toxic molecules, the better for the cell. 
 
Over the last few years, however, our understanding about these molecules has dramatically 
changed. It is true that ROS are related with a great variety of diseases, but that is just an 
oversimplification of their importance within the cell (Figure 1.3.2). Contrary to what was 
thought, ROS were discovered to be a double-edged sword, playing a crucial role in cells by 
working as second messengers in signal transduction (Burdon, 1995; Rhee, 2006; 
D’Autréaux & Toledano, 2007; Groeger et al., 2009b; Benitez-Alfonso et al., 2011; Finkel, 
2011; Gough & Cotter, 2011). This change in the perception of these molecules is the reason 
why our interest about such unexpected function has considerably increased in the last 
decades.  
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Figure 1.3.2. Dual effect produced by ROS in cells. Low or moderate ROS levels are able to act as 
second messenger in cellular signalling to mediate pro-survival response. However, they become toxic 
when their levels are excessive, leading to cell death. 
 
Low or moderate levels of ROS can participate in pro-survival signalling pathways, but it is 
the increase in their production, their persistence during the time or their presence in a wrong 
time or place, which turns them into potent pro-death molecules (Trachootham et al., 2008; 
Nathan & Cunningham-Bussel, 2013). Thus, cells use small amount of ROS to amplify the 
signal and make it more effective. 
 
Nevertheless, only hydrogen peroxide is suggested to accomplish such function given its 
stable non-radical condition which means that it reacts poorly or not at all with most 
biological molecules (Winterbourn, 2013). H2O2 is a freely diffusible molecule which allows 
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it to modulate physiological responses such as cell proliferation, differentiation, and 
migration across membranes (Rhee, 2006; Finkel, 2011; Reczek & Chandel, 2015). It is 
important to understand H2O2-mediated signalling is produced by its interaction with 
downstream target molecules, especially by the oxidation of critical residues on proteins or 
by activating protein kinases (Rhee, 2006). For example, the tyrosine kinase Scr becomes 
active when H2O2 oxidises two of its cysteine residues (Giannoni et al., 2005). Proteins, 
therefore, are believed to be the main target of ROS (Davies, 2005). 
 
1.3.1. Intracellular sources of ROS: NOX proteins 
 
Living organisms produce ROS from different systems localised in several parts of the cell: 
the cytosol, the plasma membrane, mitochondria, the endoplasmic reticulum (ER) and 
peroxisomes (Figure 1.3.3). Cytosolic ROS are mainly formed by enzymes such as xanthine 
oxidases or soluble components including catecholamines and flavins. Peroxisomes and ER 
are known to produce ROS as part of their metabolic functions (Finkel, 2011; Di Meo et al., 
2016). Peroxisomes are known to perform fatty acid α- and β-oxidation and the synthesis of 
lipid compounds. Such reactions induce the formation of ROS as by-products (Antonenkov 
et al., 2010). In the same way, among the multiple functions of the ER, the introduction of 
double bonds in fatty acids or the formation of intramolecular disulfide bonds during the 
protein folding, are known to involve oxidation reactions and therefore, to produce ROS 
(Hwang et al., 1992; Di Meo et al., 2016). Free radicals can also be formed by membrane 
associated proteins such as lipoxygenases and cyclooxygenases (COX) enzymes during the 
arachidonic acid oxidation (Nogawa et al., 1997; Farrell et al., 2011; Holmström & Finkel, 
2014).  
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Figure 1.3.3. Intracellular sources of ROS. Representation of the different ROS sources and their 
localization within the cell. Taken from Di Meo et al., 2016. 
 
However, the main source of ROS located on the plasma membrane is the enzymatic 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) family of proteins. 
Differing from other sources, their only known function is the formation of ROS and hence, 
these molecules are not generated as by-products by NOX enzymes (Bedard & Krause, 
2007; Takac et al., 2012; Brandes et al., 2014a). These proteins were first described in 
leukocytes where they produce ROS as part of their essential role in host defence. Once 
activated, neutrophils are able to internalise microorganisms by phagocytosis and inactivate 
them through the secretion of enzymes and the production of ROS (Holmström & Finkel, 
2014). We now know that these proteins are also expressed in non-phagocytic cells. 
 
The NOX family consists of seven transmembrane members (NOX1-5, DUOX1-2), differing 
mainly in their organ-specific expression, control of their activity and the type of ROS they 
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release (Katsuyama, 2010; Brandes et al., 2014a; Moloney & Cotter, 2017) as represented in 
figure 1.3.4. NOX2, originally termed glycoprotein 91 phagocyte oxidase (gp91phox), was the 
first NOX member to be identified in phagocytes. Catalytic subunit NOX2 does not generate 
superoxide on its own, but recruits different components to do so: the transmembrane 
subunit p22phox, three cytosolic proteins, p40phox, p47phox and p67phox and a small GTP-
binding protein (Rac) (Katsuyama, 2010; Holmström & Finkel, 2014). 
 
Figure 1.3.4. ROS production by NOX isoforms.  NOX1-5 and DUOX1-2 are the seven members 
of the NOX protein family. Upon activation through different subunits, the catalytic subunit removes 
an electron from cytosolic NADPH and transfers it to O2, to produce superoxide (O2•–) or hydrogen 
peroxide (H2O2) as is the case of NOX4. The transmembrane subunit p22phox is required for activation 
of NOX1-4 whereas NOX1-3 activation also requires the recruitment of other cytosolic subunits. 
NOX5 appears to only require Ca2+ for activation and DUOX1- 2 also require another transmembrane 
protein known as DUOXA1-2. 
 
Although all NOX isoforms are structurally similar, each is activated by specific 
mechanisms and regulatory subunits and has specific subcellular localization. Subunits 
p47phox and p67phox have their homologs NOX organizer 1 (NOXO1) and NOX activator 1 
(NOXA1), respectively, when it comes to the regulation of both NOX1 and NOX3. Despite 
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the fact that NOX1-4 interact with p22phox, NOX4 appears to be somewhat different to the 
other NOXs (Martyn et al., 2006) and it seems to be constitutively active (von Löhneysen et 
al., 2012). In contrast to other isoforms, NOX4 produces H2O2 rather than O2•– given a 
modification in its unique tertiary structure (Martyn et al., 2006; Takac et al., 2011; von 
Löhneysen et al., 2012; Nisimoto et al., 2014). NOX5 also differs to the others in its 
regulation, which appears to only require Ca2+ to produce O2•–. In addition, DUOX1-2 
maturation and function seem to depend on other transmembrane factors known as 
DOUXA1-2, whose function is not completely understood (Morand et al., 2009). 
 
Regarding their expression, NOX enzymes are also different. NOX1 is highly expressed in 
the colon epithelium and smooth muscle cells (Katsuyama, 2010; Takac et al., 2012) 
whereas NOX2 is mainly found in endothelial and phagocytic cells (Di Meo et al., 2016), 
and NOX3 is required for the formation of otoliths in the inner ear (Bánfi et al., 2004). 
NOX4 expression was first observed in the kidney amongst other tissues (Shiose et al., 
2001). However, we now know that this NOX isoform is ubiquitously expressed in a large 
variety of cell types (Xu et al., 2018), generally exceeding the expression of other NOX 
proteins (Ago et al., 2004). Expression of NOX5 has been reported in several tissues 
including the spleen, stomach, testis, uterus and endothelial cells, while DUOX1-2 are 
expressed mainly in the thyroid and the respiratory epithelia (Takac et al., 2012; Moloney & 
Cotter, 2017). Given that NOX5 is not expressed in rodents owing to a genetic deletion, few 
studies have been performed and its role and function are still not well understood (Takac et 
al., 2012). 
 
NOX enzymes activity is therefore exerted by protein-protein interactions or calcium, with 
the exception of NOX4, whose activity is controlled by its expression (von Löhneysen et al., 
2012; Brandes et al., 2014a). Furthermore, their activity as ROS generators is tightly 
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regulated given that the amount of ROS produced can be both beneficial and detrimental as it 
has been discussed above. Growth factors and cytokines are worth being described as 
activators of NOX function, taking into account the large amount of studies reporting such 
effect (ten Freyhaus et al., 2006; Lee et al., 2007; Hecker et al., 2009; Sancho et al., 2009; 
Schröder et al., 2011; Stanic et al., 2012; Takac et al., 2012; Brandes et al., 2014a; 
Holmström & Finkel, 2014). These studies demonstrate that neurotrophic factors utilise ROS 
production as part of their signalling response. For instance, Hecker et al. showed that the 
transforming growth factor beta 1 (TGF-β1) induces NOX4-mediated hydrogen peroxide 
production to repair functions of myofibroblasts in response to lung injury (Hecker et al., 
2009) and ten Freyhaus et al. demonstrated that NOX inhbition abrogates platelet-derived 
growth factor (PDGF)-dependent smooth muscle cell chemotaxis (ten Freyhaus et al., 2006). 
In fact, the absence of growth factors is also responsible for increased ROS levels (Lee et al., 
2010; Li et al., 2013). In this context, our laboratory has well defined the lack of growth 
factors caused by serum withdrawal as a main cause to produce ROS from NOX proteins in 
a cone photoreceptor cell line (Mackey et al., 2008; Groeger et al., 2009a). 
 
Such stimulation of NOX-dependent ROS formation induced by neurotrophic factors can 
induce either proliferation or cell death, depending on the amount of ROS formed. Diseases 
such as Alzheimer’s and Parkinson’s diseases or retinal degeneration, have been documented 
to be caused in part by an elevated ROS generation from NOX proteins (Usui et al., 2009; 
Song et al., 2016; Tao et al., 2016; Ma et al., 2017; Rastogi et al., 2017). In fact, Usui et al. 
pointed NOX proteins as the responsible source of ROS production in the cone cell death 
occuring in retinitis pigmentosa. They demonstrated a longer preservation of cones in the rd1 
mouse model when NOXs were inhibited (Usui et al., 2009). Nevertheless, NOX-generated 
ROS have been more often associated with pro-survival signal transduction cascades (Brown 
& Griendling, 2009; Groeger et al., 2009a; Takac et al., 2012; Hakami et al., 2015; Stanicka 
et al., 2015; Accetta et al., 2016; Moloney & Cotter, 2017; Moloney et al., 2017a, 2017b). 
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Their role in pro-survival mechanisms is not surprising given that their only known function 
is the synthesis of ROS molecules. This intracellular source of ROS is, therefore, an ideal 
point of regulation when it comes to control of ROS generation. 
 
1.3.2. Intracellular sources of ROS: Mitochondria 
 
 
The mitochondrion is the other large contributor to ROS generation within most mammalian 
cells. Mitochondria use oxygen to generate energy, in the form of adenosine triphosphate 
(ATP), by using intermediate metabolites from a metabolic process known as ‘tricarboxylic 
acid (TCA) cycle’, which implies the removal of one electron of those metabolites in order 
to transfer it to the electron transport chain (ETC), resulting in the reduction of O2 to form 
O2•– (Forman & Kennedy, 1974; Mclennan & Esposti, 2000; Nickel et al., 2014; Sabharwal 
& Schumacker, 2014). Electrons are transferred from nicotinamide adenine dinucleotide 
(NADH) to O2 through the four protein complexes which form the respiratory chain: NADH 
dehydrogenase, succinate dehydrogenase or succinate coenzyme Q (CoQ or Q) reductase, 
cytochrome c oxidoreductase, and cytochrome c oxidase (Figure 1.3.5). The reduction of O2 
to two molecules of H2O takes place in the complex IV. This flow of electrons through all 
these complexes creates a concentration gradient of protons that is used to produce the 
energy carrier molecule ATP at the matrix side by the complex V or ATP synthase (Murphy, 
2009).  
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Figure 1.3.5. Mitochondrial ROS production. The inner mitochondrial membrane-bound 
respiratory chain consists of complex I-V. Complex I (NADH dehydrogenase), II (succinate 
dehydrogenase or succinate coenzyme Q reductase), III (cytochrome c oxidorectuctase), IV 
(cytochrome c oxidase) and V (ATP synthase). O2•– is produced at complex I and III during the 
transfer of electrons from NADH to O2. This process ends with the generation of ATP at the matrix 
side. Mitochondrial antioxidants manganese SOD (SOD2) in the mitochondrial matrix and 
copper/zinc SOD (SOD1), localised in the intermembrane space or cytoplasm, converts O2•– into 
membrane permeable H2O2. H2O2 is reduced to water by glutathione peroxidases (GPX). 
 
Superoxide anion can be produced by at least eleven different sites of mitochondria, mainly 
at the complexes I  and III (Brand et al., 2004, 2016) of the respiratory chain. Complex I is 
believed to produce most of the O2•– generated from mitochondria, which is mainly in the 
matrix side of the inner membrane (St-Pierre et al., 2002). For this reason, several inhibitors 
to study mitochondrial involvement in ROS production have been designed to target 
specifically complex I, as is the case of Rotenone (Curtin et al., 2002; Brand et al., 2004), 
which will be discussed in the chapter 4 of this thesis. 
 
Contrary to NOX enzymes, ROS are generated as by-products of mitochondrial function, 
which makes difficult their regulation to act in signalling responses. Thus, mitochondrial 
ROS have been generally associated with aging (Choksi et al., 2008; Liochev, 2013) and 
other mechanisms related with cell damage (Sanz & Bernardi, 2016). Disease worsening 
happens due to the progressive accumulation of free radicals, which leads to decline cellular 
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function and subsequent cell death. For example, some compounds used to block the electron 
transport chain in mitochondria (e.g. Rotenone) result in increased ROS levels that cause the 
death of experimental animals in minutes or hours as reviewed by Sanz & Bernardi (Sanz & 
Bernardi, 2016). Other studies have also demonstrated that oxidative stress produces damage 
in mitochondrial DNA, which subsequently kills the cell (Yakes & Houten, 1997; 
Shokolenko et al., 2009). Yakes & Houten hypothesised that ROS-damaged mitochondrial 
DNA, characterised in several degenerative diseases, leads to decreased mitochondrial 
function, increased mitochondrial-generated ROS and persistent mitochondrial DNA damage 
(Yakes & Houten, 1997). Low quantities of ROS, specifically superoxide and hydrogen 
peroxide, are reported to be unable to cause mutations in DNA by themselves (Gutteridge, 
1982). However, they can both generate more ROS types, such as OH•, that eventually 
induce DNA damage. Unfortunately, what is not very clear yet is whether ROS are cause, 
consequence or both of mitochondrial dysfunction (Sanz & Bernardi, 2016). 
 
On the other hand, little is known about mitochondrial-mediated redox signalling. This is in 
part due to the fact that mitochondrial ROS are less well regulated that the ones generated by 
NOX enzymes (Dröge, 2002), and therefore, they have not been considered for study over 
the years. The majority of the studies regarding mitochondrial ROS signalling have been 
performed in endothelial cells and they have been suggested as an amplification method to 
sustain ROS signalling outside mitochondria (Zhang & Gutterman, 2006; Harel et al., 2017). 
Some studies suggest that mitochondrial ROS are important in several physiological 
processes, such as the control of insulin release in pancreatic β-cells (Sakai et al., 2003) or 
the elimination of bacteria by macrophages (West et al., 2011). Thus, these observations 
elucidate another area of investigation within mitochondria. 
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1.3.3. Regulation of ROS: antioxidants 
 
Since different amounts of ROS levels have opposite functions as described above, tight 
regulation is critical to their role in cellular signalling. Among these regulatory mechanisms 
which involve repair mechanisms and physical defences, cells also possess an antioxidant 
defence (Valko et al., 2007). Biological antioxidants are referred to any molecule that is able 
to delay or prevent the oxidation of a substrate (Pisoschi & Pop, 2015). This system includes 
enzymatic and non-enzymatic proteins. Superoxide dismutate (SOD) enzymes were the first 
enzymatic antioxidants to be discovered by McCord & Fridovich in 1969 (McCord & 
Fridovich, 1969). Since then, other components of this antioxidant machinery have been 
described. Glutathione (GSH), flavonoids and vitamins (A, C and E) constitute the non-
enzymatic antioxidants (Poprac et al., 2017) whilst enzymatic antioxidants are mainly SODs, 
glutathione peroxidases (GPX), superoxide reductases, glutathione reductases, 
peroxiredoxins (PRX), thioredoxins (TRX) and catalases (Usui, Oveson, et al., 2009; 
Martínez-Fernández de la Cámara et al., 2013; Moloney & Cotter, 2017). This defence 
system is primarily regulated at the transcriptional level. Initial effect of oxidative stress 
involves the activation of several antioxidant transcriptional factors such as the nuclear 
factor kappa B (NF-κB) or the nuclear factor erythroid 2 (NF-E2)-related factor-2 (Nrf2) that 
modulate the expression of antioxidant enzymes (Kaspar et al., 2009; Ray et al., 2012; 
Xiong et al., 2015; Marengo et al., 2016). In fact, SODs are well-known effector proteins of 
Nrf2 (Gwarzo, 2009; Kaspar et al., 2009; Niture et al., 2013). 
 
Under normal physiological conditions, there is a balance between ROS generation and ROS 
scavenging as shown in figure 1.3.6. Unbalance between ROS production and antioxidants 
favouring the first one, implies the occurrence of several diseases as previously described.  
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Figure 1.3.6. Schematic representation of redox homeostasis within cells. When ROS levels 
become excessive from different cellular sources, antioxidants are able to reduce them. SOD: 
superoxide dismutase; GSH: glutathione; GPX: glutathione peroxidase; PRX: peroxiredoxin; TRX: 
thioredoxin; NOX: NADPH oxidase; ER: endoplasmic reticulum; COX: cyclooxygenase; NOS: nitric 
oxide synthase; XO: xanthine oxidase. 
 
Thus, the maintenance of redox homeostasis within cells is essential for their survival. A 
disruption in redox state can happen either by an increase in ROS production or due to a 
reduction in the antioxidant activity (Valko et al., 2007). In the same way, a decrease in 
intracellular ROS levels when they become pathological, can be the consequence of reduced 
ROS generation or increased antioxidant machinery (Cadenas, 1997; Valko et al., 2007; 
Moloney & Cotter, 2017).  
 
Antioxidants are responsible for the degradation of ROS (mainly O2•– and H2O2) to prevent 
oxidative damage. SOD proteins are metalloenzymes that contain copper (Cu2+), zinc (Zn2+) 
or manganese (Mn2+) in their catalytic centre and they are the most important antioxidants 
within this defence mechanism (Fukai & Ushio-Fukai, 2011). Intracellular members of this 
family of proteins are CuZn-SOD (SOD1) and Mn-SOD (SOD2), which are located in the 
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cytosol and mitochondrial matrix, respectively (Zelko et al., 2002). The third member of 
SOD enzymes (SOD3) has not been discussed in this thesis given its extracellular location 
(Pisoschi & Pop, 2015; Moloney & Cotter, 2017). Both SOD1 and SOD2 are in charge of 
turning superoxide anion to H2O2. Given their importance within living organisms, it has 
been reported that knockout (KO) of SOD2 dramatically shortens lifespan of mice and the 
fruit fly, Drosophila melanogaster (Van Remmen et al., 2003). Since OH• and other potent 
oxidants can be formed from H2O2 reduction, enzymes that effectively reduce this molecule 
into water (H2O) are needed. Enzymes that accomplish such function are GPXs, PRX, TRX 
and catalases (Pisoschi & Pop, 2015; Reczek & Chandel, 2015). 
 
In addition, some natural substances also act as antioxidants within the cell (López-Alarcón 
& Denicola, 2013).  For example, ascorbic acid, also known as vitamin C, is able to 
scavenge hydroxyl radical and superoxide anion, preventing the oxidative decay of essential 
biomolecules (Du et al., 2012). Similar properties have also been described in the case of 
vitamin E or α-tocopherol, although vitamin C efficiency has been reported as the greatest 
(Pisoschi & Pop, 2015). Nonetheless, these two vitamins can work together to reduce 
oxidative damage (Du et al., 2012). These two antioxidants can be synthesised by most 
species of plants and animals, but not by humans, even though they have retained an absolute 
requirement for it, consequently, they must be taken in the diet (Benzie, 2000). Thus, our 
antioxidant defence system is widely influenced by nutrition owing to our lack of 
endogenous ascorbic acid and tocopherol production. 
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1.3.4. Antioxidants as therapeutic molecules 
 
In this context, synthetic antioxidants have also been developed. Antioxidants Tiron, a 
vitamin E analog; N-acetyl-L-cysteine (NAC), a precursor of the reduced glutathione; or the 
mitochondria-targeted antioxidant MitoTEMPO; are some examples that will be used 
throughout this thesis. All three have been shown to effectively reduce intracellular ROS 
levels (Curtin et al., 2002; Groeger, Mackey, et al., 2009; Dikalova et al., 2010; Woolley et 
al., 2013; Bordt & Polster, 2014; Taherian et al., 2014; McCarthy & Kenny, 2016; Zhang et 
al., 2017). McCarthy & Kenny demonstrated that targeting mitochondrial ROS through the 
use of  MitoTEMPO, reduced endothelial dysfunction and identified mitochondria-targeted 
antioxidants as potential therapeutic candidates (McCarthy & Kenny, 2016). 
 
Antioxidant supplementation has been used therefore, as a therapeutic approach to combat 
ROS-related diseases. There are evidences in the literature about the success of exogenous 
antioxidant addition in the treatment of some diseases, including RP (Jarrett et al., 2006; 
Komeima et al., 2006, 2007; Valko et al., 2007; Dong et al., 2008; Trachootham et al., 2008; 
Lu et al., 2009; Usui et al., 2009, 2011). Komeima et al. demonstrated that rd1 mice treated 
with a mixture of antioxidants, including vitamin C and E, showed significantly greater cone 
photoreceptor survival and antioxidant-treated mice preserved cone function compared with 
the vehicle-treated controls (Komeima et al., 2006, 2007). In fact, studies from the same 
group show that increased levels of SOD2 and catalase are able to reduce cone cell death in 
rd1 and rd10 mice (Usui et al., 2009, 2011). These results are very promising for the 
treatment of late stages of RP when oxidative stress plays an essential role for the cone 
degeneration (Shen et al., 2005). However, the majority of these strategies have failed so far 
(Nickel et al., 2014; Sanz & Bernardi, 2016). The idea that increased ROS levels require 
their total abolishment through the use of a high amount of antioxidants might be erroneous 
and can be harmful for cells (Sheu et al., 2006). In biological systems, nutrients may become 
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toxins and vice versa in certain circumstances (Bickham & Smolen, 1994). We cannot forget 
low ROS levels play a fundamental role in cell signalling. For this reason, a compound that 
could up-regulate the intracellular antioxidant machinery would be desirable so that cells 
could autoregulate their ROS levels. 
 
In this context, studies from our laboratory demonstrated that the FDA-approved 
Rosiglitazone, a member of the thiazolidinedione family of synthetic peroxisome 
proliferator-activated receptor (PPAR) agonists, was neuroprotective in vitro (661W cells) 
and in vivo (C57 and balb/c mice) against oxidative stress (Doonan et al., 2009). PPARs are 
a family of nuclear hormone receptors that modulate a variety of functions, including anti-
inflammatory activity and resistance to insulin (Shiojiri et al., 2002). This compound was 
able to up-regulate intracellular SOD2 expression to reduce the quantity of ROS produced by 
stress and therefore, enhance photoreceptor survival. 
 
Furthermore, numerous studies have shown that antioxidant activity can be also increased by 
progesterone and synthetic progestin treatment (Capel et al., 1981; Moorthy et al., 2005; 
Bednarek-Tupikowska et al., 2006; Unfer et al., 2015; Zhang et al., 2017). SODs and Nrf2 
protein levels were mainly up-regulated by such treatment. According to this, our laboratory 
demonstrated in 2016 that Norgestrel is able to modulate Nrf2 and SOD2 expression in order 
to reduce oxidative damage in an induced light damage mouse model (Byrne et al., 2016b). 
However, its implication in redox responses in a mouse model of inherited retinitis 
pigmentosa has not yet been described.  
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1.4. Objectives 
 
Retinal diseases have been difficult to treat so far given that little was known about the 
mechanisms that lead to blindness. During the last decades, mutations in a great number of 
genes have been discovered to be responsible for the majority of these diseases. 
Unfortunately, this is not enough. In some cases, such as retinitis pigmentosa, the fact that 
the genetic cause of about 40-50% of RP cases is still unknown (Figure 1.1.6), suggests there 
is still work to be done in the understanding of this disease. This, together with the 
complexity of its genetics, makes the development of individual therapeutic gene-therapies 
an impractical task.  
 
Despite the fact that there is currently no cure for RP, promising approaches have been 
studied. Progesterone has gained attention given its successfully neuroprotective effects on 
the brain and the retina (Gonzalez et al., 2005; Lu et al., 2008; De Nicola et al., 2013; 
Deutsch et al., 2013; Singh & Su, 2013; Allen et al., 2015; Sánchez-Vallejo et al., 2015; 
Schumacher et al., 2016). In this context, we have investigated the progesterone-analogue, 
Norgestrel, as a possible effective treatment for RP since it was discovered to rescue 
photoreceptors in vitro and in vivo (Doonan et al., 2011; Doonan & Cotter, 2012; Byrne et 
al., 2016a, 2016b; Roche & Wyse-Jackson et al., 2016; Wyse Jackson & Cotter, 2016; Wyse 
Jackson et al., 2016a, 2016b; Roche et al., 2017a, 2017b). After all these studies, we have 
understood the great potential of Norgestrel as a therapeutic compound in retinal diseases. 
This is mainly due to its effects on a wide variety of mechanisms, which include anti-
inflammatory properties, the up-regulation of some neurotrophic factors and the reduction of 
harmful reactive oxygen species in an induced light damage model. 
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Since ROS have been described as important signalling molecules as well as toxic (Figure 
1.3.2), the number of studies on such area has increased. The presence of high levels of ROS 
in diseases like RP has been demonstrated to have detrimental consequences (Punzo et al., 
2012; Campochiaro et al., 2015). However, the fact that ROS are able to protect 
photoreceptors against stress was a surprising finding as shown in previous studies from this 
laboratory (Groeger et al., 2009a,2009b, 2012; Bhatt et al., 2010). The aims of this project 
therefore, were firstly to investigate the role that ROS play at different time points in the 
Norgestrel-mediated neuroprotective response in a model of retinitis pigmentosa and their 
relationship with the known components of the Norgestrel-mediated response, such as the 
progesterone receptor PGRMC1 (Wyse Jackson et al., 2016a) and the neurotrophic factor 
bFGF (Doonan et al., 2011; Wyse Jackson & Cotter, 2016). We also wished to examine the 
possible cellular source or sources of such response, given that ROS molecules can be 
produced from different components within the cell (Figure 1.3.3-1.3.5). It has been 
previously shown that NOX enzymes produce pro-survival ROS following serum 
withdrawal in the 661W cone photoreceptor cell line (Groeger et al., 2009a), whereas COX 
proteins are responsible of such increase upon the exogenous treatment of bFGF in the same 
cell line (Farrell et al., 2011).  
 
The final aim of this study was to elucidate whether these molecules are regulated by any 
component of the endogenous antioxidant machinery (Figure 1.3.6) in a model of retinitis 
pigmentosa. Several studies have linked progesterone treatment with an increase in 
antioxidants (Capel et al., 1981; Moorthy et al., 2005; Bednarek-Tupikowska et al., 2006; 
Unfer et al., 2015; Zhang et al., 2017). Our laboratory has also demonstrated that Norgestrel 
is able to increase antioxidants Nrf2 and SOD2 in order to enhance photoreceptor survival in  
the balb/c induced light damage mouse model (Byrne et al., 2016b). However, this has not 
been studied in a genetic model of RP yet. 
  
 
 
 
 
 
 
 
 
 
 
Chapter 2: Material and Methods 
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2.1. Cell culture and treatments 
 
The mouse photoreceptor-derived 661W cell line generously provided by Dr Muayyad Al-
Ubaidi (Department of Biomedical Engineering, Cullen Eye Institute, University of Houston, 
Houston, TX USA) was used in the experiments throughout this thesis (Al-Ubaidi et al., 
2008). To ensure the identity of the cell line as a cone-like cell line, RT-qPCR analysis for 
cone specific blue opsin (Opn1sw) and rod specific rhodopsin was performed as previously 
described (Wyse Jackson et al., 2016a). Expression of Opn1sw confirmed a cone cell 
phenotype (Figure 2.1.1).  
 
Cells were routinely grown in Dulbecco’s modified Eagle’s medium (DMEM, D6429, 
Sigma, Dublin, Ireland), supplemented with 10% foetal bovine serum (FBS, F7524, Sigma) 
and 1% penicillin/streptomycin (P0781, Sigma). Cultures were maintained in a sterile 
humidified atmosphere at 37°C and 5% CO2. 500,000 cells were seeded in a T75 cm2 flask 
(Starstedt AG & Co, Nümbrecht, Germany) and allowed to attach overnight. Cells were then 
washed three times with phosphate-buffered saline (PBS, pH 7.4) prior to addition of 20 µM 
Norgestrel (N2260, Sigma) or the equivalent dimethyl sulfoxide (DMSO, D2650, Sigma) in 
complete (for untreated cells) or serum-free medium. After incubation at indicated times, 
cells were washed in PBS and detached using Accutase solution (A6964, Sigma).  
 
Figure 2.1.1. Validation of 661W cells 
as a cone photoreceptor-like cell line. 
Cone specific blue opsin (Opn1sw) and 
rod specific Rhodopsin mRNA levels 
were analysed by RT-qPCR in 661W 
cone-photoreceptor like cells. Results 
are presented as mean ± SEM. 
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2.2. Reagents, inhibitors and chemicals 
 
Table 2.2.1. List of inhibitors and modulators used throughout the course of this thesis. R&D: 
R&D Systems (Abingdon, UK). 
 
Reagent Function Supplier Cat # Conc. Vehicle Duration 
AG-205 PGRMC1 Sigma A1487 1 µM DMSO 10 min 
NAC Antioxidant Sigma A7250 100 µM H2O 1 h 
Tiron Antioxidant Sigma 172553 1 mM H2O 1 h 
DPI NOX Sigma D2926 1 µM DMSO 1 h 
VAS2870 NOX Sigma SML0273 1 µM DMSO 1 h 
Rotenone Mitochondria R&D 3616 20 µM DMSO 1 h 
Diclofenac COX Sigma D6899 1 µM H2O 1 h 
MitoTEMPO Antioxidant Sigma SML0737 5 µM H2O 1 h 
 
2.3. Primers 
 
Table 2.3.1. List of primers used throughout the course of this thesis. All primers are from Qiagen 
(West Sussex, UK). 
 
Gene Qiagen primer Product size (bp) Ref Seq ID # 
β-Actin QT00095242 149 NM_007393 
GAPDH QT00199388 144 NM_008084 
XM_001003314 
XM_990238 
NM_001001303 
NM_001289726 
HPRT QT00166768 168 NM_013556 
OPN1SW QT00257292 107 NM_007538 
Rhodopsin QT00099022 78 NM_145383 
XM_006505860 
XM_006505861 
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bFGF QT00128135 138 NM_008006 
NOX2 QT00139797 146 NM_007807 
XM_006527565 
NOX4 QT00126042 75 NM_015760 
NM_001285833 
NM_001285835 
XM_006508010 
XM_006508011 
XM_006508012 
SOD1 QT00165039 88 NM_011434 
XM_128337 
SOD2 QT00161707 159 NM_013671 
NRF2 QT00095270 77 NM_010902 
 
2.4. Antibodies 
 
Table 2.4.1. List of antibodies used throughout the course of this thesis. WB: Western Blotting, 
IF: Immunofluorescence. BD: BD Biosciences Europe (Oxford, UK), Novus Bio: Novus Biologicals 
(Abingdon, UK), Santa Cruz: Santa Cruz Biotechnology Inc. (Heidelberg, Germany). 
 
Gene Supplier Cat # Host Dilution WB Dilution IF 
β-Actin Sigma A5441 Mouse monoclonal  1:500 
bFGF BD 610073 Mouse monoclonal  1:250 
NOX2 BD 611414 Mouse monoclonal 1:500 1:200 
NOX4 Novus NB110-
58851 
Rabbit polyclonal 1:500 1:200 
p22phox Santa 
Cruz 
CS9 Mouse monoclonal  1:250 
SOD1 Abcam 13498 Rabbit polyclonal 1:500  
SOD2 Abcam 13533 Rabbit polyclonal 1:500 1:200 
pNrf2 (S40) Abcam 76026 Rabbit monoclonal 1:500 1:100 
Nrf2 Abcam 31163 Rabbit polyclonal 1:500  
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2.5. Flow cytometry 
 
Cells were incubated with the following probes for 30 min at 37°C to measure intracellular 
ROS production: 50 µM 2′,7′-dichlorofluorescein diacetate (DCFH-DA, #35845, Sigma) or 
0.5 µM dihydroethidium conjugate with hexyl triphenylphosphonium (MitoSOX Red, 
M36008, Invitrogen, Eugene, OR, USA). The difference between these probes is that these 
compounds were detected at either FL-1 (530 nm) or FL-2 (585 nm), respectively, by a 
FACScan flow cytometer (Becton Dickinson, Oxford, UK) with ROS production indicated 
by an increase in fluorescence. All samples were gated using the healthy population of the 
untreated sample and 10,000 gated events per sample were collected in the experiments. 
Each experimental condition was performed in technical triplicates and all graphs represent 
data obtained from at least three independent experiments. CellQuest software (Becton 
Dickinson) was used for data analysis. 
 
2.6. MTS assay for cell viability 
 
A colorimetric tetrazolium (MTS) assay (G3580; Cell Titer 96 AQueous One Solution kit, 
Promega, Madison, WI, USA) was used to determine the number of viable cells (Penha et 
al., 2013; Wyse Jackson et al., 2016b). 4,000 cells per well were seeded in 96-well culture 
plates (Starstedt). At 24 h post seeding, cells were washed and treated for times indicated. 20 
μl of MTS solution was added to each well and incubated at 37°C in dark for the same time 
as treatment, leaving it for a maximum of 4 h in the case of 6, 24 or 48 h treatment. The 
quantity of formazan product as measured by absorbance at 490 nm with a Spectramax Plus 
384 microplate reader (Molecular Device Corporation, Sunnyvale, CA, USA) is directly 
proportional to the number of living cells in culture. A further reading at 650 nm was also 
taken from all wells and deducted from the 490 nm readings to account for any cellular 
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debris. Untreated healthy cells were used as the 100% viable control. In all experiments 
entailing inhibitors, a control was carried out for every individual concentration. All samples 
were carried out in 6 replicates in a total of at least three independent experiments. 
 
2.7. Small interfering RNA (siRNA) silencing 
 
661W cells (300,000) were seeded in a T75 flask (Starstedt) the day before transfection. 
Both 25 nM FGF2 siRNA (GS14173, Qiagen) and AllStars Negative Control siRNA 
(Qiagen) were transfected and incubated for 24-48 h before treatment using HiPerFect 
Transfection Reagent (Qiagen). Mock-transfected cells (treated with HiPerFect Transfection 
Reagent alone) were included as a control to determine effects of transfection process 
(Figure 2.7.1) and negative control siRNA (Scrambled) was used to detect non-specific 
changes in phenotype or gene expression. Cells were then washed three times in PBS 
followed by treatment with 20 µM Norgestrel or DMSO (vehicle) in serum-free medium. 
siRNA knockdown was validated by RT-qPCR and immunofluorescence. 
                         
Figure 2.7.1. bFGF expression was not affected by transfection process itself. AllStar Negative 
Control siRNA (Scrambled) and cells treated with transfection reagent only (Mock) confirmed non-
specific effects on bFGF expression produced by the transfection reagent or process, analysed by RT-
qPCR. 
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2.8. Clustered regularly interspaced short palindromic repeats 
(CRISPR) and CRISPR- associated proteins (Cas) system 
 
The clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-
associated protein 9 (Cas9) is a natural RNA-guided DNA nuclease system used by archaea 
and bacteria for the degradation of foreign genetic material (Mojica et al., 2005). Cells were 
seeded (100,000) in antibiotic-free standard growth DMEM (Sigma) in a 6-well culture plate 
(Starstedt) and allowed to attach overnight. 5 µl of UltraCruz® Transfection Reagent (sc-
395739, Santa Cruz) were added to 1 µg of NOX4 Double Nickase Plasmid (m) (sc-424443-
NIC, Santa Cruz) (Figure 2.8.1) and incubate it for 48 h. The addition of transfection reagent 
alone was used as a negative control. After transfection, cells were treated with 1 μg/ml 
puromycin antibiotic for 6 days. Colonies were analysed to confirm complete allelic 
knockouts by immunofluorescence and western blotting. 
           
Figure 2.8.1. Double Nickase Plasmid from Santa Cruz. Double Nickase Plasmid consist of a pair 
of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA 
(gRNA or sgRNA) designed to knockout gene expression with greater specificity than its 
CRISPR/Cas9 KO counterpart. One plasmid in the pair contains a puromycin resistance gene for 
selection and the other, a green fluorescent protein (GFP) marker to visually confirm transfection. 
Modified from Santa Cruz Biotechnology Inc. website. 
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2.9. Mice 
 
All animals were handled and maintained following the Association for Research in Vision 
and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research 
(License Number AE19130/P009). Experiments were approved by University College Cork 
Animal Experimentation Ethics Committee. Both male and female homozygous rd10/rd10 
mice (B6.CXBI-Pde6brd10/J) were used and C57BL/6 mice (C57) were used as controls. Mice 
were supplied by the Biological Services Unit (BSU), University College Cork and were 
humanely euthanised by cervical dislocation (Hwang & Iuvone 2013). 
 
2.9.1. Retinal explant culture 
 
C57BL/6 and rd10 mice were sacrificed at postnatal day 30 (P30) or P15, respectively, by 
cervical dislocation and decapitated. The removed heads were wiped clean with tissue 
soaked in 70% ethanol and transported in to a laminar flow cabinet. From this point on, all 
handling was performed aseptically. Eyes were enucleated (Jin & Xiang 2012) and placed in 
to R16 medium (recipe from P.A. Ekstrom, Wallenberg, Retina Centre, Lund University, 
Lund, Sweden). R16 media is made up by dissolving one vial of R16 Dry Powder Medium 
(basal) (#07490743A, Invitrogen Life Technologies, Paisley, UK) in 800 ml sterile dH2O. 
This solution is made to a complete medium through hormones and vitamins 
supplementation (Table 2.9.1 – all from Sigma), 10% bovine serum albumin and 1% 
penicillin streptomycin (both Sigma) to a final volume of 1,000 ml and will last for up to 
three weeks at 4°C (Caffé et al., 2001). The powder is composed of 41 ingredients that can 
be classified in salts, amino acids, sugars and vitamins (Table 2.9.2). 
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Table 2.9.1. Supplements for R16 medium. Conc. (final concentration). 
 Conc.  Conc.  Conc. 
NaSeO3 30 nM T3 3.1 nM Linoleic 
acid 
3.57 μM 
MnCl2 5 nM Corticosterone 57.7 nM Linolenic 
acid 
3.59 μM 
CuSO4 10 nM Thiamine 
HCL 
8.2 μM L-Cysteine 45 μM 
NaHCO3 33.3 μM Thiocitic acid 0.22 μM Glutathione 3.25 μM 
Biotin 0.4 μM Retinol 0.35 μM Na 
Pyruvate 
454.4 μM 
Ethanolamine 16.4 μM Retinyl 
acetate 
0.3 μM Glutamine 171 μM 
Transferrin   0.125 μM Tocopherol 2.32 μM Vitamin C 567.76 μM 
Progesterone 0.02 μM Tocopherol 
acetate 
3.59 μM Vitamin 
B12 
0.23 μM 
Insulin 3.33 nM     
 
Table 2.9.2. Composition of R16 dry powder medium (basal). Conc. (final concentration). 
 Conc.  Conc.  Conc. 
L-Alanine  23 μM  L-Tyrosine  275 μM  KCl  4.29 mM  
L-Arginine HCl  494 μM  L-Valine  562 μM  MgSO4.7H2O  680 μM  
L-Asparagine 
H2O  
23 μM  Putrescine  180 μM  NaH2PO4.2H2O  610 μM  
L-Cystine Na2  134 μM  L-Carnitine  12.4 μM  Na2HPO4  230 μM  
L-Glycine  292 μM  NaCl  103 mM  ZnSO4.7H2O  0.70 μM  
L-Histidine 
HCl.H2O  
158 μM  Cytidine 5'-
diphospho 
ethanolamine  
1.28 
mg/ml  
Folic acid  6.79 μM  
L-Isoleucine  546 μM  Sodium phenol 
red  
5.0 
mg/ml  
i-Inositol  48.7 μM  
L-Leucine  562 μM  Glucose 19.1 mM  Nicotinamide  22.2 μM  
L-Lysine HCl  585 μM  D(+)-Galactose  83 μM  Hypoxanthine  6.75 μM  
L-Methionine  142 μM  D(+)-Mannose  56 μM  Riboflavine  0.74 μM  
L-Phenylalanine  276 μM  Choline chloride  43.5 μM  Thymidine  0.67 μM  
L-Proline  68 μM  Pyridoxal HCl  13.4 μM  D-calcium 
pantothenate  
5.77 μM  
L-Serine  292 μM  CaCl2.2H2O  1.28 mM  Cytidine 5'-
disphospho choline  
2.56 
mg/ml  
L-Threonine  562 μM  Fe(NO3)3.9H2O  0.17 μM    
L-Tryptophan  55 μM  FeSO4.7H2O  0.68 μM    
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The retina was flat mounted, photoreceptor side down on top of a nitrocellulose insert 
(Millipore, Billerica, MA) in 6-well culture plates (Starstedt) as shown in figure 2.9.1. 
Explants were cultured in 1.2 ml of complete R16 media and treated with 20 µM Norgestrel 
or the equivalent DMSO for the times indicated, using a total number of 4 mice per 
treatment. 
                      
Figure 2.9.1. Schematic representation of retinal explant culture. The lens, anterior segment, 
vitreous body, retinal pigment epithelium and sclera were removed and the retina was flat mounted on 
a nitrocellulose insert and culture with media in 6-well culture dishes. 
 
2.9.2. Norgestrel-supplemented diet 
 
Norgestrel-supplemented and control diets were manufactured by Testdiet (Middlesex, UK). 
Norgestrel was added to the chow at a concentration of 0.05% (500 ppm). Dams of rd10 
Chapter 2 
45 
 
pups were given a Norgestrel-supplemented diet (LabDiet 5053, custom diet containing 
Norgestrel) when the pups were P10 to allow pups to receive Norgestrel in the milk. This 
equates to a daily intake of approximately 80 mg/kg, assuming a 30 g mouse consumes 
around 5 g of food/day. Specialised diet soaked in water was also added to the cage in order 
for pups to receive Norgestrel directly, as soon as they began to eat. These pups were also 
given Norgestrel-supplemented diet post-weaning. With control litters, diet changes were 
replicated with a control diet (LabDiet 5053 control diet). Dams were given regular chow 
once pups were weaned. Supplementation of a mouse maternal diet with neuroprotective 
agents has previously been shown to provide neuroprotection in pups (Loren et al., 2005). 
 
2.9.3. FACS analysis in retinal explants 
 
After treatment, retinal explants were transferred to a trypsin-EDTA solution 0.25% (T4049, 
Sigma) containing 50 μL deoxyribonuclease II from bovine spleen (10,000 units/ml; D8764, 
Sigma) and maintained at 37°C for 15 min. Single-cell suspensions were made by pipetting 
up and down ten times using a P1000 pipette and large debris was allowed to settle. Then, 4 
ml of single-cell suspension were collected and placed into a FACS tube (BD Biosciences) 
and incubated with 50 µM DCFDA for 15 min at 37°C. Fluorescence was measured using a 
Becton-Dickinson FACScan flow cytometer. 
 
2.9.4. Terminal dUTP nick-end Labelling (TUNEL) of fragmented DNA 
 
Localization of dying cells within retinal explants was assessed with the terminal dUTP nick 
end-labelling (TUNEL) assay (Portera-cailliau et al., 1994). Retinal explants were fixed in 
4% paraformaldehyde (PFA) for 30 min followed by cryoprotection in 15% sucrose in 
1xPBS for 1 h, 20% sucrose for 1 h and 30% sucrose overnight, all at 4 °C. Eyes were 
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submerged and frozen in cryochrome (Thermo Scientific, Waltham, US). Sections of 7 μm 
were cut using a cryostat (Leica CM1950; Leica Co., Meath, Ireland) and collected on 
superfrost glass slides (Fisher Scientific, Waltham, US) and stored at −80 °C. Retinal 
sections were then permeabilised with 0.1% Triton X for 2 min followed by incubation with 
terminal deoxynucleotidyl transferase (M1875; Promega, Wisconsin, US) and fluorescein-
12-dUTP (#11373242910; Roche, Lewes, UK) according to manufacturer’s instructions. 
Nuclei were counterstained with Hoechst 33342 (1 μg/mL). Sections were incubated at 37°C 
for 1 h in a humidified chamber. After three washes with PBS, sections were mounted in 
Mowiol and viewed under a fluorescence microscope (LeicaDMLB2). For each treatment, at 
least three animals were used and two fields (x40 magnification) per section of at least three 
different sections were evaluated. Quantification was performed using ImageJ software. Per 
section, three distinct measurements were taken and averaged from at least four sections per 
mouse. 
 
2.9.5. Quantification from immunohistochemical sections 
 
Quantification of outer nuclear layer (ONL) thickness in retinal sections was carried out 
using ImageJ software. Average ONL thickness, where photoreceptor nuclei are located 
through the use of Hoechst 33342, was measured by taking measurements from at least 20 
sections per mouse. Per section, three distinct measurements were taken and averaged. 
Average outer segment length was measured by taking measurements from at least four 
sections per mouse. Three mice were analysed per group. 
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2.10. RNA isolation, cDNA synthesis and quantitative real time 
PCR (RT-qPCR) 
 
Total RNA isolation from 661W cells and retinal explants was performed using an RNeasy 
Mini Kit (Qiagen) following manufacturer’s protocol, including DNase treatment. 1 µg of 
cDNA was synthesised using QuantiTect Reverse Transcription Kit (Qiagen) to perform RT-
qPCR with QuantiTect Primer Assays and QuantiTect SYBR Green PCR Kit (Qiagen) in 96 
well-plates (Roche, West Sussex, UK). Samples were run in triplicates using 
LightCycler®96 Instrument (Roche) whose protocol include: denaturing at 95°C for 10 min, 
followed by 40 cycles of 10 s at 95°C, 10 s at 60°C for and 10 s at 72°C. mRNA values (Ct) 
were obtained using LightCycler®96 Application Software (Roche) and normalised to the 
average of three housekeeping genes (β-Actin, GAPDH and HPRT). Relative changes in 
gene expression were quantified using the comparative Ct (ΔΔCt) method (Livak & 
Schmittgen, 2001). 
 
2.11. Western blot analysis 
 
Whole cell pellets and whole retinas were lysed in RIPA buffer: Tris–HCl (50 mM, pH 7.4), 
1% NP-40, 0.25% sodium deoxycholate, NaCl (150 mM), EGTA (1 mM), sodium 
orthovanadate (1 mM), sodium fluoride (1 mM), cocktail protease inhibitors (#11836153001, 
Sigma) and phenylmethanesulfonyl fluoride (1 mM). Cell and tissue lysates were centrifuged 
at 20,800 g at 4°C for 15 min and 30 min, respectively, and protein concentration was 
measured using a Bradford assay (Bio-Rad, Hercules, CA, USA). 30-50 µg of protein per 
sample were resolved using denaturing 12% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by transfer to nitrocellulose membrane 
(GE10600001, Sigma). Total protein levels were analysed using REVERT total protein stain 
(LI-COR Biosciences, Lincoln, US) as per manufacturer’s instructions and imaged on a LI-
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COR scanner in the 700 channel as previously shown (Roche & Wyse-Jackson et al., 2016, 
Roche et al., 2017a). Membranes were blocked with 5% milk in Tris-buffered saline/0.1% 
Tween-20 (TBS-T) and incubated overnight with primary antibodies in blocking buffer. 
Table 2.4.1 lists the details of all primary antibodies used. Membranes were then probed with 
IRDye® 800 goat anti-mouse (C60726-02, LI-COR) or IRDye® 800 goat anti-rabbit 
(C61103-06, LI-COR) secondary antibody (1:10,000). The signal was detected with an 
Odyssey infrared imaging system. Western blots shown in results are representative images 
of three independent experiments. 
 
2.12. Immunofluorescence 
 
25,000 cells were seeded on glass coverslips overnight in 24-well plates (Starstedt) prior 
treatment. Cell were then washed in PBS and fixed with 4% PFA for 20 min at room 
temperature (RT). Cells and retinal sections were blocked for 30 min at RT with 5% donkey 
serum (containing 0.1% Triton X-100 for permeabilization). Coverslips and sections were 
subsequently incubated with primary antibody in 5% donkey serum overnight at 4°C. Table 
2.4.1 lists the details of all primary antibodies used. After washes, conjugated secondary 
antibody (1:500; donkey anti-mouse/goat/rabbit with either a 488 or 594 fluorescent probe, 
Life Technologies, Eugene, OR, USA) was used for 1.5 h in dark at RT. All coverslips were 
incubated with Hoechst 33342 (1 μg/ml) for 10 min at RT in dark to counterstain the nuclei. 
Coverslips were mounted on to glass slides using Mowiol and imaged using a fluorescent 
microscope Leica DM LB2 (Leica Co., Wetzlar, Germany). 
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2.13. Statistical analysis 
 
Numerical data were compiled using Microsoft Excel (Microsoft, Dublin, Ireland) and 
expressed as mean ± standard error (SEM) from at least three separate experiments, with 
each being performed in triplicate. In the case of two sample comparisons (e.g. vehicle vs. 
Norgestrel), significant differences across groups were assessed with an unpaired Student’s 
t-test using the GraphPad Prism 6 software. One-way ANOVA and post hoc Tukey’s test 
were used for multiple comparisons and post hoc Dunnett’s test was used when groups were 
only compared with one control group (e.g. untreated, scrambled). Differences were 
considered significant if P < 0.05 indicated on the graphs with asterisks (*). 
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3.1. Abstract 
 
Retinitis pigmentosa (RP) is characterised by photoreceptor cell loss. Despite a substantial 
understanding of the mechanisms leading to cell death, an effective therapeutic strategy is 
sought. Our laboratory has previously demonstrated the neuroprotective properties of 
Norgestrel, a progesterone analogue, in the degenerating retina, mediated in part by the 
neurotrophic factor basic fibroblast growth factor (bFGF). In other retinal studies, we have 
also presented a pro-survival role for reactive oxygen species (ROS), downstream of bFGF. 
Thus, we hypothesised that Norgestrel utilises bFGF-driven ROS production to promote 
photoreceptor survival. Using the 661W photoreceptor-like cell line, we now show that 
Norgestrel, working through progesterone receptor membrane complex 1 (PGRMC1); 
generates an early burst of pro-survival bFGF-induced ROS. Using the rd10 mouse model of 
RP, we confirm that Norgestrel induces a similar early pro-survival increase in retinal ROS. 
Norgestrel-driven protection in the rd10 retina was attenuated in the presence of 
antioxidants. This study, therefore, presents an essential role for ROS signalling in 
Norgestrel-mediated neuroprotection in vitro and demonstrates that Norgestrel employs a 
similar pro-survival mechanism in the degenerating retina. 
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3.2. Introduction 
 
Reactive oxygen species (ROS) are constantly being generated under normal conditions in 
aerobic respiration and for many years, they were described simply as destructive by-
products of the process (Chance, 1979; Rhee, 2006; Trachootham et al., 2008; Ray et al., 
2012; Song et al., 2017). ROS accumulation has been associated with neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s disease through induction of cellular damage 
and mitochondrial dysfunction, worsening disease progression (Gandhi & Abramov, 2012; 
Kim et al., 2015). In retinitis pigmentosa (RP), apoptosis has also been related with a high 
production of ROS (Carmody & Cotter, 2000; Tao, 2016; Usui et al., 2009). Despite the fact 
mutations causing RP mainly affect rods leading to apoptosis, cones are subsequently 
affected by such loss. The most accepted causes of cones cell death include the lack of 
growth factors production by rods (Lavail et al., 1992; Corrochano et al., 2008; Doonan et 
al., 2012) and the increase in the toxic ROS levels as a consequence of the loss of rods (Shen 
et al., 2005; Komeima et al., 2006; Usui et al., 2009; Campochiaro & Mir, 2017).  
 
In recent years, however, our understanding of these molecules has changed and they are no 
longer associated solely with damage. It has become increasingly clear that ROS signalling 
is also involved in pro-survival mechanisms. It is acknowledged that ROS function as 
intracellular signalling molecules, when present in moderate quantities (Remacle et al., 
1995; Rhee, 2006; Trachootham et al., 2008; Ray et al., 2012; Moloney & Cotter, 2017). 
Acting as second messengers, ROS often act in a pro-survival capacity (Groeger et al., 
2009b; Trachootham et al., 2008), with previous studies from our group highlighting a 
protective role for ROS in the retina (Bhatt et al., 2010; Farrell et al., 2011; Groeger et al., 
2009a, 2012; Mackey et al., 2008). This is of interest, for the retina has high oxygen 
consumption. In addition, given that the retina is constantly converting light into neural 
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signals (Eshaq et al., 2014), ROS are consequently produced from endogenous sources 
(Bhatt et al., 2010; Kim et al., 2015; Nishimura & Hara, 2016).  
 
Cytokines and neurotrophic factors have shown promise as therapeutics for 
neurodegenerative disorders, due to their neuroprotective effects and their ability to delay 
degeneration in RP and a variety of other diseases (Kolomeyer & Zarbin, 2014). The main 
neurotrophic factors that are produced by the RPE and therefore, are important in the 
treatment of RP are vascular endothelial growth factor (VEGF), pigment epithelium-derived 
factor (PEDF), platelet-derived growth factor (PDGF), ciliary neurotrophic factor (CNTF), 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and basic fibroblast 
growth factor (bFGF) (Kolomeyer & Zarbin, 2014). Several studies suggest that these 
molecules can modulate the production of ROS in different systems (Ilatovskaya et al., 2013; 
Kirkland et al., 2007; Lo & Cruz, 1995), including various cell types of the retina (He et al., 
2014; Zheng et al., 2009). Indeed, we have shown that bFGF is linked to ROS synthesis in 
the retina (Groeger et al., 2012; O’Driscoll et al., 2008). More recent studies from our group 
have presented the synthetic progesterone, Norgestrel, as a potential therapeutic for retinal 
degeneration (Byrne et al., 2016a, 2016b; Doonan et al., 2011; Roche & Wyse-Jackson et 
al., 2016, Wyse-Jackson & Cotter, 2016; Roche et al., 2017a, 2017b). Working primarily 
through activation of progesterone receptor membrane complex 1 (PGRMC1) (Wyse 
Jackson et al., 2016a, 2016b), we have shown Norgestrel’s protective effects are dependent 
on bFGF production.  
 
Therefore, in light of the above studies, we hypothesised that Norgestrel utilises bFGF-
driven ROS production to promote photoreceptor survival. The current study was designed 
to examine the role of ROS in Norgestrel-mediated neuroprotection. 
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3.3. Results 
 
3.3.1. Serum deprivation induces a pro-survival production of ROS in 
661W cells 
 
The cessation of trophic support has been related with the death of cones after rods die as a 
consequence of mutations in RP (Komeima et al., 2006, 2008; Finnegan et al., 2010; 
Athanasiou et al., 2018). Thus, serum starvation (SS) has been used as a model of cellular 
stress. It has been reported that ROS are produced as a consequence of serum deprivation in 
the cone-photoreceptor 661W cell line (Mackey et al., 2008) and other cell lines (Li et al., 
2013). In order to corroborate this, cells were incubated with 50 µM 2’,7’-dichlorofluorescin 
diacetate (DCFDA, Figure 3.3.1), one of the most commonly used probes for detecting 
intracellular ROS levels (Eruslanov & Kusmartsev, 2010; Karlsson et al., 2010). For the 
flow cytometry analyses, untreated 661W cells (UT) were used to gate the population used in 
all subsequent experiments (Figure 3.3.2).  
   
According with the results obtained by Mackey et al. and Li et al., SS produces a rapid 
increase in the ROS production in vitro (Mackey et al., 2008; Li et al., 2013). A significant 
increase in ROS was observed in this study at 30 min and up to 1 h in serum-starved cells 
compared to vehicle control (one-way ANOVA, serum starvation effect, F 4,39 = 66.91, P < 
0.0001; Dunnett’s post hoc test, 30 min: P < 0.0001; 1 h: P = 0.003; n = 3 per group; Figure 
3.3.3). 
Figure 3.3.1. DCFDA was used to detect intracellular ROS 
levels. Different concentrations were analysed by flow 
cytometry in order to find an optimal peak of fluorescence. Y-
axis represents cell counts, x-axis (logarithmic scale) measures 
the level of fluorescence. 50 µM was used in all subsequent 
experiments. 
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Figure 3.3.2. Untreated 661W cells (UT) were used to gate the population analysed in all 
subsequent experiments. 
 
 
 
 
 
 
    
 
 
 
 
Figure 3.3.3. Serum starvation increases ROS levels in 661W cells. DCFDA probe was used to 
detect ROS levels by flow cytometry and plotted on a histogram. Y-axis represents cell counts, x-axis 
(logarithmic scale) measures the level of fluorescence. A shift to the right along the x-axis represents 
an increase in DCFDA fluorescence and hence ROS levels. Geomeans were graphed compared to UT 
cells (Dunnett’s post hoc test, comparing all time points to the UT control). Cells following serum 
starvation (SS) increased ROS levels at 30 min and up to 1 h. Results are presented as mean ± SEM 
from three independent experiments. Asterisks indicate significant difference (** P < 0.01, **** P < 
0.0001). 
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Increased ROS production has been described to be  related to autophagy, a mechanism that 
can  isolate damaged organelles and cellular biomolecules  to subsequently  increase in the 
survival of the remaining cells, in some cell types (Li et al., 2013). Interestingly, Mackey et 
al. also demonstrated that the increase in ROS levels activates the protein kinase B (Akt) 
survival pathway (Mackey et al., 2008). Therefore, in order to establish whether this burst of 
ROS is beneficial to 661W cells in this study, different concentrations of the antioxidants 
sodium 4,5-dihydroxybenzene-1,3-disulfonate (Tiron) or N-acetyl-L-cysteine (NAC) were 
used to inhibit the increase in ROS (Taherian et al., 2014). 1mM and 100 µM of Tiron and 
NAC, respectively, showed no cell death compared with the vehicle (Figure 3.3.4(i)) and 
significantly decreased ROS levels (independent samples t-test, Tiron: t 16 = 7.313, P < 
0.0001; NAC: t 16 = 2.324, P = 0.0336, n = 3 per group; Figure 3.3.4(ii) and Figure 3.3.5A).  
 
Figure 3.3.4. Tiron and NAC decrease ROS formation in 661W cells. Dose-response curve 
measuring cell viability (i) and DCFDA fluorescence (ii) of 661W cells treated with increasing 
concentrations of antioxidants, Tiron (A) and NAC (B) (t-test comparing individual treatments to their 
vehicle control) for 1 h in completed media. FACS analysis: Y-axis represents cell counts, x-axis 
(logarithmic scale) measures the level of fluorescence. A shift to the right along the x-axis represents 
an increase in DCFDA fluorescence and hence ROS levels. Geomeans were graphed (t-test comparing 
individual treatments to their timed vehicle control). Results are presented as mean ± SEM from three 
independent experiments. Asterisks indicate significant difference (* P < 0.05**, P < 0.01, **** P < 
0.0001). 
Chapter 3 
57 
 
Cells pre-treated with vehicle and maintained in serum-free media for 30 min displayed a 
decrease in cellular viability compared to untreated cells (one-way ANOVA, serum 
starvation effect, F 3,88 = 30.63, P = 0.0008; Tukey’s HDS post hoc test, P < 0.0001; n = 4 
per group; Figure 3.3.5B). Pre-treatment with Tiron or NAC resulted in a further decrease in 
cell viability (Tukey’s HDS post hoc test, Tiron: P < 0.0001; NAC: P < 0.0001). These data 
suggest that the presence of ROS is essential for cells to survive normally, given that cells 
treated with Tiron or NAC showed even more cell death than cells treated with vehicle 
control only (Tukey’s HDS post hoc test, Tiron: P = 0.004; NAC: P = 0.0411), corroborating 
previous studies (Mackey et al., 2008; Groeger, et al., 2009a, 2009b; Farrell et al., 2011). 
                                  
Figure 3.3.5. Serum deprivation induces a pro-survival production of ROS in 661W cells. (A) 
Antioxidants Tiron and NAC decreased the ROS production in 661W cells (t-test comparing 
individual treatments to their vehicle control). Y-axis represents cell counts, x-axis (logarithmic scale) 
measures the level of fluorescence. (B) Changes in cell viability were measured by the MTS assay and 
graphed as a percentage of 100% viable UT control (Tukey’s HDS post hoc test for multiple 
comparisons). SS (vehicle) decreased cell viability at 30 min. Stressed cells pre-treated with 
antioxidants showed a further decrease in survival compared with the vehicle. Results are presented as 
mean ± SEM from three independent experiments. Asterisks indicate significant difference (* P < 
0.05, ** P < 0.01, **** P < 0.0001). 
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3.3.2. Norgestrel induces a pro-survival production of ROS in serum-
deprived 661W cells 
 
Previous studies have documented the protective effects of progesterone in the retina (Allen 
et al., 2015; Sánchez-Vallejo et al., 2015), including the progesterone analogue Norgestrel in 
the stressed 661W photoreceptor-like cell line (Doonan et al., 2009, 2011; Wyse Jackson & 
Cotter, 2016). However, ROS implication in this response has not been studied yet. Here, we 
sought to understand the role that ROS play in the Norgestrel-mediated protection. By means 
of flow cytometry analyses, Norgestrel significantly increased ROS levels at 30 min 
following serum-starvation compared to vehicle control (independent samples t-test, t 18 = 
3.277, P = 0.0042; n = 3-4 per group; Figure 3.3.6A). The use of DMSO as vehicle also 
increased ROS levels at all time points compared with the UT cells (Figure 3.3.6A), possibly 
through its anti-inflammatory effects as previously described (Elisia et al., 2016). For this 
reason, these serum starved samples are not comparable with samples in figure 3.3.3.  
 
Norgestrel has been demonstrated to protect 661W cells against the cell death produced by 
24 h following the stress caused by nitric oxide donor sodium nitroprusside (SNP) or SS 
(Doonan et al., 2011; Wyse Jackson & Cotter, 2016). In this study, MTS assay was used to 
analyse cellular viability and proliferation with Norgestrel over time. Norgestrel enhanced 
cell survival at all time points studied (independent samples t-test, 30 min: t 34 = 3.503, P = 
0.0015; 1 h: t 34 = 3.805, P = 0.0006; 3 h: t 34 = 4.182, P = 0.0002; 6 h: t 34 = 2.644, P = 
0.0105; n = 3-4 per group; Figure 3.3.6B), suggesting that ROS production is linked to an 
increase in cell survival.  
 
In order to test this hypothesis, the antioxidants Tiron and NAC were again used to block the 
increase in ROS 1 h prior to Norgestrel treatment. Cells pre-treated with vehicle (H2O) were 
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protected by Norgestrel following 30 min of serum deprivation (independent samples t-test, t 
33 = 3.002, P = 0.0051; n = 3 per group; Figure 3.3.6C). However, Norgestrel was no longer 
protective in the presence of the antioxidants compared with the vehicle only (Tiron: t 40 = 
3.916, P = 0.0003; NAC: t 41 = 6.204, P < 0.0001; n = 4 per group). Thus, the protective 
effects of Norgestrel in serum-deprived 661W cells are dependent on ROS production. 
 
Figure 3.3.6. Norgestrel induces a pro-survival production of ROS in serum-deprived 661W 
cells. (A) FACS analysis of 661W cells treated with 20 µM Norgestrel or vehicle control (DMSO) 
following SS. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence and 
hence ROS levels. Geomeans were graphed compared to UT cells (t-test comparing individual 
Norgestrel treatments to their timed vehicle control). ROS production was increased by Norgestrel at 
30 min. (B) MTS assay showed Norgestrel enhanced cell survival in all time points studied compared 
with the vehicle control (t-test comparing individual Norgestrel treatments to their timed vehicle 
control). (C) Antioxidants were used to reduce ROS production following serum starvation. 
Norgestrel was able to rescue cells pre-treated with the vehicle (H2O), whereas Norgestrel was no 
longer protective in the presence of antioxidans (t-test comparing individual treatments). Results are 
presented as mean ± SEM from three independent experiments. Asterisks indicate significant 
difference (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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3.3.3. Norgestrel accelerates the early survival response in stressed 661W 
cells 
 
The early ROS-mediated response which takes place in the first minutes after serum 
deprivation has been documented to induce cell survival (Groeger et al., 2009a; Mackey et 
al., 2008). Furthermore, according with some studies, the exogenous addition of hydrogen 
peroxide (H2O2) can activate the transcription factor nuclear factor kappa B (NF-κB) 
(Schreck et al., 1991; Kaul & Forman, 1996; Forman, 2007) and prolongs the activation of 
the survival Akt pathway, delays the activation of the cell death cascade and therefore, 
enhances survival of 661W cells (Mackey et al., 2008). In this context, Norgestrel-mediated 
neuroprotection in 661W cells also involves the increase in the levels of pro-survival ROS as 
seen in figure 3.3.6. Thus, to examine the effects of Norgestrel on this early pro-survival 
burst of ROS compared with the response produced by the serum deprivation itself, cells 
were serum-starved and treated with either Norgestrel or vehicle (DMSO) for shorter time 
points of 1-20 min. Norgestrel treatment increased ROS levels from 5 min (independent 
samples t-test, t 16 = 7.748, P < 0.0001; n = 3 per group; Figure 3.3.7A) compared to serum 
starved control (vehicle).  
 
The study of the whole response over time showed that increased levels of ROS were 
maintained up to 30 min following Norgestrel treatment (10 min: t 16 = 2.172, P = 0.0463; 
20 min: t 16 = 3.665, P = 0.0021; 30 min: t 18 = 3.277, P = 0.0042; n = 3 per group; Figure 
3.3.7B) but no difference in response was detected beyond this point. These data show that 
Norgestrel enhances the early pro-survival response of increased ROS levels in serum-
starved 661W cells in a quicker manner compared with the serum-starved control, 
accelerating the pro-survival signalling to enhance cell survival. 
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Figure 3.3.7. Norgestrel accelerates the early survival response in stressed 661W cells. (A) 
Various time points up to 30 min were analysed following Norgestrel treatment by flow cytometry 
and plotted on a histogram. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level 
of fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence 
and hence ROS levels. Geomeans were graphed compared to UT cells (t-test comparing individual 
Norgestrel treatments to their timed vehicle control). Norgestrel induced a significantly higher 
response compared with vehicle from 5 min. (B) Timeline of ROS levels in response to Norgestrel in 
stressed 661W cells. Norgestrel stimulated increased ROS production from 5 min and up to 30 min 
when levels reverted to normal. Results are presented as mean ± SEM from three independent 
experiments. Asterisks indicate significant difference (* P < 0.05, ** P < 0.01, **** P < 0.0001). 
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3.3.4. Norgestrel signals through PGRMC1 to mediate redox signalling 
 
Previous studies have shown that PGRMC1, a membrane-localised progesterone receptor, is 
responsible for the neuroprotective actions of progesterone and Norgestrel (Cahill, 2007; 
Wyse Jackson et al., 2016a). Therefore, FACS analysis was performed in order to investigate 
its role in ROS production. The specific inhibitor AG-205 was used to block PGRMC1 in 
stressed 661W cells in a concentration that does not affect cellular viability (Wyse Jackson et 
al., 2016b). The burst of ROS produced by Norgestrel (independent samples t-test, t 16 = 
4.096, P = 0.0008; n = 3 per group; Fig. 3.3.8) was abrogated when PGRMC1 was inhibited 
as detected by decreased DCFDA fluorescence intensity (t 16 = 0.9794, P = 0.342; n = 3 per 
group), suggesting the importance of the receptor in this response. 
                                 
Figure 3.3.8. Norgestrel signals through progesterone receptor membrane component 1 
(PGRMC1) to mediate redox signalling. 661W cells were treated with the PGRMC1 specific 
inhibitor AG-205 prior to serum starvation for 30 min and Norgestrel treatment. DMSO was used as 
vehicle control. DCFDA probe was used to detect ROS levels by flow cytometry and plotted on a 
histogram. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. 
A shift to the right along the x-axis represents an increase in DCFDA fluorescence and hence ROS 
levels. Geomeans were graphed compared to UT cells (t-test comparing individual treatments). 
PGRMC1 inhibition abrogated the burst of ROS produced by Norgestrel. Results are presented as 
mean ± SEM from three independent experiments. Asterisks indicate significant difference (NS not 
significant, *** P < 0.001). 
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3.3.5. Inhibition of bFGF abrogates the Norgestrel-induced increase in 
ROS in serum-starved 661W cells 
 
We have previously shown that Norgestrel elicits its neuroprotective effects in 661W cells at 
least in part by up-regulating the growth factor, basic fibroblast growth factor (bFGF) 
(Doonan et al., 2011; Wyse Jackson & Cotter, 2016). In other studies, addition of bFGF led 
to increased ROS production in the photoreceptors of retinal explants (O’Driscoll et al., 
2007, 2008; Farrell et al., 2011). We therefore sought to establish if Norgestrel-induced 
increase in ROS was dependent on bFGF activity. Firstly, we show that serum starvation 
alone in 661W cells does not up-regulate bFGF expression (one-way ANOVA, serum 
starvation effect, F 4,51 = 1.924, P = 0.1206; n = 3-4 per group; Figure 3.3.9(i)). However, 
when treated with Norgestrel, 661W cells displayed increased expression of bFGF following 
30 min of SS (independent samples t-test, t 21 = 2.844, P = 0.0097; n = 4 per group; Figure 
3.3.9(ii)).  
 
Figure 3.3.9. Norgestrel up-regulates bFGF expression in serum-starved 661W cells. bFGF 
mRNA levels were measured  in 661W following SS ((i), Dunnett’s post hoc test, comparing all time 
points to the UT control)  and treated with Norgestrel over time by RT-PCR ((ii), t-test comparing 
individual Norgestrel treatments to their timed vehicle control). bFGF up-regulation only took place in 
the presence of Norgestrel. Results are presented as mean ± SEM from three independent experiments. 
Asterisks indicate significant difference (NS not significant, ** P < 0.01). 
 
To understand whether bFGF is involved in the redox response produced by Norgestrel at 30 
min, siRNA was used to knockdown bFGF over 48 h. A significant reduction in bFGF 
expression was verified through RT-qPCR (one-way ANOVA, time of incubation siRNA, F 
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2,15 = 65.95, P < 0.0001; Dunnett’s post hoc test, 24 h: P = 0.0002; 48 h: P < 0.0001; n = 2 
per group; Figure 3.3.10A) and by immunofluorescence (Figure 3.3.10B). 
 
Figure 3.3.10. Successful siRNA knockdown of bFGF. bFGF levels detected by RT-PCR (A) and 
immunofluorescence (B) in 661W cells transfected with siRNA targeted against bFGF. Scale bar 30 
µm. Hoechst staining reveals cell nuclei. Results are presented as mean ± SEM from three 
independent experiments. Asterisks indicate significant difference  (*** P < 0.001, **** P < 0.0001). 
 
siRNA-treated cells were then serum-starved and treated with either DMSO (vehicle) or 20 
µM Norgestrel for 30 min before ROS were measured using DCFDA. Norgestrel was unable 
to increase ROS when bFGF was knocked down, suggesting that this response is bFGF-
dependent (independent samples t-test, t 37 = 0.2197, P = 0.8277; n = 5 per group; Figure 
3.3.11). 
 
Figure 3.3.11. Inhibition of bFGF abrogates Norgestrel-induced increases in ROS in serum-
starved 661W cells. FACS analysis of cells transfected with bFGF siRNA treated with DMSO or 
Norgestrel. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. 
A shift to the right along the x-axis represents an increase in DCFDA fluorescence and hence ROS 
levels. Geomeans were graphed compared to UT cells (t-test comparing individual treatments). bFGF 
knockdown prevented the increase of ROS produced by Norgestrel (scrambled vs siRNA). Results are 
presented as mean ± SEM from three independent experiments. Asterisks indicate significant 
difference (NS not significant, *** P < 0.001). 
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3.3.6. Norgestrel induces an increase in ROS production in 
photoreceptors ex vivo 
 
Our understanding of RP and the development of therapeutic strategies have improved due to 
the use of several animal models of this disease. One of such models is the rd10 mouse, 
which is a good approach for studying autosomal recessive RP (Barhoum et al., 2008; Rivas 
& Vecino, 2009; Arroba et al., 2011; Roche et al., 2016; Campochiaro & Mir, 2017). Results 
from this study thus far demonstrate that Norgestrel, through bFGF, utilises ROS signalling 
to promote neuronal survival of the 661W cell line. Therefore, we next sought to evaluate the 
contribution of ROS to Norgestrel-mediated protection of photoreceptors in the retina. Using 
retinas from rd10 mice we prepared single-cell suspensions as previously described, to be 
used for FACS analysis (Byrne et al., 2016b). In order to confirm the photoreceptor 
population, we compared a P30 C57 wild-type retinal preparation to that of a P30 rd10. The 
rd10 retina has undergone extensive photoreceptor loss by P30 (Roche et al., 2016). Thus, 
since the C57 wild-type retina presented a population of cells that were absent from the rd10 
retina (Figure 3.3.12), we understood this population to represent photoreceptors. This 
method of gating rd10 photoreceptors has previously been published (Byrne et al., 2016b).  
                     
Figure 3.3.12. Gated population used in the experiments performed by FACS. Photoreceptor 
population was gated using P30 C57BL/6 wild type (i) and rd10 retinas (ii), as this population was 
absent from rd10 retinas. 
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We subsequently evaluated the effects of Norgestrel on single-cell suspensions from P15 
rd10 retinas, a suitable time point as photoreceptors have initiated cell death mechanisms but 
photoreceptor loss is not yet apparent (Roche et al., 2016; Roche & Wyse-Jackson et al., 
2016). Retinal explants were treated with either 20 µm Norgestrel or DMSO (vehicle) over 3 
hours and analysed for changes in photoreceptor ROS production. The population of 
photoreceptors from rd10 retinas treated with Norgestrel showed an increase in ROS 
production compared to those treated with vehicle control, at 30 min and 1 h (independent 
samples t-test, 30 min: t 22 = 2.486, P = 0.021; 1 h: t 22 = 3.723, P = 0.0013; n = 4 per group; 
Figure 3.3.13). 
                                 
Figure 3.3.13. Norgestrel increases ROS production in photoreceptors ex vivo. FACS analysis of 
photoreceptors using single cell suspensions from P15 rd10 retinas. Y-axis represents cell counts, x-
axis (logarithmic scale) measures the level of fluorescence. A shift to the right along the x-axis 
represents an increase in DCFDA fluorescence and hence ROS levels. Geomeans were graphed and 
individual Norgestrel treatments were compared to their timed DMSO vehicle control (t-test 
comparing individual treatments). Norgestrel up-regulated ROS levels at 30 min and up to 1 h. Results 
are presented as mean ± SEM from three independent experiments. Asterisks indicate significant 
difference (* P < 0.05, ** P < 0.01). 
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Retinal explants have been used in the past to study Norgestrel effects on cell death over 24 
h assessed by TUNEL assay (Doonan et al., 2011; Roche et al., 2017a, 2017b; Wyse Jackson 
& Cotter, 2016; Wyse Jackson et al., 2016a). However, shorter time points to elucidate 
Norgestrel effects have not been utilised yet. Interestingly, Norgestrel-mediated reduction in 
photoreceptor cell death was only evident at 1 h, as assessed by the TUNEL assay 
(independent samples t-test, independent samples t-test, 30 min: t 20 = 0.1706, P = 0.8663; 1 
h: t 18 = 3.211, P = 0.0068; n = 3 per group; Figure 3.3.14). Therefore, we observed an 
increase in ROS prior to the Norgestrel-mediated protection of photoreceptors. 
      
 
 
Figure 3.3.14. Norgestrel reduces photoreceptor cell death in retinal explants. Apoptosis of 
retinal cells in the outer nuclear layer (ONL) was detected by TUNEL (green) at 30 min (i) and at 1 h 
(ii). Norgestrel reduced TUNEL-positive staining in the central rd10 retina after 1 h treatment, but not 
at 30 min compared with the vehicle control (t-test comparing individual treatments). Scale bar 50 
µm. Hoechst staining reveals cell nuclei. Results are presented as mean ± SEM from three 
independent experiments. Asterisks indicate significant difference (NS not significant, ** P < 0.01). 
 
In order to determine if this increase in photoreceptor ROS is necessary for Norgestrel-
mediated protection in rd10 explants, we utilised the antioxidant Tiron. C57 explants pre-
treated with 1mM Tiron showed a significant decrease in their basal levels of ROS compared 
to H2O vehicle control, as indicated by flow cytometry. This suggests that 1 mM Tiron is a 
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suitable method by which to abrogate ROS production in retinal explants (independent 
samples t-test t 16 = 3.337, P = 0.0042; n = 3 per group; Figure 3.3.15A). P15 rd10 explants 
were consequently pre-treated for 1 h with 1 mM Tiron before 1 h treatment with Norgestrel 
or DMSO (vehicle). TUNEL assay revealed that Norgestrel could no longer protect rd10 
explants from photoreceptor cell death over 1 h, when ROS production was inhibited 
through Tiron antioxidant (independent samples t-test t 29 = 0.06121, P = 0.9516; n = 4 per 
group; Figure 3.3.15B). This supports our findings in 661Ws that Norgestrel initiates a pro-
survival burst of ROS, assisting in the survival of retinal photoreceptor cells. 
        
Figure 3.3.15. Norgestrel induces a pro-survival production of ROS in photoreceptors ex vivo. 
(A) FACS analysis of photoreceptors from C57BL/6 retinas. Treatment with antioxidant Tiron for 1 h 
reduced significantly ROS levels. (B) TUNEL assay in ONL of P15 rd10 retinas. Norgestrel was not 
able to reduce TUNEL-positive staining after 1 h treatment in the presence of Tiron. Scale bar 50 µm. 
Hoechst staining reveals cell nuclei. Results are presented as mean ± SEM from three independent 
experiments.  Asterisks indicate significant difference (NS not significant, ** P < 0.01). 
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3.4. Discussion 
 
Studies investigating the role of reactive oxygen species in cell survival have uncovered 
contrasting findings (Burdon, 1995; Rhee, 2006; Trachootham et al., 2008; Gough & Cotter, 
2011; Ray et al., 2012; Schieber & Chandel, 2014; Leveillard & Sahel, 2016; Moloney & 
Cotter, 2017). These molecules are thought to be in part responsible for the death of cones 
after the loss of rods in RP (Shen et al., 2005; Komeima et al., 2006, 2008; Barhoum et al., 
2008; Usui et al., 2009; Kim et al., 2015; Campochiaro & Mir, 2017). On the other hand, 
their role as signalling molecules to enhance cell survival has also been well studied during 
the last decades (Remacle et al., 1995; Abid et al., 2000; Lee, Yu, et al., 2003; Rhee, 2006; 
D’Autréaux & Toledano, 2007; Trachootham et al., 2008; Bae et al., 2011; Finkel, 2011; 
Gough & Cotter, 2011; Ray et al., 2012; Marinho et al., 2014; Schieber & Chandel, 2014; 
Brandes et al., 2014b; Tao, Geng, et al., 2016; Battistelli et al., 2016; Brand, 2016; Harel et 
al., 2017). In the retina, our group has previously documented both protective and 
detrimental properties of ROS signalling (Carmody et al., 1999; Sanvicens et al., 2004; 
Sanvicens & Cotter, 2006; Carmody & Cotter, 2007; Mackey et al., 2008; O’Driscoll et al., 
2008; Groeger et al., 2009a; Bhatt et al., 2010; Farrell et al., 2011; O ’Driscoll et al., 2011; 
Groeger et al., 2012; Byrne et al., 2016b).  
 
Under normal conditions, cells maintain a delicate balance between ROS production and 
elimination through many mechanisms. Thus, any alteration that disrupts this redox 
homeostasis can cause an increase of intracellular ROS and thus, oxidative stress. In this 
way, ROS become cytotoxic under specific conditions. For instance if an increased 
production occurs at the wrong time or place, if the signal is too strong or if it persists for 
long periods of time (Nathan & Cunningham-Bussel, 2013; Trachootham et al., 2008). 
Several therapeutic strategies of the retina have utilised this system: increasing antioxidant 
machinery in order to reduce oxidative stress and increase survival (Komeima et al., 2006, 
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2007; Lu et al., 2009; Taherian et al., 2014). Komeima et al. proved that injections in rd1 
and rd10 mice, both models of RP, with a cocktail of antioxidant substances between P18 
and P35, significantly reduced oxidative damage markers which resulted in an increase in a 
higher cone density and improved their functionality in the retina (Komeima et al., 2006, 
2007). Indeed, studies from our group establish that Norgestrel can reduce the damaging 
ROS levels produced after 24-48 h light exposure. This enhances neuroprotection in the 
balb/c induced light damage mouse model of retinal degeneration, and involves the up-
regulation of the antioxidant transcription factor NF-E2-related factor-2 (Nrf2) (Byrne et al., 
2016b). Norgestrel, therefore, is able to act as an antioxidant when ROS levels become toxic 
to the retina after the damage produced by a long exposure to light. 
 
Nevertheless, to state that these molecules are always damaging would be an 
oversimplification, for ROS can have opposing effects under different physiological 
conditions. In fact, under normal physiological conditions, moderate levels of ROS 
participate in many biological processes as second messengers or intermediates (Holmström 
& Finkel, 2014; Remacle et al., 1995; Rhee, 2006). For this reason, the implication of ROS 
in survival responses has gained attention. Previous studies from our laboratory have shown 
that hydrogen peroxide acts as a second messenger in intracellular signalling pathways 
inducing cell survival in 661W cells and C57BL/6 retinal explants (Groeger et al., 2009a; 
2009b; Mackey et al., 2008). The current study also reveals how these molecules have a 
survival nature in the first 30 min of 661W serum deprivation (Figure 3.3.3). In light of 
previous and current findings, it therefore appears that ROS signalling can play a protective 
or detrimental role depending on the intensity, cellular location and period of the event. 
 
In 2009, the synthetic progesterone Norgestrel was found by this group to possess 
neuroprotective effects due to a study in the cone photoreceptor 661W cell line (Doonan et 
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al., 2009, 2011). Since then, Norgestrel-mediated neuroprotection has been demonstrated in 
different neuronal/retinal degeneration models (Doonan et al., 2011; Byrne et al., 2016a, 
2016b; Roche & Wyse-Jackson et al., 2016; Wyse Jackson & Cotter, 2016; Wyse Jackson et 
al., 2016a, 2016b; Roche et al., 2017a, 2017b). In those studies, Norgestrel has been 
involved in many responses in order to enhance cell survival. Such responses mainly consist 
of the up-regulation of some neurotrophic factors (Doonan et al., 2011; Byrne et al., 2016a; 
Wyse Jackson & Cotter, 2016), the attenuation of inflammation and gliosis processes 
produced by RP in the rd10 retina (Roche & Wyse-Jackson et al., 2016; Roche et al., 2017a, 
2017b) and the reduction of harmful ROS levels in a light damage model (Byrne et al., 
2016b).  
 
However, its mechanism of action at earlier time points is not well understood yet. The 
importance of the current study, therefore, was to comprehend the role that ROS play in an 
earlier response following Norgestrel treatment. Norgestrel, acting through the progesterone 
receptor PGRMC1 (Figure 3.3.8) (Wyse Jackson et al., 2016a), increases some neurotrophic 
factors expression such as bFGF (Figure 3.3.11) (Wyse Jackson & Cotter, 2016) and the 
leukemia inhibitory factor (LIF) (Byrne et al., 2016a), resulting in an early up-regulation of 
ROS levels in 661W cells (Figure 3.3.6 and 3.3.7). In fact, the relationship between 
progesterone-mediated neuroprotection and the stimulation of growth factors production is 
not surprising. Progesterone has been stablished to be protective due to the up-regulation of 
growth factors such as bFGF or the brain-derived neurotrophic factor (BDNF) in multiple 
neurodegenerative models (Campochiaro et al., 1996; Peluso & Pappalardo, 1999; Gonzalez 
Deniselle et al., 2003; Peluso, 2003; Gonzalez et al., 2005; Yu et al., 2010; Espinosa-García 
et al., 2014; Qin et al., 2015). 
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Decreasing ROS production using two different antioxidants (Tiron and NAC) revealed the 
survival nature of these molecules (Figure 3.3.5 and 3.3.6). Tiron, a vitamin E analog which 
acts as a superoxide scavenger, and NAC, being a precursor of the reduced glutathione, have 
been previously used as antioxidant compounds (Curtin et al., 2002; Groeger, Mackey, et al., 
2009; Taherian et al., 2014). This result highlights the importance of moderate levels of ROS 
as intermediate molecules in the Norgestrel-mediated signalling. Future studies will 
investigate the downstream pathways stimulated by ROS up-regulation, leading to enhanced 
survival.  
 
Results from the 661W photoreceptor-like cell line so far (Figure 3.3.1-3.3.11) suggested 
that Norgestrel’s neuroprotective role in the retina involved an up-regulation of pro-survival 
ROS. In order to substantiate this claim, we next employed the rd10 mouse model of retinitis 
pigmentosa. The rd10 mouse model represents a very useful tool when it comes to study 
retinal neurodegeneration, allowing for development of potential therapeutics (Pittler & 
Baehr, 1991; Barhoum et al., 2008; Samardzija et al., 2012; Han et al., 2013; Cuenca et al., 
2014; Roche et al., 2016). Through the use of rd10 mice, our group has discovered the 
mechanisms behind the Norgestrel-mediated neuroprotection ex vivo and in vivo (Doonan et 
al., 2011; Roche & Wyse-Jackson et al., 2016; Roche et al., 2017a, 2017b). Roche & Wyse-
Jackson et al. showed that mice who were given a Norgestrel-supplemented diet showed 
significant retinal protection compared with the control diet. This was in part achieved by the 
anti-inflammatory properties of Norgestrel, which attenuates microglial activity in the 
diseased retina (Roche & Wyse-Jackson et al., 2016) and reduces the gliosis produced by the 
crosstalk between microglia and Müller glial cells (Roche et al., 2017b). These studies 
demonstrate the effectiveness of Norgestrel and its capacity to produce a wide response 
within the retina to enhance neuroprotection. However, there is little information on the role 
of ROS in the Norgestrel-mediated response in the rd10 retina. 
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Using single cell suspensions of rd10 retinal explants for FACS analysis, we investigated the 
response of photoreceptors to Norgestrel, in terms of ROS levels. Given that the aim of the 
study was to analyse the response in the photoreceptor layer, we harvested retinas at P15, 
prior to the loss of photoreceptors which takes place from P18~P21 in the rd10 retina 
(Barhoum et al., 2008; Samardzija et al., 2012; Roche et al., 2016). The time course of the 
retinal degeneration is slower in the rd10 model compared with others, such as the rd1, in 
which rods begin to die around P8~P10 (Chang et al., 2007; Barhoum et al., 2008). 
Norgestrel produced a similar early increase in ROS levels from 30 min in photoreceptors of 
the rd10 retina (Figure 3.3.13). We hypothesise that this peak in the production of ROS 
might be in some part responsible for the proceeding decrease in TUNEL-positive staining 
observed at 1 h following Norgestrel treatment, in light of our findings in 661W cells and 
rd10 explants pre-treated with antioxidants (Figure 3.3.14 and 3.3.15). In support of this, 
ROS have been implicated in survival mechanisms in the retina (Groeger et al., 2009a, 2012) 
and in other systems (Mackenzie et al., 2013; Shafique et al., 2013; Trachootham et al., 
2008).  
 
This study presents an important aspect to Norgestrel’s neuroprotective properties, up-
regulating ROS production as an immediate response, through the activation of PGRMC1 
and increased production of bFGF (Figure 3.4.1). This early burst of ROS is an essential 
step, as Norgestrel’s neuroprotective effects are prevented in the presence of antioxidants. 
Although this early burst of ROS is short-lived, the protective effects of Norgestrel persist 
for several weeks in a mouse model of RP (Roche & Wyse-Jackson et al., 2016), with 
Norgestrel affecting various cellular and molecular targets throughout the course of 
degeneration (Byrne et al., 2016a, 2016b; Roche & Wyse Jackson et al., 2016; Wyse 
Jackson & Cotter, 2016; Roche et al., 2017a, 2017b). The current study therefore reinforces 
the prospect of Norgestrel as a promising therapeutic for retinal degeneration, utilising ROS 
signalling in the early stages of injury to promote survival. 
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Figure 3.4.1. Schematic representation of Norgestrel-mediated pro-survival redox signalling. 
This shows the proposed pathway Norgestrel uses to promote neuroprotection in serum-starved 661W 
cells, including the compounds used to inhibit each step. 
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4.1. Abstract 
 
Reactive oxygen species (ROS) have been related not only to cellular damage, but also to 
survival responses in recent years. Our laboratory has demonstrated that these molecules 
participate in protecting both the 661W photoreceptor-like cell line and the rd10 retina, a 
model of retinitis pigmentosa (RP), following the treatment with the progesterone analogue, 
Norgestrel. We already know this compound involves a great variety of responses to induce 
neuroprotection in the diseased retina. One of such effects is that Norgestrel uses the 
neurotrophic factor basic fibroblast growth factor (bFGF) to stimulate intracellular ROS 
production in early stages under stress conditions. However, the mechanism by which ROS 
levels are increased remains unclear. This study is therefore focused on delineating the 
source of the Norgestrel-mediated redox signalling. Through the use of specific inhibitors in 
the photoreceptor-derived 661W cell line, we confirm that this increase in pro-survival ROS 
levels stimulated as a consequence of the treatment with Norgestrel, is produced by NADPH 
oxidases (NOX), specifically NOX4. Furthermore, we also demonstrate that mitochondria 
and cyclooxygenases (COX), which represent other sources of ROS production within the 
cell, do not play a role in this signalling pathway. Therefore, this study demonstrates how 
Norgestrel stimulates NOX4 in order to induce cell survival in stressed 661W cells. 
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4.2. Introduction 
 
The potential sources of reactive oxygen species (ROS) within the cell are numerous. These 
molecules can be formed as by-products, as a consequence of biological reactions. One of 
the most widely recognised sources is the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (NOX) family of proteins, which was the first source identified to have an 
exclusive role in producing ROS rather than generate them as a by-product (Bedard & 
Krause, 2007; Finkel, 2011; Brandes et al., 2014a). In fact, these enzymes have been 
demonstrated to participate in several distinct mechanisms such as cellular proliferation, 
survival and death (Abid et al., 2000; Clark & Valente, 2004; Bedard & Krause, 2007; 
Brown & Griendling, 2009; Bhatt et al., 2010; Brandes et al., 2014b; Moloney et al., 2017a, 
2017b; Moloney & Cotter, 2017). In support of this, our group has previously highlighted a 
role of these enzymes in the production of ROS leading to cell survival (Groeger et al., 
2009a). The NOX family consists of seven transmembrane members (NOX1-5, DUOX1-2), 
differing mainly in their organ-specific expression, control of their activity and the type of 
ROS they release (Brandes et al., 2014a; Moloney & Cotter, 2017). NOX1-4 are known to 
interact with the small transmembrane protein p22 phagocyte oxidase (p22phox) whereas 
activation of NOX1-3 require the formation of a complex with other cytosolic proteins 
(Ambasta et al., 2004; Bae et al., 2011; Brandes et al., 2014a; Moloney & Cotter, 2017).  
 
Mitochondria are also a major site of free radical production, given that this organelle 
generates adenosine triphosphate (ATP) in an oxygen-dependent manner (Harman, 1956; 
Jarrett et al., 2008; Murphy, 2009; Liochev, 2013; Lefevere et al., 2017). Superoxide anion 
(O2•–) is the primary ROS produced by mitochondria, which is not diffusible (Andreyev et 
al., 2005; Liochev, 2013). Thus, it is rapidly converted to hydrogen peroxide (H2O2) to cross 
biological membranes and act in both pro-survival and pro-death cellular responses (Rhee, 
2006; Groeger et al., 2009b; Finkel, 2011; Bordt & Polster, 2014; Holmström & Finkel, 
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2014; Marinho et al., 2014; Dan Dunn et al., 2015; Antunes & Brito, 2017; Moloney & 
Cotter, 2017; Sies, 2017). These molecules can be generated in at least eleven different 
mitochondrial sites, mainly at complexes I and III of the electron transport chain (Andreyev 
et al., 2005; Murphy, 2009; Brand, 2016). In addition to the mitochondria and NADPH 
oxidases, other sources of ROS production include cyclooxygenases (COX), peroxisomes, 
lysosomes, cytochrome p450 enzymes in the endoplasmic reticulum (ER), xanthine oxidases, 
nitric oxide synthases and lipoxygenases (Trachootham et al., 2008; Finkel, 2011; Birben et 
al., 2012; Holmström & Finkel, 2014). ROS produced by these other sources have been 
linked mainly with cellular damage (Di Meo et al., 2016). 
 
Over the last decade, we have demonstrated the neuroprotective effects of Norgestrel, a 
compound commonly used in the female oral contraceptive pill. This has been demonstrated 
in a variety of models and involves multiple mechanisms (Doonan et al., 2011; Byrne et al., 
2016a; 2016b; Roche & Wyse-Jackson et al., 2016; Wyse Jackson & Cotter, 2016; Wyse 
Jackson et al., 2016a; 2016b; Roche et al., 2017a, 2017b). For example, we have recently 
discovered the role of ROS in survival responses produced by Norgestrel in both the 661W 
cell line and the rd10 retina (Chapter 3; Ruiz-Lopez et al., 2017). This was shown by the use 
of antioxidants to decrease ROS production alongside Norgestrel administration, which 
prevented Norgestrel from providing neuroprotection. However, the mechanism responsible 
for this increase in ROS levels has not been elucidated yet. Therefore, the aim of this study is 
to investigate the possible sources of pro-survival ROS in the Norgestrel-mediated response. 
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4.3. Results 
 
4.3.1. Inhibition of NOX abrogates the Norgestrel-induced increase in ROS 
in stressed 661W cells  
 
Previous studies from this group have documented the production of pro-survival ROS 
following Norgestrel treatment for 30 min under serum-deprived conditions (Chapter 3; 
Ruiz-Lopez et al., 2017). In the current study we utilised inhibitors to establish the possible 
source of this increase in endogenous ROS levels. Diphenyleneiodonium (DPI) is commonly 
used to block NOX activity (Cross & Jones, 1986; Greene et al., 2000; Clark & Valente, 
2004; Abid et al., 2007; Shi et al., 2015; Demelash et al., 2017; Prieto-Bermejo & 
Hernández-Hernández, 2017). However, its specificity has been widely debated over the 
years. It is thought to be a nonspecific inhibitor of flavoenzymes such as NOX proteins 
(Maghzal et al., 2012) due to its effects on mitochondrial ROS production (Majanders et al., 
1994; Li & Trush, 1998; Murphy, 2009; Sena & Chandel, 2012; Prieto-Bermejo & 
Hernández-Hernández, 2017).  
 
In light of this, the effects of DPI on NOX enzymes in this study were corroborated using the 
specific NOX inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-tria-zolo[4,5-d]pyrimidine 
(VAS2870) (ten Freyhaus et al., 2006; Wingler et al., 2011, 2012; Gatto et al., 2013; 
Altenhö et al., 2015; Ma et al., 2017; Rastogi et al., 2017). Wingler et al. showed that 
VAS2870 is able to block NOX1 and NOX2 (Wingler et al., 2011). In addition, they 
demonstrated that NOX inhibition by VAS2870 in wild-type mice produced the same effect 
that NOX4 delection in NOX4 knockout mice (Wingler et al., 2012), demonstrating its 
specificity is not relevant for any NOX isoform. In the current study, a range of 
concentrations was tested for its effects on cellular viability as measured by MTS assay and 
on ROS production as measured by flow cytometry. 1 µM of DPI caused a decrease in cell 
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viability compared with the vehicle, whereas VAS2870 did not affect cell viability 
(independent samples t-test, DPI: t 22 = 3.324, P = 0.0031; VAS2870: t 22 = 0.7210, P = 
0.4785; n = 4 per group; Figure 4.3.1A) and both inhibitors at this concentration significantly 
decreased ROS levels (independent samples t-test, DPI: t 16 = 6.808, P < 0.0001; VAS2870: t 
16 = 7.006, P < 0.0001, n = 3 per group; Figure 4.3.1B).  
 
Figure 4.3.1. NOX inhibition produced by DPI and VAS2870 in 661W cells. Dose-response curve 
measuring cell viability (A) and DCFDA fluorescence (B) of 661W cells treated with increasing 
concentrations of inhibitors against NOX proteins, DPI and VAS2870 (t-test comparing individual 
treatments). Results are presented as mean ± SEM from three independent experiments. Asterisks 
indicate significant difference (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).  
 
Cells were then pre-treated with either DPI or VAS2870 at a concentration 1 µM for 1 h in 
complete media prior to 20 µM Norgestrel treatment in serum-free media for 30 minutes. 
The burst of ROS produced by Norgestrel after 30 min (independent samples t-test, t 15 = 
3.006, P = 0.0089; n = 3-4 per group; Figure 4.3.2A) was abrogated when NOX proteins 
were inhibited using either DPI or VAS2870 as detected by decreased DCFDA fluorescence 
intensity (DPI: t 18 = 4.082, P = 0.0007; VAS2870: t 15 = 3.626, P = 0.0005; n = 3-4 per 
group). According to these results, although DPI is considered a less specific inhibitor of 
NOX proteins than VAS2870, both inhibitors had a similar effect, demonstrating that this 
response is NOX-dependent. 
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Figure 4.3.2. Pro-survival ROS-induced increase in stressed 661W cells by Norgestrel is NOX-
dependent. (A) FACS analysis of 661W cells pre-treated with 1 µM DPI or VAS2870 prior to 
Norgestrel treatment. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence and 
hence ROS levels. Geomeans were graphed compared to UT cells (t-test comparing individual 
treatments). Norgestrel-mediated ROS up-regulation only took place in the absence of inhibitors 
(vehicle control). (B) Changes in cell viability were measured by the MTS assay and graphed as a 
percentage of 100% viable UT control (t-test comparing individual treatments). NOX inhibition by 
DPI and VAS2870 abolish Norgestrel-mediated protection at 30 min following serum starvation. 
Results are presented as mean ± SEM from three independent experiments. Asterisks indicate 
significant difference (NS not significant, ** P < 0.01). 
 
According to previous studies, the increase in ROS produced by Norgestrel has been proved 
to be pro-survival (Ruiz-Lopez et al., 2017). In order to corroborate this, cell viability was 
assessed by MTS assay following NOX inhibition. We found that protection enhanced by 
Norgestrel at 30 min (independent samples t-test, t 28 = 3.498, P = 0.0016; n = 3 per group; 
Figure 4.3.2B) was abolished in the when NOX were blocked by DPI and VAS2870 (DPI: t 
28 = 0.7924, P = 0.4348; VAS2870: t 28 = 0.04007, P = 0.9683; n = 3 per group). This 
confirms that NOX-induced ROS production is pro-survival as shown before. 
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Given that some studies also use knockdowns/knockouts to verify the results obtained by the 
use of inhibitors (Block et al., 2009; Wingler et al., 2012; Dikalov et al., 2014; Demelash et 
al., 2017), we sought to investigate whether the lack of NOX activity would affect 661W 
cells. Incubation of these NOX inhibitors, DPI and VAS2870, for 24 h produced a dramatic 
decrease in cell viability in all concentrations studied (independent samples t-test, 1 µM: t 22 
= 6.014, P < 0.0001; 5 µM: t 22 = 7.376, P < 0.0001; 10 µM: t 22 = 5.820, P < 0.0001; 50 µM: 
t 22 = 21.62, P < 0.0001; n = 3 per group; Figure 4.3.3), indicating other approaches such as 
the use of knockdowns are unsuitable to block NOX activity in 661W cells.  
                          
Figure 4.3.3. DPI and VAS2870 decrease cell viability after 24 h treatment in 661W cells. Dose-
response curve measuring cell viability of 661W cells treated with increasing concentrations of 
inhibitors against NOX proteins, DPI and VAS2870 (t-test comparing individual treatments to their 
vehicle control). Results are presented as mean ± SEM from three independent experiments. Asterisks 
indicate significant difference (**** P < 0.0001).  
 
4.3.2. NOX4 is up-regulated by Norgestrel in serum-deprived 661W cells 
 
Next, we sought to identify which NOX isoforms may be responsible for this protection. It 
has been previously shown that only two members of the NOX family are expressed in 
661W cells: as two isoforms, NOX2 and NOX4 (Groeger et al., 2009a). Interestingly, some 
studies have suggested a link between these two isoforms, which have been described to 
signal to kinases/phosphatases in a similar manner (Brown & Griendling, 2009). 
Furthermore, it has been demonstrated that both NOX2 and NOX4 are involved in the pro-
survival production of ROS in endothelial cells (Petri et al., 2006). 
Chapter 4 
83 
 
Therefore, both NOX2 and NOX4 mRNA levels were analysed using RT-qPCR. NOX4 was 
up-regulated at 30 min (independent samples t-test, t 12 = 2.604, P = 0.023; n = 3 per group; 
Figure 4.3.4) followed by NOX2 which showed an increase at 1 h following Norgestrel 
treatment (t 14 = 2.337, P = 0.0348; n = 4 per group). 
 
Figure 4.3.4. Norgestrel increases NOX2 and NOX4 expression in stressed 661W cells. NOX2 
and NOX4 mRNA levels were measured in stressed 661W cells following Norgestrel treatment (t-test 
comparing individual Norgestrel treatments to their timed vehicle control). Norgestrel stimulates 
NOX4 and NOX2 expression at 30 min and at 1 h, respectively. Results are presented as mean ± SEM 
from three independent experiments. Asterisks indicate significant difference (* P < 0.05).  
 
We subsequently studied protein levels by western blotting. Norgestrel significantly 
increased NOX4 at 30 min (independent samples t-test, t 7 = 4.335, P = 0.0034; n = 3 per 
group; Figure 4.3.5), supporting the mRNA results and predicting an important role of 
NOX4 in this survival response. In addition, NOX2 was up-regulated at 1 h (t 7 = 2.752, P = 
0.0284; n = 3 per group), suggesting that this protein might not be involved in the early 
Norgestrel-mediated response at 30 min. 
 
Figure 4.3.5. Norgestrel increases NOX2 and NOX4 protein levels in stressed 661W cells. 
Western blotting confirmed an increase in NOX2 and NOX4 (t-test comparing individual Norgestrel 
treatments to their timed vehicle control). Equal loading of protein was demonstrated by REVERT 
total protein stain. Blots are representative of n=3. Results are presented as mean ± SEM from three 
independent experiments. Asterisks indicate significant difference (* P < 0.05, ** P < 0.01).  
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To corroborate the increase of NOX4 in stressed 661W cells, protein levels were also 
analysed by immunofluorescence. We confirmed that Norgestrel stimulated both NOX4 and 
the subunit p22phox at 30 min compared with the vehicle control (Figure 4.3.6). This result 
supports other studies in which NOX4 has been related with survival responses in the eye 
and other systems (Mahadev et al., 2004; Groeger, MacKey, et al., 2009; Ghatak et al., 
2017; Harel et al., 2017; Moloney et al., 2017a, 2017b).  
 
Figure 4.3.6. Norgestrel increases NOX4 and p22phox subunit levels in 661W cells following 30 
min serum starvation. Fluorescent microscopic images confirmed that Norgestrel stimulates both 
NOX4 and p22phox at 30 min following serum starvation. For a better interpretation of the results, 
colours were replaced with black & white in the left region. Secondary antibody only was added as 
negative control. Images are representative of n=3. Scale bar 30 µm. Hoechst staining reveals cell 
nuclei. 
 
In order to demonstrate Norgestrel-mediated neuroprotection is NOX4-dependent, we sought 
to generate a NOX4 knockout (KO) cell line using the clustered regularly interspaced short 
palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) gene editing system. 
Since the field of genome engineering was discovered, the CRISPR/Cas9 technology has 
gained considerable attention in the last years. This complex is part of the prokaryotic 
immune system of archaea and bacteria to defence against invading viruses (Mojica et al., 
2005). It consists of repeating sequences separated by variable short DNA sequences termed 
as ‘spacers’ which are remnants of the genetic code from past invaders (Mojica et al., 2005; 
Mojica & Rodriguez-Valera, 2016; Khan et al., 2018). This system, therefore, serves as a 
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genetic memory that helps the cell to detect and destroy invaders when they return. Using 
modified versions of Cas9, we can now target a specific sequence and modulate gene 
expression (Schaeffer & Nakata, 2015; Khan et al., 2018).  
 
In this study, we used the CRISPR/Cas9 gene editing system to generate a NOX4 KO cell 
line using 661W cells. To do so, we use the double nickase technique which differs to the 
traditional CRISPR/Cas9 engineering. In the latter one, the guide RNA (gRNA) binds to one 
target sequence and Cas9 produces a double-strand DNA break, whereas with the double 
nickase, a modified Cas9 interacts with gRNAs targeted to two sites, one that binds upstream 
and another that binds downstream of the target sequence, which results in single-strand 
cleavage activity as represented in figure 4.3.7, increasing its specificity (Schaeffer & 
Nakata, 2015; Gopalappa et al., 2018).  
            
 
Figure 4.3.7. CRISPR/Cas9-mediated gene editing technologies. (A) Traditional CRISPR/Cas9 
engineering where gRNA specifically binds to target sequence in genome. Cas9 introduces a double-
strand cleavage to target DNA. It is during this repair process that a small insertion or deletion events 
occurs. (B) Double nickase where modified Cas9 interacts with gRNAs targeted to two sites. 
Modifications to Cas9 result in only single-strand cleavage activity. Modified from Schaeffer & 
Nakata, 2015. 
Chapter 4 
86 
 
Given that the results obtained in figure 4.3.3 suggest that the blockage of NOX proteins 
during 24 h has detrimental consequences on cell viability of 661W cells, we next sought to 
determine the effect of NOX4 KO following 48 h plasmids transfection. Cells treated with 
transfection reagent alone, which were used as a negative control (Mock), showed a decrease 
in cellular viability compared with the untreated (UT) control (one-way ANOVA, 
transfection effect, F 2,51 = 209.3, P < 0.0001; Tukey’s HDS post hoc test, P < 0.0001; n = 3 
per group; Figure 4.3.8). Cell survival and proliferation were severely compromised in cells 
transfected with the NOX4 Double Nickase Plasmid compared with both UT and Mock 
controls (Tukey’s HDS post hoc test, P < 0.0001), confirming the pro-survival nature of 
NOX4. In 2017, Jafari et al. demonstrated that CRISPR/Cas9-mediated NOX4 KO inhibits 
cell proliferation in HeLa cells (Jafari et al., 2017).  
                            
Figure 4.3.8. NOX4 is essential for cellular survival and proliferation in 661W cells. Changes in 
cell viability and proliferation were measured by the MTS assay and graphed as a percentage of 100% 
viable UT control (Tukey’s HDS post hoc test for multiple comparisons). Results are presented as 
mean ± SEM from three independent experiments. Asterisks indicate significant difference (**** P < 
0.0001). 
 
After transfection, cells were screened by immunofluorescence for green fluorescent protein 
(GFP)-positive cells. We found that GFP+ cells were enucleated cells as revealed by Hoechst 
staining, suggesting they die in the absence of NOX4 expression (Figure 4.3.9). UT and 
Mock (transfection reagent alone) confirmed no GFP+ cells as expected. Enucleation has 
Chapter 4 
87 
 
been previously described as a mechanism of cell death (Paunescu et al., 2014), 
corroborating our results in 661W cells. 
 
Figure 4.3.9. NOX4 KO produces cell death in 661W cells. GFP-positive cells screening by 
immunofluorescence. GFP+ cells were enucleated cells and hence, dying cells (white arrows). Images 
are representative of n=2. Scale bar 30 µm. Hoechst staining reveals cell nuclei.  
 
In order to select NOX4 KO colonies, if any, cells were treated with 1 μg/ml puromycin 
antibiotic for 6 days. This concentration was selected among other two for being the lowest 
concentration that killed 100% cells of non-transfected cells in 6 days (one-way ANOVA, 
puromycin treatment, F 3,68 = 893.4, P < 0.0001; Dunnett’s post hoc test, 1 μg/ml: P < 
0.0001; 5 μg/ml: P < 0.0001; 10 μg/ml: P < 0.0001; n = 3 per group; Figure 4.3.10). 
 
Immunofluorescence studies demonstrated that untreated cells die after puromycin treatment 
(Figure 4.3.11A). We observed a few cells in the NOX4 KO samples, however, these cells 
expressed NOX4 and hence, were non-transfected cells that survived to both the transfection 
process and puromycin treatment. It is possible that these cells survived due to a partial, 
Figure 4.3.10. Puromycin treatment 
optimisation in 661W cells. Changes in 
cell viability were measured by the MTS 
assay and graphed as a percentage of 
100% viable UT control (Dunnett’s post 
hoc test, comparing all concentrations to 
the UT control). Results are presented as 
mean ± SEM from three independent 
experiments. Asterisks indicate 
significant difference (**** P < 0.0001). 
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rather than a total, deletion of the NOX4 gene. Such cells were grown in completed media 
for two weeks to reach ~80% confluence in order to confirm NOX4 expression by western 
blotting (Figure 4.3.11B). KO cells expressed same levels of NOX4 than the UT control and 
therefore, it suggests that GFP+ cells (NOX4 KO) observed in figure 4.3.9 died and were 
lost during the subsequent washes performed in the protocol.  
   
We concluded that NOX4 has an important pro-survival role within the cell, taking into 
account its complete abrogation using the CRISPR/Cas9 system produces the death of 
transfected cells. Since several evidences are found in the literature describing the pro-
survival role of NOX4 protein (Brown & Griendling, 2009; Takac et al., 2012; Moloney & 
Cotter, 2017; Moloney et al., 2017a, 2017b), these results are not surprising. We hypothesise 
this occurs given that 661W cells only express two NOX isoforms: NOX2 and NOX4, as 
described before. In the absence of NOX4, NOX2 might not be able to assume NOX4 role, 
leading to cell death of NOX4 KO 661W cells. This suggests that the use of inhibitors during 
shorter time points would be a better approach to study NOX proteins in 661W cells. 
 
Figure 4.3.11. NOX4 KO colonies analysis after 
puromycin treatment in 661W cells. (A) NOX4 
protein levels were studied in 661W cells by 
immunofluorescence following transfection and 
puromycin treatment. No cells were found in untreated 
(UT) cells whereas a few cells were present in the 
NOX4 knockout (KO) samples. However, these cells 
expressed NOX4. Secondary antibody only was added 
as negative control. Images are representative of n=2. 
Scale bar 30 µm. Hoechst staining reveals cell nuclei. 
(B) Results were confirmed by western blotting. Equal 
loading of protein was demonstrated by REVERT total 
protein stain. 
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4.3.3. Mitochondrial ROS production is induced by the mitochondrial 
inhibitor Rotenone in 661W cells 
 
Given that mitochondria are another main producer of ROS within the cell, we asked 
whether they participate in the Norgestrel-mediated pro-survival response at 30 min. We 
treated cells with various concentrations of Rotenone, a widely used mitochondrial inhibitor 
that acts by supressing complex I superoxide production (Barrientos & Moraes, 1999; 
Isenberg & Klaunig, 2000; Chauvin et al., 2001; Curtin et al., 2002; Fato et al., 2009). We 
found 20 µM to be the lowest concentration that effectively reduced ROS production, 
resulting in a decrease in DCFDA fluorescence intensity (independent samples t-test, t 20 = 
15.23, P < 0.0001; n = 4 per group; Figure 4.3.12B), although it did result in cell death (t 16 = 
6.752, P < 0.0001; n = 3 per group; Figure 4.3.12A). This effect on cellular viability has 
been documented so far in several in vitro and in vivo systems (Abdo et al., 1988; 
Cunningham et al., 1995; Isenberg & Klaunig, 2000; Chauvin et al., 2001; Li et al., 2003; 
Heinz et al., 2017). 
 
Figure 4.3.12. Rotenone treatment only decreases intracellular ROS levels at 20 µM. Dose-
response curve measuring cell viability (A), DCFDA fluorescence (B) of 661W cells treated with 
increasing concentrations of Rotenone, an inhibitor of mitochondria (t-test comparing individual 
treatments). Treatment with 20 µM effectively attenuates intracellular ROS production measured by 
DCFDA. Results are presented as mean ± SEM from three independent experiments. Asterisks 
indicate significant difference (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).  
 
In order to corroborate mitochondrial inhibition produced by Rotenone, mitochondrial ROS 
were studied by flow cytometry using the probe MitoSOX (Figure 4.3.13). MitoSOX is a 
derivative from dihydroethidium (DHE) that detects specifically O2•– produced by 
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mitochondria from the one-electron reduction of O2 (Murphy, 2009) and it has been widely 
used in fluorescence/confocal microscopy and flow cytometry studies in live cells (Robinson 
et al., 2006; Mukhopadhyay et al., 2007a, 2007b; Pehar et al., 2007; Zimmerman et al., 
2007).  
    
Surprisingly, mitochondrial ROS production was increased in the presence of Rotenone in all 
the concentrations used in the current study (independent samples t-test, 1 µM: t 16 = 10.98, 
P < 0.0001; 10 µM: t 16 = 3.117, P = 0.0109; 20 µM: t 16 = 26.14, P < 0.0001; n = 3 per 
group; Figure 4.3.14). We suggest this increase may be explained by a severe impairment in 
mitochondrial activity shown by a decrease in cellular viability in cells treated with 
Rotenone, demonstrating this inhibitor it is not an accurate way to study mitochondrial 
implication in this signalling pathway.  
                                 
Figure 4.3.14. Mitochondrial inhibition by Rotenone increases the production of mitochondrial 
ROS in 661W cells. Dose-response curve measuring MitoSOX fluorescence of 661W cells treated 
with increasing concentrations of Rotenone, an inhibitor of mitochondria (t-test comparing individual 
treatments). None of the concentrations studied showed a decrease in mitochondrial ROS levels as 
shown by MitoSOX fluorescence. This suggests the effects of Rotenone on mitochondria are not 
specific enough to block mitochondrial participation in ROS production in 661W cells. Results are 
presented as mean ± SEM from three independent experiments. Asterisks indicate significant 
difference (* P < 0.05, ** P < 0.01, **** P < 0.0001). 
Figure 4.3.13. MitoSOX was used to detect 
mitochondrial superoxide levels. Different 
concentrations were tested in order to find an 
optimal peak of fluorescence. Y-axis represents cell 
counts, x-axis (logarithmic scale) measures the 
level of fluorescence. 0.5 µM was used in all 
subsequent experiments. 
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According to this, Li et al. confirmed that treatment with Rotenone leads to cytochrome c 
release, activation of caspase 3 activity and DNA fragmentation, all biomarkers of apoptosis 
(Li et al., 2003). This Rotenone-induced ROS production has also been related with an 
inhibition of cell proliferation given that it binds to tubulin, affecting therefore the 
microtubule assembly (Srivastava & Panda, 2007). 
 
4.3.4. Mitochondria do not participate in the pro-survival production of 
ROS in 661W cells 
 
In light of the results obtained with Rotenone, we decided to use an alternative compound to 
target mitochondrial production of ROS without affecting cell viability. As a result,               
(2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)2oxoethyl)triphenylphosphoniumchloride 
monohydrate (MitoTEMPO), a mitochondria-targeted antioxidant, was used due to its 
specific effects on mitochondrial ROS (Dikalova et al., 2010; Woolley et al., 2013; Bordt & 
Polster, 2014; McCarthy & Kenny, 2016; Zhang et al., 2017).  
 
A range of concentrations was tested for its effects on cellular viability as measured by MTS 
assay and on ROS production as measured by flow cytometry. 5 µM resulted in similar 
levels of cell viability compared with the vehicle (independent samples t-test, t 34 = 1.775, P 
= 0.0848; n = 3 per group; Figure 4.3.15A), whilst significantly decreasing both intracellular 
(independent samples t-test, t 16 = 5.311, P < 0.0001; n = 3 per group; Figure 4.3.15B) and 
mitochondrial ROS levels (t 16 = 4.701, P < 0.0001; n = 3 per group; Figure 4.3.15B) 
measured by DCFDA and MitoSOX, respectively.  
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Figure 4.3.15. MitoTEMPO reduces ROS levels in 661W cells. Dose-response curve measuring 
cell viability (A), DCFDA fluorescence and MitoSOX fluorescence (B) of 661W cells treated with 
increasing concentrations of MitoTEMPO, a mitochondria-targeted antioxidant (t-test comparing 
individual treatments). Results are presented as mean ± SEM from three independent experiments. 
Asterisks indicate significant difference (* P < 0.05, *** P < 0.001, **** P < 0.0001).  
 
Thus, cells were pre-treated with 5 µM MitoTEMPO for 1 h in complete media prior to 20 
µM Norgestrel treatment in serum-free media for 30 minutes. Use of MitoTEMPO induced a 
slight decrease of ROS levels compared with the vehicle control, which confirms that it is 
inhibiting production of ROS (Figure 4.3.16). Norgestrel could still produce an increase in 
ROS at 30 min in the absence or presence of the antioxidant as detected by DCFDA 
fluorescence intensity, suggesting that mitochondrial-derived ROS are not involved in this 
response (independent samples t-test, vehicle: t 16 = 7.878, P < 0.0001; MitoTEMPO: t 16 = 
4.903, P = 0.0002; n = 3 per group; Figure 4.3.16).  
 
Figure 4.3.46. Mitochondria are not 
involved in the Norgestrel-mediated 
production of ROS in serum-starved 661W 
cells. FACS analysis of 661W cells pre-treated 
with 5 µM MitoTEMPO prior to Norgestrel 
treatment. Y-axis represents cell counts, x-axis 
(logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-
axis represents an increase in DCFDA 
fluorescence and hence ROS levels. Geomeans 
were graphed compared to UT cells (t-test 
comparing individual treatments). Norgestrel 
was able to increase ROS levels in the presence 
or absence of the mitochondria-targeted 
antioxidant MitoTEMPO, suggesting this 
response is not mitochondria-dependent. 
Results are presented as mean ± SEM from 
three independent experiments. Asterisks 
indicate significant difference (**** P < 
0.0001).  
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In support of this, repetition of this experiment but using MitoSOX rather than DCFDA 
demonstrated that Norgestrel does not increase mitochondrial superoxide levels in the 
absence or presence of MitoTEMPO (independent samples t-test, vehicle: t 16 = 0.3778, P = 
0.7105; MitoTEMPO: t 16 = 0.6440, P = 0.5287; n = 3 per group; Figure 4.3.17).  
MitoTEMPO also decreased MitoSOX fluorescence corroborating its effect on reducing 
mitochondrial ROS production as previously described (Dikalova et al., 2010; McCarthy & 
Kenny, 2016; Zhang, Wang, et al., 2017). All together suggests that ROS production 
stimulated by Norgestrel is not mitochondria-dependent. 
                      
Figure 4.3.17. Mitochondrial superoxide levels are not affected by Norgestrel in stressed 661W 
cells. FACS analysis of 661W cells pre-treated with 5 µM MitoTEMPO prior to Norgestrel treatment. 
Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of MitoSOX fluorescence 
and hence mitochondrial superoxide levels (t-test comparing individual treatments). Results are 
presented as mean ± SEM from three independent experiments. Asterisks indicate significant 
difference (NS not significant).  
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4.3.5. COX proteins are not involved in the response induced by 
Norgestrel in stressed 661W cells 
 
Cyclooxygenase (COX) enzymes, also known as prostaglandin synthase, have been 
described to produce ROS as a result of their peroxidase activity (Pepicelli et al., 2002; 
Nathan & Cunningham-Bussel, 2013; Holmström & Finkel, 2014; Di Meo et al., 2016). 
Such ROS production is suggested to contribute to an increase in inflammation and cellular 
damage in different models, including Alzheimer’s and cardiovascular diseases (Nogawa et 
al., 1997; Pasinetti, 1998; Pepicelli et al., 2002; Virdis et al., 2005; Hernanz et al., 2014; Hee 
Kim et al., 2015; Yin et al., 2017).  
 
During years there was little, if any, evidence in the literature about the implication of COX-
induced ROS production in survival signalling. In fact, little is known about how these 
enzymes produce ROS. Hernanz et al. suggested that ROS can be generated both during the 
process of prostaglandin synthesis itself and through the effects on other ROS sources such 
as NOX proteins (Hernanz et al., 2014), which has also been shown before (Martínez-
Revelles et al., 2012). Since studies in this group have suggested that COX enzymes are 
implicated in pro-survival ROS production downstream of bFGF (Farrell et al., 2011), we 
sought to investigate whether these proteins play a role in the Norgestrel-mediated response. 
Cells were treated with four different concentrations of Diclofenac sodium salt, a well-
known inhibitor of COX activity (Gan, 2010; Moloney et al., 2017a; Ulubay et al., 2017). 1 
µM did not affect cell viability (independent samples t-test, t 28 = 0.1587, P = 0.875; n = 3-4 
per group; Figure 4.3.18A) and it significantly decreased ROS levels (t 16 = 11.58, P < 
0.0001; n = 4 per group; Figure 4.3.18B). 
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Figure 4.3.18. COX inhibition produced by Diclofenac in 661W cells. Dose-response curve 
measuring cell viability (A) and DCFDA fluorescence (B) of 661W cells treated with increasing 
concentrations of Diclofenac which inhibits COX enzymes (t-test comparing individual Norgestrel 
treatments to their timed vehicle control). Results are presented as mean ± SEM from three 
independent experiments. Asterisks indicate significant difference (* P < 0.05, **** P < 0.0001).  
 
Therefore, cells were pre-treated with 1 µM Diclofenac for 1 h before Norgestrel treatment 
for 30 min. Norgestrel treatment produced a burst of ROS at 30 min even in the presence of 
inhibitor (independent samples t-test, vehicle: t 15 = 3.006, P = 0.0089; Diclofenac: t 11 = 
2.431, P = 0.0333; n = 3 per group; Figure 4.3.19), suggesting that COX are not essential in 
this response. 
 
 
 
Figure 4.3.19. Norgestrel-mediated 
response is not COX-dependent in 
stressed 661W cells. FACS analysis of 
661W cells pre-treated with 1 µM 
diclofenac prior Norgestrel treatment. 
Y-axis represents cell counts, x-axis 
(logarithmic scale) measures the level 
of fluorescence. A shift to the right 
along the x-axis represents an increase 
in DCFDA fluorescence and hence 
ROS levels. Geomeans were graphed 
compared to UT cells (t-test comparing 
individual treatments). Norgestrel 
increased ROS production in the 
absence or presence of COX 
inhibitor.Results are presented as mean 
± SEM from three independent 
experiments. Asterisks indicate 
significant difference (NS not 
significant, * P < 0.05, **** P < 
0.0001).  
 
Chapter 4 
96 
 
4.4. Discussion 
 
Interest in the hormone progesterone was initiated by Atella et al. in 1987, who observed that 
this hormone was able to improve functionality in pseudopregnant rats compared with the 
normal-cycling females, both suffering from traumatic brain injury (TBI) (Attella et al., 
1987). Some years later, it was confirmed that progesterone administration was beneficial in 
both male and female rats (Roof et al., 1992, 1994) and mice presenting TBI (Hua et al., 
2011). Since then, experimental and clinical evidences indicating the neuroprotective 
properties of progesterone are numerous in the literature (Gonzalez Deniselle et al., 2003; 
Gonzalez et al., 2005; Garay et al., 2009, 2011, 2012; De Nicola et al., 2013; Singh & Su, 
2013; Schumacher et al., 2016; Espinosa-Garcia et al., 2017; Fabres et al., 2018).  
 
Studies on neurodegeneration and Norgestrel-mediated neuroprotection have also been 
previously described in various models of photoreceptor cell death, through in vitro, in vivo 
and ex vivo preparations (Doonan et al., 2011; Byrne et al., 2016a; 2016b; Roche et al., 
2016, 2017a, 2017b; Roche & Wyse-Jackson et al., 2016; Wyse Jackson & Cotter, 2016; 
Wyse Jackson et al., 2016a; 2016b; Ruiz-Lopez et al., 2017). Norgestrel elicits 
neuroprotective effects by binding to the progesterone receptor PGRMC1, increasing the 
expression of the neurotrophic factor bFGF to promote cell survival using redox-signalling 
as shown in the previous chapter (Wyse Jackson & Cotter, 2016; Wyse Jackson et al., 2016a; 
Ruiz-Lopez et al., 2017).  
 
Furthermore, the relationship between ROS generation and growth factors, especially in 
cases of induced stress, has been well documented so far (Lieberthal et al., 1998; 
Tammariello et al., 2000; Curtin et al., 2002; Bae et al., 2011; Dikalov et al., 2014; Ghatak 
et al., 2017). Several growth factors including bFGF appear to modulate ROS formation 
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within the cell (Sundaresan et al., 1995; Tammariello et al., 2000; Kirkland et al., 2007; Bai 
et al., 2014; Ghatak et al., 2017). Kirkland et al., showed that nerve growth factor (NGF) 
withdrawal induces an increase in oxidative stress, leading to apoptosis in mice neurons. 
They also showed that readdition of NGF suppresses the up-regulation of ROS levels and 
inhibits the release of cytochrome c (Kirkland et al., 2007). According to this, Ghatak et al. 
and Bai et al. presented an important role of the transforming growth factor β1 (TGFβ1) in 
the NOX4-induced ROS production (Bai et al., 2014; Ghatak et al., 2017), elucidating the 
importance of neurotrophic factors in the production and modulation of ROS. 
 
In fact, studies in our laboratory have demonstrated how ROS production induces cellular 
survival (Mackey et al., 2008; Groeger et al., 2009) downstream of bFGF in 661W cells and 
retinal explants from both wild-type and diseased mice (Farrell et al., 2011; Groeger et al., 
2012; Ruiz-Lopez et al., 2017). Nevertheless, this pro-survival nature of redox state should 
be always considered as a short event that happens in a specific moment in the cell, 
essentially as a first mechanism to respond against any stressful stimuli and always in a 
regulated manner (Remacle et al., 1995; Rhee, 2006; Ray et al., 2012; Reczek & Chandel, 
2015; Prieto-Bermejo & Hernández-Hernández, 2017).  
 
The importance of NOX enzymes participating in cellular signalling is not surprising, as the 
only known function of which is ROS production (Lambeth, 2004; Bedard & Krause, 2007; 
Brown & Griendling, 2009; Wingler et al., 2011; Takac et al., 2012; Brandes et al., 2014b; 
Moloney & Cotter, 2017). This has been demonstrated by previous studies from our group in 
stressed 661W cells (Groeger et al., 2009a). The current study also validates the role of NOX 
proteins, mainly NOX4, as ROS generators at an early stage in serum-starved 661W cells, 
but also as a result of Norgestrel treatment, which had not been shown previously (Figure 
4.3.2). In fact, the role of NOX proteins in diseases such as RP is not well understood. Some 
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studies have suggested that the elevated levels of oxygen in the retina when rods die produce 
the participation of NOX proteins, increasing the generation of ROS molecules (Usui et al., 
2009). However, which NOX isoform is responsible for such effects is still unknown. In the 
current study, NOX4 expression, both mRNA and protein levels, were increased by 
Norgestrel at 30 min following stress (Figure 4.3.4-6). Interestingly, this protein has been 
shown to be constitutively active and therefore, its activity depends on its expression level 
(Bae et al., 2011; Brandes et al., 2014a; Nisimoto et al., 2014). This is not the first time 
NOX4 has been implicated in redox signalling (Crestani et al., 2011; Nisimoto et al., 2014; 
Moloney et al., 2017b). Thus, NOX4 produces hydrogen peroxide in the signalling of 
different growth factors such as insulin (Mahadev et al., 2004), bFGF (Lo & Cruz, 1995) and 
TGFβ1 (Peshavariya et al., 2014; Hakami et al., 2015). 
 
On the other hand, ROS derived from mitochondria have traditionally been associated with 
aging and other mechanisms related with cell damage (Choksi et al., 2008; Nakamura et al., 
2012; Ni et al., 2016; Sanz & Bernardi, 2016; Jelinek et al., 2018). However, our 
understanding of these processes is changing. Mitochondrial involvement in redox signalling 
has been gaining attention in recent years (Zhang & Gutterman, 2006; Sena & Chandel, 
2012; Harel et al., 2017). Several mitochondrial-targeted inhibitors have been widely utilised 
to study mitochondrial role in multiple responses, with one of the most commonly used 
being Rotenone given its action on complex I of the mitochondrial respiratory chain (Curtin 
et al., 2002; Brand, 2016; Heinz et al., 2017).  
 
The effects of Rotenone have been tested in this study using different concentrations in 
661W cells. Despite the fact that 20 µM Rotenone decreased intracellular ROS production 
measured by DCFDA, none of the concentrations used reduced mitochondrial O2•– as 
measured by MitoSOX fluorescence (Figure 4.3.14). A loss of ROS by DCFDA fluorescence 
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could be linked to the detrimental effects on cell viability (Figure 4.3.12). Hence, use of 
Rotenone was an unsuitable method to demonstrate mitochondrial participation in this 
signalling pathway, in support of other studies (Abdo et al., 1988; Cunningham et al., 1995; 
Isenberg & Klaunig, 2000; Li et al., 2003; Beretta et al., 2006; Srivastava & Panda, 2007; 
Fato et al., 2009; Karlsson et al., 2016; Heinz et al., 2017). In the mentioned studies, 
Rotenone resulted toxic due to its ability to induce cell death in a variety of cells. This 
compound has been shown to elevate the production of ROS, which results lethal for cells. In 
addition to this, Rotenone has been linked with the prevention of microtubules assembly as 
mentioned in the results section (Srivastava & Panda, 2007). Srivastava & Panda showed 
that treatment with Rotenone depolymerised spindle microtubules of two different cell lines. 
As a result, Rotenone treatment inhibited cell proliferation (Srivastava & Panda, 2007). In 
2012, this process was also confirmed by Hongo et al., who demonstrated that Rotenone 
reduces the amount of polymerised tubulin, which indicates and induction of microtubule 
desestabilization  (Hongo et al., 2012). 
 
The use of a more specific approach in the study of mitochondrial-ROS was employed 
through the use of the mitochondria-targeted antioxidant MitoTEMPO. MitoTEMPO is 
known to act specifically in mitochondria given that it accumulates in the mitochondrial 
matrix, acting as a superoxide dismutase mimetic (Dikalova et al., 2010; Dikalov, 2011; 
McCarthy & Kenny, 2016; Zhang, Wang, et al., 2017). Using MitoTEMPO to reduce 
mitochondrial ROS activity, the current study indicates that these organelles are not involved 
in the pro-survival Norgestrel-mediated response at 30 min following serum starvation 
(Figure 4.3.16 and 4.3.17).  
 
Given that COX enzymes were responsible for the bFGF-mediated response in 661W cells 
shown by our lab in 2011 (Farrell et al., 2011), we next employed the COX inhibitor 
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Diclofenac in order to investigate whether these proteins participate in the up-regulation of 
ROS levels by Norgestrel. Diclofenac is an anti-inflammatory drug widely used as analgesic 
due to its effects on COX proteins, blocking the prostaglandin synthesis (Euchenhofer et al., 
1998; Gan, 2010; Van Den Brandhof & Montforts, 2010; Ulubay et al., 2017; Fontes et al., 
2018), and making it a suitable approach to elucidate COX implication in cellular processes. 
In the current study, inhibition of COX enzymes did not prevent Norgestrel-induced ROS 
increase in 661W cells (Figure 4.3.19), demonstrating that these enzymes are not implicated 
in this process. 
 
As a conclusion, this study clarifies the pro-survival mechanism behind Norgestrel-mediated 
response (Ruiz-Lopez et al., 2017), identifying NOX4 as the responsible source for 
increasing pro-survival ROS levels within the first 30 min following the stress caused by 
serum starvation in 661W cells (Figure 4.4.1). 
          
Figure 4.4.1. Proposed pathway of Norgestrel-mediated response. It has been previously shown 
that Norgestrel acts through the progesterone receptor membrane complex I (PGRMC1) to produce 
ROS downstream of bFGF (Ruiz-Lopez et al., 2017). This schematic represents how Norgestrel uses 
NOX4 to induce ROS production and promote neuroprotection in serum-starved 661W cells, 
including the compounds used to inhibit each step.  
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5.1. Abstract 
 
Norgestrel, a progesterone analogue, has shown promising results for the potential treatment 
of retinal diseases like retinitis pigmentosa (RP). Our laboratory has demonstrated a wide 
variety of pro-survival responses produced by this compound in both the 661W 
photoreceptor-like cell line and the rd10 retina, a model of RP. This neuroprotective 
response is explained in part by the utilization of neurotrophic factors such as the basic 
fibroblast growth factor (bFGF), anti-inflammatory properties through alleviating 
detrimental microglial activity and gliosis, and the modulation of reactive oxygen species 
(ROS). Moderate levels of ROS are known to participate as second messengers in survival 
responses. For instance, our group has recently demonstrated that Norgestrel up-regulates 
pro-survival ROS levels at very early time points following stress in both 661W cells and 
rd10 photoreceptors. At sustained high levels, these molecules can become toxic for cells, 
leading to the worsening of different diseases including RP. To counteract this, cells possess 
two mechanisms: reducing the production of ROS or increasing the antioxidant defence. The 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) family of proteins 
and superoxide dismutases enzymes (SOD) constitute the major ROS generators and ROS 
scavengers within the cell, respectively. This study was designed to investigate Norgestrel’s 
ability to reduce toxic levels of ROS in the diseased retina. Through the analysis of 
intracellular ROS levels, mRNA and protein levels, we conclude that Norgestrel decreases 
ROS levels in the rd10 retina via activation of the transcription factor nuclear factor 
erythroid 2 (NF-E2)-related factor 2 (Nrf2) and one of its effector antioxidant enzymes, 
SOD2. 
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5.2. Introduction 
 
Retinitis pigmentosa (RP), among other retinopathies, is characterised by the progressive 
loss of photoreceptors leading to morphological and functional damage of the retina (Cuenca 
et al., 2014; Roche et al., 2016). This disease firstly affects rods with the subsequent 
degeneration of cones (Hamel, 2006; Punzo et al., 2012; Daiger et al., 2013; Tao et al., 
2016; Athanasiou et al., 2017). The complex nature of developing a treatment for RP is 
based on the heterogeneity of genetic mutations, which disrupts a host of mechanisms, 
including the phototransduction cascade, RNA splicing machinery and retinal metabolism 
(Soest et al., 1999; Dias et al., 2017). Neurotrophic factors have been studied as a possible 
strategy to treat this disease given their role in stimulating cell survival. However, their short 
half-lives have come as a limitation for treatment so far (Buch et al., 2007; Guadagni et al., 
2015; Dias et al., 2017). Therefore, a therapeutic approach that stimulates endogenous 
production of neurotrophic factors is desirable. 
 
In this context, the synthetic progesterone Norgestrel, which is used in some oral 
contraceptives, was found by our laboratory to be neuroprotective in the retina in 2011 
(Doonan et al., 2011; Doonan & Cotter, 2012). Since then, we have elucidated some 
components of its mechanism of action in the retina, including the up-regulation of 
neurotrophic factors such as basic fibroblast growth factor (bFGF) and leukemia inhibitory 
factor (LIF) (Byrne et al., 2016a; Wyse Jackson & Cotter, 2016). In addition, 
neuroprotective effects of this compound include anti-inflammatory and anti-oxidative 
properties within the diseased or injured retina (Byrne et al., 2016b; Roche & Wyse-Jackson 
et al., 2016; Wyse Jackson et al., 2016a, 2016b; Roche et al., 2017a, 2017b; Ruiz-Lopez et 
al., 2017). 
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Futhermore, reactive oxygen species (ROS) have been linked with RP, given that they 
represent one of the main contributing factors to cone photoreceptor cell death (Shen et al., 
2005; Komeima et al., 2006, 2007, 2008; Usui et al., 2009). Implication of ROS in RP and 
other retinal diseases is not surprising due to the fact that the retina has a high demand of 
oxygen (Ames, 2000; Cuenca et al., 2014). This largest use of oxygen renders the retina very 
sensitive tissue to oxidative damage (Cingolani et al., 2005; Shen et al., 2005; Martínez-
Fernández de la Cámara et al., 2013). It is known that ROS can participate as signalling 
molecules when levels are low as described in chapters 3 and 4 (Rhee, 2006; Groeger et al., 
2009b; Ruiz-Lopez et al., 2017).  
 
However, once ROS levels become pathological, the cell attempts to eliminate them, either 
by reducing the production of ROS or by increasing the amount of antioxidants present in the 
cell (Cadenas, 1997; Valko et al., 2007; Moloney & Cotter, 2017). The nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (NOX) family of proteins and mitochondria 
constitute the major ROS generators whilst the endogenous antioxidant machinery mainly 
consists of enzymes: superoxide dismutases (SOD), glutathione peroxidases, superoxide 
reductases, glutathione reductase, peroxiredoxin, thioredoxin and catalases (Usui, Oveson, et 
al., 2009; Martínez-Fernández de la Cámara et al., 2013; Moloney & Cotter, 2017). As a 
result, biological and non-biological antioxidants have gained attention in the treatment of 
diseases such as RP (Guadagni et al., 2015). Norgestrel’s antioxidant properties have been 
demonstrated in the balb/c induced light damage mouse model by activating the transcription 
factor nuclear factor erythroid 2 (NF-E2)-related factor-2 (Nrf2) which induces an increase 
in SOD2 activity when ROS become toxic (Byrne et al., 2016b). Our study investigates the 
relevance of this mechanism in the inherited rd10 mouse model of retinitis pigmentosa. 
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5.3. Results 
 
5.3.1. Exogenous H2O2 addition does not affect serum-starved 661W cells 
 
In RP the death of rods, which represent >90% of the photoreceptor population in the retina 
and thus, consume the majority of oxygen, causes a sharp increase in the oxygen level 
(hyperoxia) of cones and their subsequent death (Curtin et al., 2002; Punzo et al., 2012; Tao, 
Chen, et al., 2016). Another cause of cone cell death after rods die is the cessation of trophic 
support (Komeima et al., 2006, 2008; Finnegan et al., 2010; Athanasiou et al., 2018). 
Studies in mouse models of RP have shown how hyperoxia, caused after the death of rods, 
results in the narrowing of retinal blood vessels and the subsequent down-regulation of 
several growth factors (Komeima et al., 2006). Komeima et al. demonstrated that vascular 
endothelial growth factor (VEGF) expresion was reduced as a consequence of such effect 
produced by hyperoxia in rd1 mice (Komeima et al., 2006).  
 
In order to mimic the stress suffered by the cones in such circumstances, cells were serum-
starved and treated with 20 µM Norgestrel or vehicle (DMSO) and different concentrations 
of a hydrogen peroxide (H2O2) solution for 24 h to increase oxidative stress. Exogenous 
addition of H2O2 has been widely used as a signalling molecule to induce cellular survival at 
short time points (Carmody & Cotter, 2007; Forman, 2007; Mackey et al., 2008; Wang et al., 
2018). However, it is thought to produce oxidative damage and cell death when it becomes 
toxic after a long exposure (Wang et al., 2018). In the current study, a range of 
concentrations was tested for its effects on cellular viability as measured by MTS assay. 
Norgestrel was only significantly protective in the presence of 1 µM H2O2 (independent 
samples t-test, t 30 = 2.695, P = 0.0114; n = 3 per group; Figure 5.3.1).  
Chapter 5 
106 
 
                           
Figure 5.3.1. Norgestrel enhances cell survival at a sublethal dose of H2O2 in serum-starved 
661W cells. Dose-response curve measuring cell viability of 661W cells treated with increasing 
concentrations of hydrogen peroxide (H2O2) solution following serum starvation (t-test comparing 
individual treatments). Norgestrel was only able to enhance cell survival at 1 µM H2O2 compared with 
the vehicle control. Asterisks indicate significant difference (* P < 0.05).  
 
We subsequently aimed to understand the effects produced by the addition of H2O2 
compared with serum starvation (SS) itself in order to find a valid model to study cell death 
caused by oxidative damage. 661W cells were treated with the same H2O2 concentrations 
used in figure 5.3.1 in serum-free media for 24 h, and cell viability was measured by MTS 
assay. Vehicle (DMSO) concentrations from figure 5.3.1 were not considered in this 
experiment given that DMSO might affect the results due to its anti-inflammatory properties 
(Elisia et al., 2016).  
 
We did not find differences in cellular viability between H2O2 treatment and SS only at any 
concentration used, except from 500-1,000 µM, which resulted in a dramatic reduction of 
cell survival (one-way ANOVA, H2O2 effect, F 7,132 = 34.38, P < 0.0001; Dunnett’s post hoc 
test, 500 and 1000 µM: P < 0.0001; n = 3 per group; Figure 5.3.2). This increase in cell 
death at higher H2O2 concentrations has been already reported in 661W cells (Mackey et al., 
2008).  
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Figure 5.3.2. H2O2 addition has the same effect on cell viability as SS in 661W cells. Dose-
response curve measuring cell viability of 661W cells treated with increasing concentrations of 
hydrogen peroxide (H2O2) solution following serum starvation (Dunnett’s post hoc test, comparing all 
concentrations to the SS only control). Asterisks indicate significant difference (**** P < 0.0001).  
 
Once confirmed that SS and H2O2 have the same effect on 661W cells, we sought to 
investigate whether Norgestrel-mediated protection was the same in both cases. Thus, cells 
were treated with 20 µM Norgestrel or vehicle with the addition or not of 1 µM H2O2 in 
serum-free media for 24 h, and cell viability was measured by MTS assay. Protection 
induced by Norgestrel compared with the vehicle control with or without the addition of 
H2O2 presented similar values in 661W cells (independent samples t-test, SS: t 42 = 3.537, P 
= 0.001; SS+H2O2: t 30 = 2.695, P = 0.0114; n = 3-4 per group; Figure 5.3.3). 
                             
Figure 5.3.3. SS and H2O2 present similar effects in Norgestrel-mediated protection on 661W 
cells. Changes in cell viability were measured by MTS assay and graphed as a percentage of 100% 
viable UT control. Norgestrel-mediated protection was similar in the presence or absence of H2O2 (t-
test comparing individual treatments). Asterisks indicate significant difference (* P < 0.05, ** P < 
0.01).  
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In order to verify H2O2 addition had no different effects as SS on 661W photoreceptor cells, 
we use β-actin to stain the cytoskeleton and therefore, to study changes in cellular 
morphology by immunofluorescence (Figure 5.3.4). Untreated cells (UT) showed an 
expanded cytoplasm which was widely connected with surrounding cells, whilst cells of both 
vehicle controls (SS and SS+H2O2) presented a retracted cytoplasm and affected cell-cell 
connections (white arrows). Norgestrel partially restored UT morphology. 
 
Figure 5.3.4. SS and H2O2 present similar effects on 661W cells morphology. Fluorescent 
microscopic images showed that both SS and H2O2 addition retracted the cytoplasm and cell-cell 
connections (white arrows) of 661W cells. Norgestrel partially rescued untreated (UT) morphology in 
both cases. Secondary antibody only was added as negative control. Scale bar 30 µm. 
 
According with the results obtained, we decided to use SS as a valid model to study 
oxidative damage, given that exogenous addition of H2O2, a well-known oxidative molecule, 
had the same effect on the 661W cone photoreceptor-like cell line.  
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5.3.2. Norgestrel decreases ROS in order to enhance cell survival in long 
term stressed 661W cells  
 
In addition to the above results, SS has been demonstrated to produce ROS as a consequence 
of the lack of growth factors support (Gómez-Vicente et al., 2005; Mackey et al., 2008; 
Groeger et al., 2009a; Kuznetsov et al., 2011; Li et al., 2013; Ruiz-Lopez et al., 2017) and is 
therefore, a valid model to study photoreceptors cell death. In chapters 3 and 4, we have 
shown how Norgestrel is able to up-regulate ROS levels at early time points under stress in 
order to enhance cell survival in both 661W cells and rd10 mice. Nevertheless, we also 
demonstrated that Norgestrel reduces ROS levels at later time points in the balb/c induced 
light damage mouse model (Byrne et al., 2016b). However, this response has not been 
demonstrated in 661W cells. 
 
In the current study, cells were treated with 20 µM Norgestrel or vehicle (DMSO) in serum-
free media for 24 h and levels of ROS were studied by flow cytometry using the probe 
DCFDA. Norgestrel treatment decreased intracellular ROS levels produced by the oxidative 
stress induced by serum deprivation (independent samples t-test, t 30 = 11.56, P < 0.0001; n = 
4-5 per group; Figure 5.3.5A). To investigate the effect of reducing ROS levels on cell 
survival, the MTS assay was used to analyse cellular viability and proliferation with 
Norgestrel at 24 h following SS. Norgestrel significantly increased cell survival in stressed 
661W cells (independent samples t-test, t 42 = 3.537, P = 0.001; n = 4 per group; Figure 
5.3.5B). This increase in the survival coinciding with a decrease in the ROS production 
suggests that Norgestrel enhances cellular survival by reducing the damaging ROS produced 
by a long exposure to stress in 661W cells. 
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Figure 5.3.5. Norgestrel decreases damaging ROS levels in stressed 661W cells. (A) DCFDA 
probe was used to detect ROS levels by flow cytometry and plotted on a histogram. Y-axis represents 
cell counts, x-axis (logarithmic scale) measures the level of fluorescence. A shift to the right along the 
x-axis represents an increase in DCFDA fluorescence and hence ROS levels. Geomeans were graphed 
compared to UT cells (t-test comparing individual treatments). ROS levels produced by serum 
starvation (SS) were abolished by Norgestrel at 24 h. (B) Changes in cell viability were measured by 
the MTS assay and graphed as a percentage of 100% viable UT control (t-test comparing individual 
treatments). Norgestrel induced cellular survival at 24 h compared with the vehicle. Asterisks indicate 
significant difference (** P < 0.01, **** P < 0.0001). 
 
We subsequently repeated the experiment using 48 h serum deprivation in order to 
investigate whether Norgestrel effects last over time. By means of flow cytometry analyses, 
Norgestrel treatment significantly decreased intracellular ROS levels at 48 h (independent 
samples t-test, t 31 = 2.483, P = 0.0186; n = 4-5 per group; Figure 5.3.6A), although this 
reduction was smaller than the decrease seen at 24 h (Figure 5.3.5A). In contrast with results 
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obtained at 24 h, Norgestrel was no longer protective in stressed 661W cells at 48 h 
(independent samples t-test, t 46 = 1.364, P = 0.1792; n = 4 per group; Figure 5.3.6B). 
                                    
Figure 5.3.6. Norgestrel cannot longer protect 661W cells following 48 h following SS. (A) 
DCFDA probe was used to detect ROS levels by flow cytometry and plotted on a histogram. Y-axis 
represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. A shift to the 
right along the x-axis represents an increase in DCFDA fluorescence and hence ROS levels. 
Geomeans were graphed compared to UT cells (t-test comparing individual treatments). Norgestrel 
significantly reduced ROS levels produced by serum starvation (SS) at 48 h compared with the 
vehicle. (B) Changes in cell viability were measured by the MTS assay and graphed as a percentage of 
100% viable UT control (t-test comparing individual treatments). Norgestrel was no longer protective 
at 48 h following SS in 661W cells. Asterisks indicate significant difference (NS not significant, * P < 
0.05). 
 
These results suggest that the exposure of 661W cells to stress for 48 h cause an irreparable 
damage that Norgestrel is not able to counteract. Thus, all subsequent experiments conducted 
in the 661W cell line were performed using 24 h serum withdrawal.  
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5.3.3. Norgestrel does not modulate NOX-mediated ROS production in 
long term stressed 661W cells 
 
Under physiological conditions, cells have two main mechanisms to maintain a reduction-
oxidation (redox) homeostasis and avoid oxidative damage: decreasing ROS production and 
increasing the amount of scavenging enzymes. NOX proteins are implicated in endogenous 
ROS production. The only known function of NOX family members is as ROS generators 
within the cell (Bedard & Krause, 2007; Finkel, 2011; Moloney & Cotter, 2017). Despite the 
fact that NOX isoforms have been demonstrated to participate in survival signalling in 661W 
cells at early time points after serum starvation (Groeger et al., 2009), these proteins have 
also been related with the worsening of neurodegenerative diseases such as Alzheimer’s and 
Parkinson’s diseases (Ma et al., 2017) and with cone cell death in RP (Usui, Oveson, et al., 
2009). We also have demonstrated that Norgestrel utilises NOX4 to increase ROS levels to 
act as signalling molecules at early time points (Chapter 4). However, the role of these 
proteins following Norgestrel treatment after a longer exposure of stress has not been 
elucidated yet.  
 
Given that only NOX2 and NOX4 are expressed in 661W cells (Groeger et al., 2009), 
mRNA levels of both proteins were analysed using RT-qPCR. Neither NOX2 nor NOX4 
expression were affected by Norgestrel treatment at 24 h following SS (independent samples 
t-test, NOX2: t 14 = 0.01506, P = 0.9882; NOX4: t 16 = 0.6402, P = 0.5311; n = 3 per group; 
Figure 5.3.7A). We subsequently studied protein levels by western blotting, confirming that 
there were no changes in either NOX isoform following serum deprivation and Norgestrel 
treatment for 24 h (independent samples t-test, NOX2: t 4 = 0.2094, P = 0.8444; NOX4: t 4 = 
0.4322, P = 0.6879; n = 3 per group; Figure 5.3.7B). These results suggest that Norgestrel 
does not alter NOX activity as a mechanism to reduce intracellular ROS levels in 661W 
cells. 
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Figure 5.3.7. Norgestrel does not decrease ROS production at 24 h in serum-starved 661W cells. 
(A) NOX2 and NOX4 mRNA levels were measured by RT-qPCR in stressed 661W cells following 
Norgestrel treatment (t-test comparing individual treatments). Neither NOX2 nor NOX4 expression 
were changed by Norgestrel at 24 h following serum starvation. (B) Western blotting confirmed no 
changes in NOX2 and NOX4 protein levels (t-test comparing individual treatments). Equal loading of 
protein was demonstrated by REVERT total protein stain. Blots are representative of n=3. Asterisks 
indicate significant difference (NS not significant). 
 
5.3.4. Norgestrel increases the expression of pNrf2 and SOD2, but not 
SOD1, in long term serum-starved 661W cells 
 
As presented in figure 5.3.7, Norgestrel does not combat ROS levels through a decrease in 
ROS production. Thus, we next investigated a second mechanism known to decrease 
intracellular ROS levels. Given that oxidative stress contributes to many neurological 
diseases including RP, cells have integrated antioxidant systems, which consist of enzymatic 
and non-enzymatic antioxidants to maintain redox homeostasis and counteract the harmful 
effects of ROS (Birben et al., 2012; Holmström & Finkel, 2014; Moloney & Cotter, 2017). 
This system is very effective but it can become overwhelmed under pathological conditions, 
leading to the progression of many diseases (Birben et al., 2012; Ray et al., 2012; Pisoschi & 
Pop, 2015) as happens during cone cell death in RP (Usui, Oveson, et al., 2009).  
 
This antioxidant machinery includes glutathione, flavonoids and vitamins (A, C and E) as 
non-enzymatic antioxidants and different enzymes including SODs, glutathione peroxidases 
and catalases (Poprac et al., 2017). Although these enzymes are expressed in all cells, they 
are subject to regulation by transcription factors such as the nuclear factor kappa B (NF-κB) 
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or Nrf2 (Ray et al., 2012; Xiong et al., 2015; Marengo et al., 2016). Interestingly, some of 
those components of the antioxidant machinery have been shown to be up-regulated by 
Norgestrel treatment in the balb/c induced light damage model, including the transcription 
factor Nrf2 and its antioxidant effector SOD2 (Byrne et al., 2016b). Hence, expression levels 
of SOD proteins and Nrf2 were analysed by RT-qPCR. Norgestrel significantly increased 
SOD2 but not SOD1 or Nrf2 mRNA levels compared with the vehicle control (independent 
samples t-test, SOD1: t 16 = 0.7189, P = 0.4826; SOD2: t 15 = 2.453, P = 0.0269; Nrf2: t 14 = 
1.408, P = 0.1827; n = 3 per group; Figure 5.3.8A). 
  
Protein levels were subsequently studied by western blotting. We confirmed the up-
regulation of SOD2 with Norgestrel treatment. We also found that phosphorylation levels at 
serine 40 (S40) of Nrf2 (pNrf2) were significantly increased at 24 h following serum 
starvation (independent samples t-test, SOD1: t 4 = 0.7924, P = 0.4725; SOD2: t 4 = 2.845, P 
= 0.0466; pNrf2: t 4 = 3.011, P = 0.0395; Nrf2: t 4 = 0.6478, P = 0.5524; n = 3 per group; 
Figure 5.3.8B). All together, we suggest that Norgestrel reduces intracellular ROS levels by 
Figure 5.3.8. Norgestrel utilises 
antioxidants to reduce ROS 
levels in stressed 661W cells. 
(A) SOD1, SOD2 and Nrf2 
mRNA levels were measured by 
RT-qPCR in serum-starved 
661W treated with Norgestrel for 
24 h (t-test comparing individual 
treatments). SOD2 expression 
was significantly increased by 
Norgestrel. (B) Protein levels 
were studied by western blotting 
(t-test comparing individual 
treatments). Norgestrel produced 
a significant increase in SOD2 
and the phosphorylated form of 
Nrf2 (pNrf2) in 661W following 
24 h serum starvation. Equal 
loading of protein was 
demonstrated by REVERT total 
protein stain. Blots are 
representative of n=3. Asterisks 
indicate significant difference (* 
P < 0.05). 
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increasing antioxidant defences rather than by decreasing ROS production in stressed 661W 
cells. These results are not surprising, given that SOD enzymes have been documented to be 
up-regulated by progesterone treatment (Unfer et al., 2006, 2015). 
  
5.3.5. Norgestrel decreases ROS in order to enhance cell survival in long 
term stressed photoreceptors ex vivo 
 
Above results in 661W cells demonstrate that Norgestrel acts as an antioxidant, decreasing 
ROS levels following 24 h serum deprivation. Therefore, we next sought to validate our 
results in photoreceptors using retinas from the rd10 model of RP. Retinal explants were 
treated with either 20 µM Norgestrel or vehicle (DMSO) for 24 h and analysed for changes 
in photoreceptor ROS production through the preparation of single-cell suspensions to be 
used for FACS analysis (Byrne et al., 2016; Ruiz-Lopez et al., 2017). P15 rd10 retinas were 
used given that photoreceptors have initiated cell death mechanisms but photoreceptor loss is 
not yet apparent (Roche et al., 2016). Photoreceptor populations were identified by the 
comparison between a P30 C57 wild-type retinal preparation to that of a P30 rd10, where all 
photoreceptors are absent in the latter, as previously described (Ruiz-Lopez et al., 2017). 
Norgestrel was able to successfully reduce intracellular ROS production in the 
photoreceptors from rd10 retinas compared with those treated with the vehicle control, as 
indicated by flow cytometry (independent samples t-test, t 22 = 4.462, P = 0.0002; n = 4 per 
group; Figure 5.3.9A).  
 
In order to determine if this decrease in photoreceptor ROS levels is necessary for 
Norgestrel-mediated protection in rd10 explants, we used TUNEL assay to analyse cell death 
in the photoreceptor layer/outer nuclear layer (ONL). We found that Norgestrel significantly 
protected rd10 explants from photoreceptor cell death (independent samples t-test, t 9 = 
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4.570, P = 0.0013; n = 5-6 per group; Figure 5.3.9B). This suggests that Norgestrel reduces 
damaging ROS levels to enhance photoreceptor survival in rd10 retinal explants. 
  
Figure 5.3.9. Norgestrel decreases damaging ROS levels in diseased photoreceptors ex vivo. (A) 
FACS analysis of photoreceptors using single cell suspensions from P15 rd10 retinas. Y-axis 
represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. A shift to the 
right along the x-axis represents an increase in DCFDA fluorescence and hence ROS levels. 
Geomeans were graphed and Norgestrel treatment was compared to its DMSO vehicle control (t-test). 
ROS production was significantly decreased by Norgestrel in rd10 photorreceptors. (B) Apoptosis of 
retinal cells in the outer nuclear layer (ONL) was detected by TUNEL (green) at 24 h. Norgestrel 
reduced TUNEL-positive staining in the central rd10 retina after 24 h treatment compared with the 
vehicle control (t-test). Images are representative of n=3. Scale bar 50 µm. Hoechst staining reveals 
cell nuclei. Asterisks indicate significant difference (** P < 0.01, *** P < 0.001).  
 
5.3.6. Norgestrel decreases ROS levels by increasing the antioxidants 
SOD2 and pNrf2 ex vivo 
 
Using the 661W cell line, we suggest that Norgestrel-mediated reduction of ROS levels 
occurs through an increase in antioxidants rather than by decreasing their production from 
NOX proteins (Figures 5.3.7 and 5.3.8). To substantiate our hypothesis, P15 rd10 retinal 
explants were treated with either Norgestrel or vehicle for 24 h and mRNA levels of NOX2 
and NOX4 were studied by RT-qPCR. Due to the fact that NOX1 and NOX3 are not 
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expressed in the retina at this stage (Groeger et al., 2009) and NOX5 is not found in rodents 
(Lambeth et al., 2007), only NOX2 and NOX4 were analysed. Neither NOX2 nor NOX4 
were affected by treatment with Norgestrel (independent samples t-test, NOX2: t 10 = 
0.06509, P = 0.9494; NOX4: t 10 = 0.01837, P = 0.9857; n = 2 per group; Figure 5.3.10A). In 
order to confirm this, protein levels were analysed by western blotting. We confirmed that 
there were no changes in either NOX2 or NOX4 after Norgestrel treatment in rd10 retinal 
explants (independent samples t-test, NOX2: t 4 = 1.260, P = 0.2762; NOX4: t 4 = 0.6788, P 
= 0.5345; n = 3 per group; Figure 5.3.10B). 
 
Figure 5.3.10. Norgestrel does not decrease ROS production at 24 h in rd10 retinal explants. 
NOX2 and NOX4 were studied by RT-qPCR (A) and western blotting (B) of rd10 retinal explants 
treated with Norgestrel for 24 h. Norgestrel did not change either of them (t-test comparing individual 
treatments). Equal loading of protein was demonstrated by REVERT total protein stain. Blots are 
representative of n=3. Asterisks indicate significant difference (NS not significant). 
 
We subsequently sought to investigate whether Norgestrel treatment affects antioxidant 
expression in the rd10 retina. Thus, SOD1, SOD2 and Nrf2 were analysed by RT-qPCR. 
Norgestrel did not change SOD1 expression (independent samples t-test, SOD1: t 10 = 
0.2106, P = 0.8374; n = 2 per group; Figure 5.3.11A), whereas SOD2 and Nrf2 were 
increased at 24 h (SOD2: t 10 = 4.402, P = 0.0013; Nrf2: t 10 = 2.670, P = 0.0235; n = 2 per 
group). In order to corroborate these results, western blotting was used to study changes in 
protein levels. Levels of SOD1 were not affected by Norgestrel treatment at 24 h, supporting 
the mRNA results (independent samples t-test, SOD1: t 4 = 0.4912, P = 0.649; n = 3 per 
group; Figure 5.3.11B). In addition, SOD2 and the active form of Nrf2 (pNrf2) were 
significantly increased by Norgestrel as previously seen by RT-qPCR (SOD2: t 4 = 3.021, P 
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= 0.0391; pNrf2: t 4 = 3.308, P = 0.0297; Nrf2: t 4 = 0.03685, P = 0.9724; n = 3 per group). 
This supports our findings in 661Ws that Norgestrel increases the antioxidant defenses in 
order to reduce the production of ROS when they become toxic in photoreceptor cells. 
 
5.3.7. Norgestrel decreases ROS levels by increasing the antioxidants 
SOD2 and pNrf2 in vivo 
 
Norgestrel has been demonstrated to reduce ROS in vivo in a balb/c induced light damage 
mouse model (Byrne et al., 2016b). Importantly, the current study confirms that this effect is 
evident in the inherited disease model ex vivo. We have demonstrated the role of antioxidants 
in this response, specifically SOD2 and the active form of Nrf2. To test our hypothesis in 
vivo, we administered a Norgestrel-supplemented diet to rd10 mice from P10. In the rd10 
mouse, rod degeneration begins ~P15 and peaks at P25 (Chang et al., 2002; Gargini et al., 
2007; Barhoum et al., 2008; Samardzija et al., 2012; Roche et al., 2016). We have 
demonstrated significant neuroprotective effects of Norgestrel in the rd10 retina (Roche & 
Wyse-Jackson et al., 2016; Roche et al., 2017a, 2017b).  
Figure 5.3.11. Norgestrel 
reduces damaging ROS by 
increasing antioxidants in rd10 
retinal explants. SOD1, SOD2 
and Nrf2 were subsequently 
analysed by RT-qPCR (A). 
SOD2 and Nrf2 expression was 
up-regulated by Norgestrel at 24 
h (t-test comparing individual 
treatments), which was 
confirmed by western blotting 
(B). Both SOD2 and 
phosphorylated Nrf2 (pNrf2) 
protein levels were increased by 
Norgestrel treatment compared 
with the vehicle (t-test) Equal 
loading of protein was 
demonstrated by REVERT total 
protein stain. Blots are 
representative of n=3. Asterisks 
indicate significant difference (* 
P < 0.05, ** P < 0.01).  
 
Chapter 5 
119 
 
     
This is not the first time progesterone treatment has been associated with a reduction in 
oxidative stress (Webster et al., 2015; Yousuf et al., 2016) and with increased levels of 
antioxidants (Unfer et al., 2015; Byrne, Ruiz-Lopez, et al., 2016; Zhang, Wu, et al., 2017). 
In order to establish whether the antioxidant proteins, SOD2 and Nrf2, play a role in the 
Norgestrel-mediated protection in the diseased rd10 retina, immunohistochemical analysis 
was performed at P15, P20 and P25. We found that Norgestrel significantly increased SOD2 
and pNrf2 protein levels at P20 and P25 in the diseased retina (independent samples t-test, 
P20 SOD2: t 22 = 6.240, P < 0.0001; P25 SOD2: t 22 = 2.533, P = 0.019; n = 3 per group; 
Figure 5.3.12; P20 pNrf2: t 20 = 8.255, P < 0.0001; P25 pNrf2: t 20 = 5.344, P = 0.019; n = 3 
per group; Figure 5.3.13). 
Figure 5.3.12. Norgestrel 
increases antioxidants SOD2 
in the diseased retina in vivo. 
SOD2 protein levels were 
studied by immunofluorescence 
in rd10 retinas from P15 to P25 
Norgestrel-fed or control-fed 
mice. SOD2 was significantly 
up-regulated by Norgestrel at 
P20 and P25 (t-test comparing 
individual treatments). Images 
are representative of n=3. Scale 
bar 50 µm. Hoechst staining 
reveals cell nuclei. RGC: retinal 
ganglion cells, INL: inner 
nuclear layer, ONL: outer 
nuclear layer. Asterisks indicate 
significant difference (* P < 
0.05, **** P < 0.0001). 
 
Chapter 5 
120 
 
 
Figure 5.3.13. Norgestrel increases antioxidants SOD2 in the diseased retina in vivo. Active Nrf2 
(pNrf2) protein levels were studied by immunofluorescence in rd10 retinas from P15 to P25 
Norgestrel-fed or control-fed mice. pNrf2 was significantly up-regulated by Norgestrel at P20 and P25 
(t-test comparing individual treatments). Images are representative of n=3. Hoechst staining reveals 
cell nuclei. RGC: retinal ganglion cells, INL: inner nuclear layer, ONL: outer nuclear layer. Asterisks 
indicate significant difference (**** P < 0.0001). 
 
The progression of RP was clearly identified by measuring ONL thickness. Norgestrel 
enhanced the preservation of photoreceptors in the three time points studied compared with 
the control diet as previously shown (Roche & Wyse-Jackson et al., 2016) (independent 
samples t-test, P15: t 22 = 0.06578, P = 0.9481; P20: t 22 = 16.79, P < 0.0001; P25: t 22 = 
16.02, P < 0.0001; n = 3 per group; Figure 5.3.14). Norgestrel-mediated protection through 
the preservation of the ONL became clearer when RP progression was obvious from P20 in 
the rd10 control-fed mice.  
   
Norgestrel therefore, acts through the modulation of antioxidants in order to reduce harmful 
ROS levels in the rd10 retina in vivo. These results are supported by other in vivo studies, 
which have shown similar findings. In 2008, Lu et al. demonstrated that progesterone 
treatment offers retinal protection against ischemia-reperfusion injury by increasing SOD 
activity in rats (Lu et al., 2008). 
 
Figure 5.3.14. Norgestrel delays 
photoreceptor degeneration in rd10 mice. 
Photoreceptor layer/outer nuclear layer 
(ONL) thickness was measured and 
represented in a histogram. Norgestrel 
delays photoreceptor cell death and 
preserves ONL thickness in rd10 retinas (t-
test comparing individual treatments). 
Asterisks indicate significant difference 
(**** P < 0.0001). 
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5.4. Discussion 
 
Previous studies from our laboratory have demonstrated that Norgestrel stimulates ROS 
production in order to enhance cell survival at 30 min following serum starvation (Ruiz-
Lopez et al., 2017). This response is just one among a great variety of mechanisms 
Norgestrel is able to produce in in vitro, in vivo and ex vivo models (Doonan et al., 2011; 
Byrne et al., 2016a; 2016b; Roche & Wyse-Jackson et al., 2016; Wyse Jackson & Cotter, 
2016; Wyse Jackson et al., 2016a; 2016b; Roche et al., 2017a; 2017b).  
 
Low or moderate levels of ROS have been discovered to constitute an important part of 
signalling pathways within the cell during the first minutes after any cell damage (Remacle 
et al., 1995; Rhee, 2006; D’Autréaux & Toledano, 2007; Mackey et al., 2008; Finkel, 2011; 
Ray et al., 2012; Moloney & Cotter, 2017; Hashad et al., 2018). Nevertheless, an increase in 
the amount of ROS present in the cell or a longer exposure to them can cause the cell to die 
(Yakes & Houten, 1997; Kim et al., 2015; Fam et al., 2018). This disruption of the redox 
homeostasis is known as ‘oxidative stress’. Shokolenko et al. demonstrated that oxidative 
stress results in the degradation of mitochondrial DNA (Shokolenko et al., 2009), which is 
one of the main causes of mutations and their subsequent effects, such as aging or some 
diseases (Fam et al., 2018). In the current study, hydrogen peroxide, together with serum 
starvation, was used in order to find a valid model to study oxidative stress in the 661W cone 
photoreceptor cell line. Despite the fact that this molecule has been shown to be toxic after a 
long exposure and induce oxidative stress (Wang et al., 2018), we found that its effects are 
very similar to serum withdrawal itself in 661W cells (Figure 5.3.1-5.3.4) and therefore, 
serum deprivation represents a valid model of oxidative stress. 
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Fortunately, cells house defence mechanisms which involve enzymatic antioxidants to 
counteract the damaging effects of ROS (Cadenas, 1997; Benzie, 2000; Valko et al., 2007; 
Pisoschi & Pop, 2015; Moloney & Cotter, 2017).  
 
However, this system cannot cope with sustained high levels of ROS. Diseases such as RP 
are characterised by an increase in the oxidative stress when rods first die, resulting in the 
subsequent death of the other type of photoreceptors: the cones (Cuenca et al., 2014; 
Elachouri et al., 2015; Campochiaro & Mir, 2017). For this reason, several therapeutic 
strategies target antioxidant machinery or incorporate exogenous antioxidant addition in 
order to reduce oxidative stress and enhance survival (Komeima et al., 2006, 2007; Cuenca 
et al., 2014; Taherian et al., 2014; Tao et al., 2016; Poprac et al., 2017). Tao et al. 
hypothesised that exogenous addition of antioxidants might be useful in the treatment of RP 
when endogenous antioxidant machinery becomes insuficient for maintaining retinal 
homeostasis or optimal visual function. They suggest that such approach not only benefits 
photoreceptors, but also helps subjacent cells types to maintain visual signal transduction 
(Tao et al., 2016). The molecule proposed to accomplish such function is hydrogen given its 
low molecular weight and lipid solubility to easily penetrate the blood-retina barrier. 
However, hydrogen therapy needs to be optimised to help RP patients. Even though not all 
the clinical trials employing antioxidant supplementation have successfully worked, 
antioxidant therapies are still very promising. Some of the possible explanations regarding 
their failure might be related with finding an optimal dose, the use of several antioxidants to 
work in combination or the stage of the disease in which the therapy starts (Poprac et al., 
2017). For these reasons, a compound that could stimulate endogenous intracellular 
antioxidant mechanisms, rather than exogenous addition, would be ideal given that cells 
could autoregulate these pathways. 
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We show in the current study that Norgestrel enhances cell survival through the decrease of 
damaging ROS produced at 24 h following serum starvation in 661W photoreceptor cells 
(Figure 5.3.5). However, we found that Norgestrel is no longer protective at 48 h following 
SS (Figure 5.3.6). We hypothesise that the stress suffered at this time point is so severe that 
Norgestrel is not able to face such damage. Studies on other cell lines confirm this 
hypothesis (Tavaluc et al., 2007; Chen et al., 2012). In fact, Chen et al. also described a 
remarkable decrease in cell survival upon 48 h SS (Chen et al., 2012). As previously 
mentioned, the reduction in ROS levels can be either the result of a decrease in the 
production by intracellular sources, or because of an increase in the antioxidant defence 
(Moloney & Cotter, 2017). In this study, we have shown that Norgestrel does not change 
levels of NOX proteins (Figure 5.3.7), which are known to be one of the major generators of 
ROS molecules within the cell. These proteins were of interest in this study due to the fact 
that they have been associated with cone cell death occurring in RP (Usui et al., 2009; Zeng 
et al., 2014). Usui et al. proved that NOX-mediated ROS production, and not other sources, 
is responsible of such cell death in the rd1 mouse model of RP.  
 
On the other hand, Norgestrel was able to increase levels of the antioxidant SOD2 and 
phosphorylation levels of the transcription factor Nrf2 (pNrf2) in order to reduce ROS 
produced by suppression of trophic supplementation in 661W photoreceptor-like cells 
(Figure 5.3.8). In fact, Chen et al. demonstrated in 2017 that exposure to blue light for 24 h 
increases Nrf2 levels in 661W cells (Chen et al., 2017). Our findings were more profound in 
retinal explants from rd10 mice (Figure 5.3.9-5.3.11) and in retinas of rd10 mice fed with a 
Norgestrel-supplemented diet (Figure 5.3.12-5.3.14), strengthening our hypothesis that 
Norgestrel utilises antioxidants to decrease harmful ROS in the diseased retina. Moreover, 
increased levels of SOD2 but not SOD1 have been observed in stressed 661W cells and rd10 
retinal explants treated with another neuroprotective compound, Rosiglitazone, during 24 h 
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(Doonan et al., 2009). Our results reinforce the use of 661W cells and retinal explants as 
valid approaches to study photoreceptor degeneration occurring in RP. 
 
Nrf2 is a basic-leucine-zipper protein that once activated by phosphorylation acts as a 
transcription factor in the nucleus, modulating the expression of different genes, including 
antioxidant enzymes such as SOD proteins (Gwarzo, 2009; Kaspar et al., 2009; Niture et al., 
2013). Thus, Nrf2, which is ubiquitously expressed in a wide range of tissues and cell types, 
serves as a sensor of oxidative stress in the cell and is regarded as a critical component of the 
antioxidant defence (Dhakshinamoorthy et al., 2001; Jaiswal, 2004). Several studies support 
the idea that Nrf2 plays an important role in cell survival (Lee, Calkins, et al., 2003; 
Manandhar et al., 2007; Dong et al., 2008; Park et al., 2018). In addition, Nrf2 has been 
linked with neuroprotection in neurodegenerative diseases (Chen et al., 2009; Dinkova-
Kostova et al., 2018) and protection in the eye (Himori et al., 2013; Xu et al., 2014; Xiong et 
al., 2015; Nakagami, 2016) as a result of progesterone treatment (Zhang et al., 2017). 
Indeed, Norgestrel has been demonstrated to modulate activation of Nrf2 to reduce damaging 
ROS in an induced light damage mouse model (Byrne et al., 2016b). Therefore, Norgestrel-
mediated activation of this important cellular component of the protective response against 
oxidative damage in the rd10 retina is not surprising.  
 
SOD metalloproteins, which contain cooper, zinc or manganese in their catalytic centre, are 
the most important antioxidants in the defence system against ROS (Fukai & Ushio-Fukai, 
2011). CuZn-SOD (SOD1) and Mn-SOD (SOD2) are located in the cytoplasm and 
mitochondria, respectively (Zelko et al., 2002), and are key effectors of Nrf2. They were of 
interest in this study given that there is evidence in the literature showing that they can be 
up-regulated by progesterone (Unfer et al., 2006, 2015; Byrne et al,. 2016b). Unfer et al. 
demonstrated not only that progesterone treatment prevented the decrease in blood SOD1 
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and SOD2 levels that occurs in postmenopausal women, but also an increase in both 
enzymes activity to increase antioxidant capacity (Unfer et al., 2006, 2015). 
 
In summary, this study presents an important function in the Norgestrel-mediated 
neuroprotection in the diseased retina through the utilization of antioxidants to reduce 
damaging ROS (Fig. 5.4.1). 
            
 
Figure 5.4.1. Proposed pathway of Norgestrel-mediated response in diseased photoreceptors. It 
has been previously shown that Norgestrel acts through the progesterone receptor membrane complex 
I (PGRMC1) to modulate ROS signalling (Ruiz-Lopez et al., 2017). This schematic represents how 
Norgestrel induces Nrf2 phosphorylation (pNrf2) and increases mitochondrial SOD2 to reduce 
intracellular ROS levels and promote neuroprotection in diseased photoreceptor cells.  
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The study of molecules such as reactive oxygen species (ROS) has completely changed in 
the last decades. Traditionally believed to induce cellular damage, attempts have been made 
to find mechanisms to reduce their production in order to prevent cell death. Throughout this 
thesis, we have shown a dual nature of these molecules, being also able to participate as 
signalling messengers to enhance photoreceptor survival (Chapter 3 and 4). Their persistence 
during time convert ROS into toxic molecules that subsequently induce cell death (Chapter 
5). Numerous studies from this group (Carmody et al., 1999; Sanvicens et al., 2004; 
Sanvicens & Cotter, 2006; England et al., 2006; Carmody & Cotter, 2007; Mackey et al., 
2008; Groeger et al., 2009a, 2009b; Bhatt et al., 2010; Farrell et al., 2011; Gough & Cotter, 
2011; Groeger et al., 2012; Stanicka et al., 2015; Byrne et al., 2016b; Moloney et al., 2017a, 
2017b) and others (Herrlich & Böhmer, 2000; Imlay, 2003; Lee et al., 2003; Andreyev et al., 
2005; Rhee, 2006; Lee et al., 2007; Bae et al., 2011; Benitez-Alfonso et al., 2011; Finkel, 
2011; Burgoyne et al., 2013; Schieber & Chandel, 2014; Brandes et al., 2014b; Kim et al., 
2015; Reczek & Chandel, 2015; Battistelli et al., 2016; Di Meo et al., 2016; Antunes & 
Brito, 2017; Sies, 2017) have described this double nature of ROS so far.  
 
This thesis highlights a novel and important property of Norgestrel: the modulation of 
intracellular ROS levels in retinal degeneration (Chapter 3, 4 and 5). This is the first time 
that Norgestrel has been demonstrated to utilise ROS as second messengers as part of its 
mechanism of action in photoreceptors (Chapter 3; Ruiz-Lopez et al., 2017). Furthermore, 
we have also demonstrated that such increases in ROS levels at early time points are the 
consequence of the Norgestrel-mediated modulation of intracellular sources, as is the case of 
NOX4 (Chapter 4). 
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The importance of such findings relies on the fact that even though Norgestrel is an 
exogenous compound, its binding to the transmembrane progesterone receptor PGRMC1 
(Figure 3.3.8) (Wyse Jackson et al., 2016a; Ruiz-Lopez et al., 2017) causes an intracellular 
signalling cascade that cells can easily autoregulate. Hence, despite both bFGF (Figure 3.3.9) 
and ROS (Figure 3.3.6), being up-regulated as the consequence of Norgestrel’s effects, we 
believe their levels are most probably controlled by photoreceptors depending on the 
duration of the signalling response. According to this, we observed that bFGF and ROS 
levels go back to normal once the signalling response has finished.  
 
Similarly, Norgestrel modulates NOX4 expression as the main source of pro-survival ROS in 
photoreceptor cells. We have shown that Norgestrel is no longer protective in the absence of 
NOX enzymes (Chapter 4). Other studies have also demonstrated that these proteins, 
especially NOX4, are important in the stimulation of survival mechanisms in a wide range of 
cell types (Abid et al., 2007; Brown & Griendling, 2009; Groeger et al., 2009a; Takac et al., 
2012; Brandes et al., 2014b; Accetta et al., 2016; Moon et al., 2016; Prieto-Bermejo & 
Hernández-Hernández, 2017). Abid et al. demonstrated that NOX-derived ROS are required 
for the VEGF-mediated activation of the Akt pathway and subsequent proliferation of 
endothelial cells (Abid et al., 2007). Moreover, ROS produced by NOX enzymes are thought 
to play a role in the vascular and inmune systems, hormone synthesis and the physiology of 
the brain as reviewed by Brown & Griendling (Brown & Griendling, 2009), Brandes et al. 
(Brandes et al., 2014b) and Prieto-Bermejo & Hernández-Hernández (Prieto-Bermejo & 
Hernández-Hernández, 2017). This is not surprising given that the only known function of 
NOX proteins is the production of ROS (Bedard & Krause, 2007; Takac et al., 2012; 
Brandes et al., 2014a), suggesting they are easier to regulate than other intracellular sources. 
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Both mitochondria, the other major ROS generators, and COX proteins, which have been 
related with bFGF-mediated ROS response in 661W cells (Farrell et al., 2011), were found 
not to play a role in the Norgestrel-mediated signalling response (Figure 4.3.16-4.3.19). The 
fact that NOX4 was responsible for such mission was not surprising (Figure 4.3.4-4.3.11) 
given that NOX4 appears to be constitutively active (von Löhneysen et al., 2012). Our 
results therefore, strengthen our hypothesis that Norgestrel uses NOX4 to produce pro-
survival quantities of ROS, provided that it might be a source that cells can effectively 
autoregulate.  
 
Although this autoregulated system seems to be infallible, a prolonged exposure to stress, 
such as serum starvation, inevitably leads to cell death. We have widely discussed 
throughout this thesis that the presence of high amounts of ROS can be lethal (Chance, 1979; 
Gorman et al., 1997; Curtin et al., 2002; Rhee, 2006; Battistelli et al., 2016). In fact, some 
types of cell death produced in diseases such as retinitis pigmentosa have been linked with 
oxidative damage (Shen et al., 2005; Carmody & Cotter, 2007; Punzo et al., 2012; 
Campochiaro et al., 2015). Thus, an effective antioxidant defence machinery is required in 
order to balance ROS levels and avoid oxidative stress. This system has widely changed 
during the evolution of the atmosphere and living organisms. Due to a hydrogen-rich 
atmosphere, procaryotic organisms used hydrogen as an electron donor and released oxygen 
as a waste product. However, once atmospheric O2 levels began to rise, more complex and 
compartmentalised eukaryotic forms appeared to use oxygen as a final electron acceptor. 
Consequently, antioxidant defence mechanisms evolved to combat oxidative damage 
produced by the toxic intermediates of oxygen, such as O2•– and OH• (Benzie, 2000). 
“Living with the risk of oxidative stress is a price that aerobic organisms must pay for more 
efficient bioenergetics” (quoted from Skulachev (Skulachev, 1996)).  
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Given that superoxide is the first free radical formed as the consequence of the partial 
reduction of oxygen, its elimination represents a major step in the antioxidant response. Such 
task is performed by superoxide dismutases (SODs), which therefore, constitute the first line 
of defence against ROS. CuZn-SOD (SOD1), Mn-SOD (SOD2) and SOD3 are the three 
isoforms of this family of proteins. SOD3 has not been considered in this thesis taking into 
account its extracellular location as mentioned in chapter 1. Overall, SOD1 (cytoplasmic) 
and SOD2 (mitochondrial) are responsible for the intracellular conversion of O2•– to H2O2, 
and SOD2, the most important member of the SOD family providing superoxide is mainly 
generated in the mitochondria  (Murphy, 2009). These enzymes are regulated by 
transcription factors such as Nrf2 (Gwarzo, 2009; Kaspar et al., 2009; Niture et al., 2013). In 
2009, Gwarzo showed a 50% reduction in the brain levels of SOD2 in the Nrf2 knockout 
mice, Nrf2(-/-) (Gwarzo, 2009), confirming the link between these proteins.   
 
In 2016, we demonstrated that Norgestrel was able to increase the transcription factor Nrf2 
and its antioxidant effector, SOD2, in order to reduce damaging ROS in the balb/c induced 
light damage mouse model (Byrne et al., 2016b). Despite the fact that this mouse model is an 
invaluable tool to study cell death within the stressed retina, it is important to notice that the 
photoreceptor cell death occuring in the balb/c mouse is light-induced and therefore, is not a 
model of any genetic disease, including retinitis pigmentosa. In this context, we designed 
this study in order to elucidate such response in the genetic rd10 mouse model of RP. 
Interestingly, we could confirm such results, being the first time that Norgestrel’s effects on 
harmful ROS levels have been studied in the diseased retina (Chapter 5). Norgestrel 
decreases the amount of ROS when they become pathological in vitro (Figure 5.3.5) and in 
the photoreceptors of the rd10 retina (Figure 5.3.9) through the up-regulation of Nrf2 and its 
antioxidant effector SOD2 as described before (Byrne et al., 2016b). 
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These results are very promising in the treatment of late stages of RP, given that the majority 
of RP cases are detected when rods degeneration has already started and preservation of the 
remaining photoreceptor cells is essential. Taking into that account subsequent cone cell 
death happens due to oxidative damage (Shen et al., 2005; Carmody & Cotter, 2007; Punzo 
et al., 2012; Campochiaro et al., 2015), the use of antioxidants as therapeutic molecules for 
retinitis pigmentosa is desirable. Numerous studies have demonstrated that the exogenous 
addition of natural and/or synthetic antioxidants successfully prevents cell death (Jarrett et 
al., 2006; Komeima et al., 2006, 2007; Valko et al., 2007; Dong et al., 2008; Trachootham et 
al., 2008; Lu et al., 2009; Usui et al., 2009, 2011; Cuenca et al., 2014). In fact, antioxidant 
supplementation is able to slow the progression of the disease in both the rd1 and the rd10 
mice model of RP (Komeima et al., 2006, 2007). 
 
Unfortunately, the majority of these antioxidant strategies have proved inefficient (Nickel et 
al., 2014; Sanz & Bernardi, 2016), although the reasons are not very clear. One explanation 
is that the exogenous addition of antioxidants in order to abolish the total production of ROS 
might be erroneous. The importance of moderate and controlled quantities of ROS acting as 
signalling molecules has been demonstrated throughout this thesis. We believe the total 
abolishment of such action would not only be inefficient, but also prejudicial for cells as 
suggested by other authors (Bickham & Smolen, 1994; Sheu et al., 2006; Nickel et al., 
2014). Nickel et al. suggested that the blockage of NOX4-derived ROS might have 
detrimental results due to its protective roles, and proposed that an antioxidant therapy 
directed to specific sources, such as mitochondria, would improve this strategie (Nickel et 
al., 2014). Therefore, mitochondria-targeted drugs are being developed for such purposes 
(Sheu et al., 2006; McCarthy & Kenny, 2016), as is the case of MitoTEMPO (Ni et al., 
2016; Zhang et al., 2017), which has been used in the chapter 4 of this thesis. 
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Nevertheless, some studies suggest that mitochondrial ROS can also participate in cell 
signalling (Dan Dunn et al., 2015; Diebold & Chandel, 2016; Sanz & Bernardi, 2016). 
Interestingly, some authors have demonstrated the existence of a crosstalk between 
mitochondria and NOX proteins to produce pro-survival ROS (Kimura et al., 2005; Daiber, 
2010; Dikalov, 2011; Bordt & Polster, 2014; Dikalov et al., 2014; Harel et al., 2017; Kim et 
al., 2017; Zinkevich et al., 2017). This system represents a feed-forward vicious cycle of 
ROS production that might serve to amplify the signal within the cell as reviewed by 
Dikalov (Dikalov, 2011). If true, mitochondrial-targeted drugs might be inefficient as well.  
 
We believe that a compound that could stimulate the intracellular antioxidant machinery 
when needed would be a more efficient approach. In this context, Norgestrel has been 
demonstrated to be a perfect candidate to do so. Rosiglitazone, another FDA-approved 
compound that has been mentioned in this thesis, also shows such ability through the up-
regulation of the intracellular levels of the antioxidant SOD2 (Doonan et al., 2009). 
Nonetheless, the level of neuroprotection of this compound was not as important as the one 
observed following Norgestrel treatment. We hypothesise that the reason for such difference 
relies on the broad spectrum of mechanisms that Norgestrel is able to modulate in order to 
consolidate a neuroprotective environment to enhance cell survival.  
 
Despite the fact that progesterone has been used to regulate pro-survival pathways in the 
CNS (De Nicola, 1993; Joëls, 1997; Azcoitia et al., 1999; McEwen, 1999; Schumacher et 
al., 2000; Petersen et al., 2013), retinal studies have failed to show beneficial effects of 
progesterone (Káldi & Berta, 2004). Doonan et al. however, achieved retinal neuroprotection 
using Norgestrel in the balb/c induced light damage mouse model and in the genetic rd10 
mouse (Doonan et al., 2011). This protection could be produced given that synthetic 
progestins, such as Norgestrel, are rapidly absorbed, have a longer half-life and maintain 
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stable levels in the blood in comparison to natural progesterone, which means that higher 
concentrations of Norgestrel last for longer in the body (Doonan & Cotter, 2012).  
 
Since 2011, our laboratory has focussed on elucidating Norgestrel’s mechanism of action. 
All this work has greatly improved since a Norgestrel-supplemented diet was developed by 
Testdiet (Middlesex, UK), which prevents adverse reactions of invasive techniques, such as 
intraperitoneal injections. The level of success of this non-invasive techinque in the rd10 
retina has been demonstrated so far (Roche & Wyse-Jackson et al., 2016; Roche et al., 
2017a, 2017b), being the first time that such a great protection has been seen in this model of 
RP. 
 
Clearly, our understanding of how this progesterone-analogue works to prevent cell death is 
expanding. This thesis elucidates another important aspect of its mechanism of action, 
demonstrating that redox biology is another part of the multi-faceted action of Norgestrel 
within the diseased retina. Reactive oxygen species are both up- (Chapter 3 and 4) and 
down-regulated (Chapter 5) by Norgestrel according to the needs of photoreceptors. We 
believe these results, together with Norgestrel’s ability to modulate neurotrophic factors 
expression (Doonan et al., 2011; Byrne et al., 2016a; Wyse Jackson & Cotter, 2016; Ruiz-
Lopez et al., 2017) and to regulate inflammation and gliosis (Roche & Wyse-Jackson et al., 
2016; Roche et al., 2017a, 2017b), are the reasons why Norgestrel is a particularly 
interesting neuroprotectant.  
 
Mutations in the Pde6b gene, which result in both the rd1 and rd10 mouse models, represent 
only a 4-5% of autosomal recesive RP cases as discussed in chapter 1. Other types of retinitis 
pigmentosa also display a rod-cone dystrophy caused by the first lost of rods and subsequent 
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death of cones, as is the case of autosomal dominant RP produced by mutations in the 
rhodopsin (RHO) gene (Athanasiou et al., 2018). Since rhodopsin is also part of the 
phototransduction cascade and therefore, photoreceptors cell death might be produced in a 
similar way as the one seen in rd1 and rd10 mice, we believe that Norgestrel could also 
enhance neuroprotection in this and other types of RP. In fact, some therapies used in the 
treatment of RP produced by rhodopsin mutations include the use of neurotrophic factors 
(Mendes et al., 2005), which have been demonstrated to be up-regulated by Norgestrel 
(Doonan et al., 2011; Byrne et al., 2016a; Wyse Jackson & Cotter, 2016; Ruiz-Lopez et al., 
2017).   
 
Furthermore, other diseases in which inflammation, gliosis and reactive oxygen species are 
in part responsible for irreversible blindness (Jarrett et al., 2008; Dogru et al., 2009; Schrier 
& Falk, 2011; Kruk et al., 2015), such as glaucoma and age-related macular degeneration 
(AMD), can also be considered for the study of the Norgestrel-mediated neuroprotection. 
Hormone therapy used for the patients with glaucoma has shown promising results 
(Nakazawa et al., 2006; Kolomeyer & Zarbin, 2014), indicating that Norgestrel could be a 
suitable candidate to be taken into account. Thus, we hope to bring our work to the point that 
this treatment is ready for clinical trials, closer to patients suffering from retinal 
degeneration. 
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